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SUMMARY	
	
Rare coding variants in the PLD3	 gene coding for Phospholipase D3 were recently 
identified to increase the risk of developing late onset Alzheimer´s disease (LOAD). In 
order to address in more detail a possible influence of PLD3 on AD development, it was 
important to perform a fundamental biochemical characterization of PLD3 that provides 
a better understanding of its potential function. In this project evidence was provided 
that the type II transmembrane protein PLD3 is transported through the secretory and 
endocytic route to reach lysosomes. Using a newly described pathway, PLD3 is delivered 
to lysosomes via the endosomal sorting complex required for transport (ESCRT) 
machinery. An ubiquitination of PLD3 is required for its sorting into intraluminal vesicles 
of multivesicular bodies (MVBs). After fusion of MVBs with lysosomes, PLD3 is 
proteolytically processed into a stable luminal domain, to exert its main enzymatic 
function in this compartment.  
In the course of this project, PLD3 was identified as a lysosomal 5’ single-stranded acid 
exonuclease in immune cells. We could reveal that PLD3 is predominantly expressed in 
the brain, with highest expression in the hippocampus and the cerebral cortex. It could 
be further shown that PLD3 is the main 5’-exonuclease in the mouse brain. Almost absent 
5’ exonuclease activity was observed in the brain lysates of Pld3 knockout (KO) mice.  
Pld3 KO mice did not show cerebellar dysfunction, suggesting that a previously reported 
PLD3 mutation is not causative for spinocerebellar ataxia. In Pld3-deficient mice, 
microglia alterations in the dentate gyrus of the hippocampus and the subventricular 
zone, both sites of adult neurogenesis, and a depression-like behavior were revealed. This 
suggests an important role of PLD3 in neuronal homeostasis, possibly affecting the onset 
and course of LOAD. Pld3 KO mice were bred with the 5xFAD Alzheimer´s disease (AD) 
mouse model. Although Pld3 was enriched in amyloid plaques (a hallmark of AD), no 
obvious changes on APP protein levels or cleavage products were observed in 5xFAD 
Pld3-/- mice, suggesting a more complex role of PLD3 in the etiology of AD. 	
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ZUSAMMENFASSUNG	 	
	
Seltene Varianten im PLD3-Gen, welches für die Phospholipase D3 kodiert, wurden 
kürzlich als Risikofaktor einer spät einsetzenden Alzheimer-Erkrankung (‚late onset 
Alzheimer´s disease‘, LOAD) identifiziert. Um einen möglichen Einfluss von PLD3 auf die 
Pathogenese des Morbus Alzheimers zu verstehen, war es wichtig, eine grundlegende 
biochemische Charakterisierung von PLD3 vorzunehmen, die ein besseres Verständnis 
seiner potenziellen Funktion ermöglicht. In diesem Projekt wurde der Nachweis 
erbracht, dass das Typ-II-Transmembranprotein PLD3 über den sekretorischen und 
endozytotischen Weg zu den Lysosomen transportiert wird. PLD3 wird mittels der 
Transportmaschinerie der ESCRT-Proteine (‚endosomal sorting complexes required for 
transport‘) an Lysosomen geliefert, ein Transportweg der bislang nur für vakuoläre 
Proteine in Hefe bekannt war. Für die Sortierung in intraluminale Vesikel innerhalb 
multivesikulärer Körper (‚multivesicular bodies‘, MVBs) ist eine Ubiquitinierung von 
PLD3 erforderlich. Nach der Fusion von MVBs mit Lysosomen wird dann proteolytisch 
die luminale Domäne von PLD3 abgespalten, welche ihre enzymatische Funktion in den 
Lysosomen ausübt. 
Während dieses Projektes wurde PLD3 als lysosomale saure 5‘ Exonuklease mit Spezifität 
für einzelsträngige Nukleinsäuren in Immunzellen identifiziert. Es konnte gezeigt 
werden, dass PLD3 vorwiegend im Gehirn exprimiert wird, wobei die höchste Expression 
im Hippokampus und in der Großhirnrinde nachweisbar ist. Weiterhin wurde der 
Nachweis erbracht, dass Pld3 die primäre 5'-Exonuklease im Gehirn von Mäusen ist. In 
Gehirnlysaten von Pld3-Knockout (KO) -Mäusen wurde nur geringe5'-Exonuklease-
Aktivität beobachtet. 
Pld3-KO-Mäuse zeigten keine cerebelläre Dysfunktion, was darauf hindeutet, dass eine 
zuvor beschriebene PLD3-Mutation nicht ursächlich für eine spinocerebelläre Ataxie ist. 
In Pld3 KO-Mäusen zeigten sich neben einem Depressions-ähnlichem Verhalten, 
Mikroglia-Veränderungen im Gyrus dentatus des Hippocampus und der 
subventrikulären Zone, beides Bereiche der adulten Neurogenese. Dies lässt auf eine 
wichtige Rolle von PLD3 bei der neuronalen Homöostase schließen, was möglicherweise 
den Beginn und den Verlauf der LOAD beeinflusst. Pld3-KO-Mäuse wurden mit dem 
 XI 
 
5xFAD Alzheimer-Mausmodell gekreuzt. Obwohl Pld3 in Amyloid-Plaques angereichert 
war, wurden bei 5xFAD Pld3-/- Mäusen keine offensichtlichen Änderungen der APP-
Protein-Spiegel oder APP proteolytischen Spaltprodukte beobachtet, was auf eine 
komplexere Rolle von PLD3 in der Ätiologie der Alzheimer Erkrankung hindeutet. 
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1  INTRODUCTION 
1.1 Lysosomes	
Lysosomes were first described in 1955 by Christian de Duve. These ubiquitous 
organelles are considered the cell’s degradation center primarily responsible for the 
breakdown of various macromolecules (Bainton, 1981; Barrett, 1980; De Duve et al., 
1955; Wartosch et al., 2015). Lysosomes mediate the degradation of extracellular 
substrates obtained through endocytosis and phagocytosis and of intracellular 
components from autophagy (Bonifacino, 2004; Dell’Angelica et al., 2000). The digestion 
of the macromolecules occurs in the lumen of lysosomes, catalyzed by a cocktail of more 
than 50 hydrolytic enzymes with characteristic acidic pH-optima (Saftig and 
Klumperman, 2009; Winchester, 2001). The lysosomal membrane separates this potent 
catalytic activity from the cytosol (Lübke et al., 2009). Around 25 lysosomal membrane 
proteins (LMPs) have been extensively characterized. However, proteomics analyses 
have identified around 300 lysosomal membrane candidates which might be involved in 
lysosomal function (Callahan et al., 2009; Chapel et al., 2013; Schröder et al., 2007). 
Although lysosomes are considered the digestive system of the cell, increasing evidence 
suggest that LMPs play essential roles in a number of cellular events linked to processes 
occurring along the endocytic and biosynthetic pathways, ranging from autophagy, 
phagocytosis, plasma membrane repair, pathogen defense and cell signaling (Saftig and 
Klumperman, 2009; Schwake et al., 2013). Moreover, proper transport and delivery of 
lysosomal hydrolases and lysosomal membrane proteins is pivotal to regulate lysosomal 
distribution and size, ion homeostasis, membrane potential, catabolite export and 
sensing nutrient availability (Xu and Ren, 2015).  
Newly synthesized lysosomal hydrolases and lysosomal membrane proteins are 
transported throughout the secretory and endocytic pathway following specific and 
regulated pathways. Defects in degradation, export or trafficking results in lysosomal 
dysfunction underlying the pathogenesis of many lysosomal storage disorders (LSDs) 
and other metabolic disorders (Shen et al., 2012; Slaugenhaupt, 2002; Stauber and 
Jentsch, 2013).  
1. Introduction 2 
 
 
 Transport	of	lysosomal	membrane	proteins	
The great majority of lysosomal membrane proteins (LMPs) are highly glycosylated. This 
post-translational modification is important to preserve their own stability and the 
integrity of the lysosome (Schwake et al., 2013). The lysosomal associated membrane 
proteins LAMP-1 and LAMP-2 are heavily glycosylated at their luminal domain, 
containing 19 and 16 potential N-glycosylation sites, respectively (Carlsson et al., 1988; 
Chen et al., 1988; Fukuda et al., 1988). These glycoproteins represent ~50 % of all 
proteins of the lysosomal membrane (Marsh et al., 1987). Two major pathways have been 
described for the transport of LMPs to lysosomes, referred as the “direct” and the 
“indirect” pathway (Figure 1A). After synthesis in the endoplasmic reticulum (ER), LMPs 
can follow the constitutive “indirect” transport from the trans Golgi network (TGN) to the 
plasma membrane, followed by internalization into early endosomes (EE) and further 
delivery to late endosomes and lysosomes (Braulke and Bonifacino, 2009; Janvier and 
Bonifacino, 2005). Alternatively, in the “direct” pathway LMPs can be transported 
directly from the TGN to either early or late endosomes to finally reach lysosomes 
(Carlsson and Fukuda, 1992; Harter and Mellman, 1992). 
Both sorting pathways are mediated by the specific interaction of cytosolic adaptor 
protein complexes that recognize peptide motifs in the cytosolic domain of 
transmembrane proteins. Two major sorting signals consisting of short, linear arrays of 
amino acid residues have been described (Bonifacino and Traub, 2003). Tyrosine-based 
sorting signals, formed by the NPXY or YXXØ consensus motifs (where Ø correspond to 
any amino acid), are recognized by the heterotetrameric adaptor protein (AP) complexes 
AP-1, AP-2, AP-3 and AP-4. On the other hand, dileucine-based sorting signals, formed by 
the [DE]XXXL[LI] or DXXLL consensus motifs, are recognized by another family of 
adaptors known as Golgi-localized, gamma-ear containing, ADP-ribosylation factor 
binding proteins (GGAs) (Braulke and Bonifacino, 2009).  
Depending on the cargo protein, sorting of LMPs is initiated by its interaction with AP-
1/AP-3 with chlatrin or GGA-clathrin complexes. This facilitates the exit of the complex 
from the TGN to the plasma membrane or directly to early or late endodomes (Figure 1A) 
(Janvier and Bonifacino, 2005). The contribution of each transport pathway depends on 
the cell type (Peden et al., 2004), the type of cargo protein and its expression level 
1. Introduction 3 
 
 
(Carlsson and Fukuda, 1992; Groux-Degroote et al., 2008; Janvier and Bonifacino, 2005) 
and the cellular conditions. 
Members of the LAMP family, as well as members of the lysosomal integral membrane 
proteins (LIMPs), are typical examples of LMPs transported via the direct pathway 
through the interaction of AP/clathrin complexes (Harter and Mellman, 1992; Lippincott-
Schwartz and Fambrough, 1987). However, transport of these proteins via the indirect 
pathway has been reported as a salvage route for a small population of molecules that are 
not correctly sorted from the TGN to endosomes (Harter and Mellman, 1992). On the 
other hand, transport of the lysosomal acid phosphatase (LAP), is a well-described 
example of proteins sorted via the indirect pathway (Braun et al., 1989). LAP is 
transported from the TGN to the cell surface, followed by several cycles of endocytosis 
and recycling, dependent on AP-2 (Obermüller et al., 2002; Peters et al., 1990). In each 
cycle, LAP is sorted to lysosomes where proteolytic processing releases a soluble form 
(Peters et al., 1990).  
A very different mechanism of sorting to lysosomes has been reported for the lysosomal 
transmembrane protein LAPTM5. This protein contains three L/PPXY motifs that bind 
the ubiquitin ligase Nedd4 and GGA-3, both acting as lysosomal targeting adaptors (Pak 
et al., 2006).  
 
 Transport	of	soluble	lysosomal	proteins	
Lysosomes are composed of several acid hydrolases responsible for the breakdown of 
proteins, polysaccharides, complex lipids, nucleic acids, etc., into their respective building 
blocks: amino acids (AAs), monosaccharides, free fatty acids and nucleotides (Huotari 
and Helenius, 2011; Luzio et al., 2007). The well characterized mannose 6-phosphate 
receptor (M6PR) pathway mediates the transport of most lysosomal hydrolases. 
However, alternative M6PR-independent pathways have been described (Figure 1B). 
Once in late endosomes/lysosomes, several hydrolases undergo proteolytic processing 
dependent on the presence of lysosomal endopeptidases. For some hydrolases this 
proteolytic cleavage is associated with conversion to active and stable forms. However, 
for many hydrolases, processing does not affect their hydrolytic activity (Ishidoh and 
Kominami, 2002; Roberts, 2005).  
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Figure	1	|	Schematic	representation	of	lysosomal	protein	sorting	pathways.	A, lysosomal membrane 
proteins (LMPs) can be sorted to lysosomes via a “direct” (black arrows) or “indirect” (red arrows) 
pathway. In the “direct” pathway, proteins are directly transported from the trans Golgi network (TGN) to 
early (EE) or late (LE) endosomes in a clathrin/AP-1-AP-2-dependent manner. In the “indirect” pathway, 
LMPs are first transported to the plasma membrane, followed by clathrin-AP-2-dependent endocytosis and 
further sorting to late endosomes/lysosomes. B,	lysosomal hydrolases can be transported via the mannose 
6-phosphate receptor (M6PR) –dependent or –independent pathway. In the first pathway, mannose 6-
phosphate (M6P)-modified hydrolases are recognized by the M6PR in the TGN and transported to EE via 
clathrin-GGA-AP-1-containing vesicles. Invagination of the limiting membrane of endosomes leads to the 
formation of multivesicular bodies (MVBs) containing intraluminal vesicles (ILVs). Due to the acidic pH of 
lysosomes (~4.5-5), M6P-modified hydrolases are released in the lumen of lysosomes and M6PR are 
recycled back for further rounds of transport. Transport of β-glucocerebrosidase (β-GC) is a typical 
example of a M6PR-independent pathway. In the TGN, β-GC is recognized by its receptor (LIMP-2) following 
a similar route along the endocytic pathway to reach lysosomes. In contrast to M6PRs, LIMP-2 ends up as 
a component of the limiting membrane of lysosomes, following the described “direct” pathway of LMPs.  
  
1.1.2.1 Mannose	6‐phosphate	receptor‐dependent	transport	
Soluble lysosomal proteins are synthesized in the ER as precursor polypeptides. In this 
compartment, asparagine (Asn)-linked oligosaccharides (N‐glycosylation) undergo 
extensive processing necessary for protein folding, oligomerization, quality control, 
sorting and transport (Helenius and Aebi, 2001; Ruddock and Molinari, 2006). Upon 
arrival in the Golgi, oligosaccharide chains of lysosomal enzymes are either trimmed and 
modified resulting in complex-type sugars, or selected mannose residues are modified 
with phosphate groups (Braulke and Bonifacino, 2009). The attached mannose 6-
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phosphate (M6P) tag is catalyzed by the sequential action of two enzymes: (1) N-
acetylglucosaminyl-1-phosphotransferase (GlcNac-1- phosphotransferase), which 
transfers GlcNac-1-phosphate to hydroxyl groups of mannose residues (Lazzarino and 
Gabel, 1989), and (2) N-acetylglucosamine-1-phosphodiester alpha N-acetyl-
glucosaminidase (known as “uncovering” enzyme, UCE), which removes a covering N‐
acetylglucosamine (GlcNac) from the M6P recognition marker on lysosomal hydrolases 
(Kornfeld et al., 1999; Rohrer and Kornfeld, 2001). The M6P residues of lysosomal 
enzymes are then recognized by ubiquitously expressed M6P-receptors (M6PR) in the 
TGN (Figure 1B) (Kornfeld and Mellman, 1989; von Figura and Hasilik, 1986). After 
endosome-mediated transport of the M6PR-ligand complex, due to the low pH in these 
organelles (<5.5), the complex dissociates and hydrolases are released into the 
endosomal lumen (van Meel and Klumperman, 2008). MPRs recycle to the TGN for 
further rounds of transport. Several proteins are decorated with M6P residues, but no 
lysosomal function or localization has been assigned, making them candidates for 
lysosomal storage diseases of unknown etiology (Della Valle et al., 2006; Sleat et al., 
2006).   
 
1.1.2.2 Mannose‐6‐phosphate	receptor‐independent	transport	
Patients with I-cell disease (mucolipidosis type II) are defective in GlcNac-1-
phosphotransferase, thus some lysosomal hydrolases do not acquire M6P tags (Hasilik et 
al., 1981; Waheed et al., 1982). Nevertheless, analysis of I-cell diseased cells, such as 
hepatocytes, Kupffer cells and lymphocytes, and tissues of these patients showed normal 
lysosomal enzyme levels in many organs. Similar observation were observed in GlcNac 
phosphotransferase-knockout mice and mice deficient of both MPRs (Dittmer et al., 1999; 
S. Kornfeld, 2001). Increasing number of studies have reported different M6P-
independent transport routes of lysosomal proteins, as well as the identification of 
alternative receptors to lysosomes (Braulke and Bonifacino, 2009). An example of such 
receptor is sortilin, which mediates lysosomal trafficking of prosaposin and acid 
sphingomyelinase (Körner et al., 1994; Rosorius et al., 1993). Another M6PR-
independent pathway is the sorting of β-glucocerebosidase (β-GC). Its transport to 
lysosomes is dependent on the direct interaction with the integral membrane protein 
LIMP-2 (Figure 1B) (Reczek et al., 2007).   
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 Protein	transport	pathways	to	the	yeast	vacuole	
S.	cerevisiae	 is one of the most studied and best characterized yeast species, sharing a 
complex intracellular organization with higher eukaryotes. Proteins synthesized in the 
Golgi apparatus are either sorted to the plasma membrane, secreted  or targeted to the 
vacuole (the yeast equivalent of the lysosome) (Bonifacino and Glick, 2004; Feyder et al., 
2015; Novick et al., 1981). Protein sorting to the vacuole can occur via endosomes 
(vacuolar sorting pathway or CPY pathway) or directly (alkaline phosphatase or ALP 
pathway). Specific sorting to the vacuoles via the ALP pathway requires the function of 
the AP-3 adaptor protein (Cowles et al., 1997; Stepp et al., 1997). AP-3 binds to an acidic 
di-leucine sorting signal found in the cytoplasmic tail of the cargo proteins (Darsow et al., 
1998; Honing et al., 1998) and directs these cargoes into Golgi-derived vesicles that are 
then transported to the vacuole (Rehling et al., 1999). The CPY pathway transports 
different vacuolar proteins, either membrane-bound as the CPS (carboxypeptidase S) or 
soluble as the CPY (carboxypeptidase Y) pro-protease (Feyder et al., 2015).  
CPS- and CPY-containing vesicles are transported to endosomes where they fuse and 
liberate CPS to the endosomal membrane and CPY into the lumen (Bonifacino and Glick, 
2004; Novick et al., 1981). CPS transport to vacuoles (Figure 2) requires ubiquitination 
as a sorting signal for the ESCRT (endosomal sorting complexes required for transport) 
machinery (see section 1.2), which will cluster CPS into invaginated endosomal 
membranes and pinching off vesicles for the formation of multivesicular bodies (MVBs). 
Fusion of the MVBs with the vacuole releases their content. This process is dependent on 
the phosphatidylinositol(3)-P 5-kinase activity of the Fab1p, highlighting the significant 
role of phosphoinositides in the regulation of protein trafficking (Odorizzi et al., 1998; 
Reggiori and Pelham, 2001). An equivalent for the CPS pathway in mammals has yet not 
been identified.  
 
 
 
▼Figure	 2	 |	 Schematic	 representation	 of	 carboxypeptidase	 S	 (CPS)	 biogenesis. In yeast, protein 
vacuolar sorting from the Golgi can occur via endosomes (CPY pathway) or directly to the vacuole (ALP 
pathway, red arrow). An example of the CPY pathway (black arrows) is the transport of the 
carboxypeptidase S (CPS) protein. In early endosomes, precursor CPS is ubiquitinated for sorting transport 
into multivesicular bodies (MVBs). Fusion of MVBs with the vacuole releases a mature form of CPS into the 
lumen of the vacuole.  
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1.2 The	ESCRT	pathway	
The endosomal sorting complexes required for transport (ESCRT) assemble into a 
multisubunit machinery that performs a topologically unique membrane bending and 
scission reaction away of the cytoplasm, leading to the biogenesis of multivesicular 
bodies (MVBs) (Figure 3) (Gruenberg and Stenmark, 2004; Hurley, 2008; Piper and 
Katzmann, 2007; Wollert et al., 2009). MVBs are formed at early endosomes by the 
inward budding of the limiting membrane into the lumen. The resulting intraluminal 
vesicles (ILVs) can carry cytoplasmic proteins in temporary storage or serve as a device 
to deliver the entire protein to the lysosomes for degradation (Piper and Katzmann, 
2007).  
The ESCRT machinery consists of five protein complexes ESCRT-0, ESCRT-I, ESCRT-II, 
ESCRT-III and Vps4-Vta1 (Hurley, 2008; Saksena et al., 2009; Williams and Urbé, 2007). 
ESCRT-0, ESCRT-I, ESCRT-II and Vps4-Vta1 are soluble complexes that cycle between 
cytosolic and membrane-bound states. By contrast, the subunits of ESCRT-III are soluble 
monomers that assemble in membranes into tightly bound filaments, tubes and spirals 
that can only be released by the ATP-dependent action of Vps4-Vta1 (Ghazi-Tabatabai et 
al., 2008; Hanson et al., 2008; Lata et al., 2008; Wollert et al., 2009a).  
Ubiquitination is the molecular signal that designates cargo for the ESCRT pathway for 
lysosomal degradation. The ESCRT proteins interact with ubiquitinated receptors and 
other ubiquitinated cargo through various motifs, including the ubiquitin interacting 
motif (UIM) and the double-sided ubiquitin-interacting motif (DUIM) of the yeast and 
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human Hrs subunits of ESCRT-0 (Hurley, 2008; Williams and Urbé, 2007). The complexes 
of the ESCRT machinery were first characterized in yeast through the analysis of vacuolar 
protein sorting (vps) mutants which could no longer transport proteins to the vacuoles 
(Wollert et al., 2009a). Biochemical characterization of these mutants first resulted in the 
identification of ESCRT-I complex (Katzmann et al., 2001) and subsequently defined the 
ESCRT-II and ESCRT-III complexes (Babst et al., 2002a; Babst et al., 2002b). These studies 
were preceded by the identification of the AAA (ATPase associated with various cellular 
activities) ATPase Vps4 in 1997, which disassembles the ESCRT complexes from 
endosomes for delivery of cargo to the vacuoles/MVBs and recycles them back to the 
cytoplasm to maintain the function of the MVB pathway (Figure 3) (Hurley, 2008; 
Stuchell-Brereton et al., 2007).  
 
 
Figure	3	|	Scheme	of	ubiquitin‐dependent	sorting	of	proteins	by	the	ESCRT	machinery. The different 
ESCRT complexes are sequentially recruited at the limiting membrane of endosomes for the recognition 
and sorting of ubiquitin-modified transmembrane proteins (gray oval). The Vps4-Vta1 complex is 
responsible for the disassembly of the ESCRT complexes and further delivery of ubiquitinated cargo to 
intraluminal vesicles (IVLs). Modified from Vingtdeux et al., 2012. 
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1.3 Lysosomal	degradation	of	intracellular	nucleic	acids	
A variety of cellular components are delivered to lysosomes or the vacuole for the 
hydrolysis of macromolecules (Fujiwara et al., 2017). This process of “self-eating” is 
called autophagy, a regulated process that involves the formation of an autophagosome 
that captures random or selective targets for degradation. Fusion of the autophagosome 
with lysosomes leads to proteolytic degradation of engulfed substrates by lysosomal 
enzymes (Axe et al., 2008; Mizushima, 2007; Saftig et al., 2008). Despite the diversity of 
hydrolases observed within the lysosome, studies on selective autophagy have been 
mainly focused on its protein-targeting machineries and less attention has been devoted 
to the degradation of other macromolecules such as nucleic acids (Dice, 2007; Johansen 
and Lamark, 2011; Sahu et al., 2011). Three kinds of autophagy have been described: 
macroautophagy, microautophagy and chaperone-mediated autophagy (CMA). In 
macroautophagy, cytosolic components are sequestered by autophagosomes and 
delivered to lysosomes by membrane fusion. In microautophagy, substrates are 
entrapped in lysosomes by invagination of the lysosomal membrane. Conversely, CMA is 
a highly selective form of autophagy where specific cytosolic proteins containing a 
KFERQ-like motif are unfolded by a chaperone complex and directly imported into 
lysosomes via a lysosomal membrane receptor, LAMP2A (Mizushima and Komatsu, 
2011).  
DNA and RNA can be selectively delivered to lysosomes/vacuoles as a component of 
larger structures such as ribosomes, mitochondria, a portion of the nucleus and RNA 
granules (Figure 4) (Fujiwara et al., 2017). Approximately 80 % of total RNA in living cells 
is ribosomal RNA (rRNA, Warner, 1999). Kraft et al. proposed a selective degradation of 
ribosomes by macroatophagy which they termed “ribophagy” (Kraft et al., 2008).  Later, 
NUFIP1 (nuclear fragile X mental retardation-interacting protein 1) was identified as a 
receptor for the selective autophagy of ribosomes (Wyant et al., 2018). Another pathway 
of DNA delivery to lysosomes is a process called “mitophagy”. As a consequence of ATP 
production, mitochondria generate large amounts of reactive oxygen species (ROS) as 
byproducts (Loschen et al., 1971). As a result, mitochondrial DNA (mtDNA) is frequently 
exposed to ROS, leading to higher DNA damage, thus elimination of damaged 
mitochondria is critical for cell survival (Yakes and Van Houten, 1997).  
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Figure	4	|	Schematic	diagram	of	selective	delivery	of	DNA	and	RNA	to	lysosomes. DNA and RNA can 
be delivered to lysosomes as a component of larger structures such as ribosomes (ribophagy), 
mitochondria (mitophagy) and a portion of the nucleus (nucleophagy). (1) Stress conditions and damage of 
cellular components activates the formation of the phagophore. Vesicle nucleation and expansion of the 
phagophore requires the recruitment of the LC3 (the microtubule-associated protein light chain 3) and Atg 
(autophagy-related protein), important for the recognition of the autophagic cargos. The resulting 
autophagosome (2) fuses with lysosomal compartments, forming the autolysosome (3). In 
RNautophagy/DNautophagy, nucleic acids are directly transported into the lumen of the lysosome via the 
interaction with receptor proteins and transporters. In all described processes, the autophagic cargo is 
degraded by lysosomal acidic hydrolases.  
 
Similar to ribosomes and mitochondria, the existence of macroautophagy in selective 
degradation of the nucleus, or “nucleophagy” has been described (Ivanov et al., 2013).  
In addition to the canonical types of autophagy, a type of autophagy that directly delivers 
RNA and DNA into lysosomes, processes termed “RNautophagy” and “DNautophagy”, 
respectively, has been tentatively described (abbreviated as RDA) (Figure 4) (Fujiwara et 
al., 2013b, 2013a). Both pathways are ATP-dependent and the lysosomal membrane 
protein LAMP2C may serve as a receptor, directly binding to nucleic acids. Additionally, 
the same group found that SIDT2, a putative nucleic acid transporter, mediates direct 
uptake of RNA and DNA by lysosomes (Aizawa et al., 2016a; Aizawa et al., 2016b). 
After translocation to the lysosomal lumen, autophagic substrates undergo degradation 
by catabolic enzymes. RNase T2 and DNase II are well-characterized lysosomal RNases 
and DNases, respectively (Fujiwara et al., 2017). RNase T2 is an endonuclease that cleaves 
single-stranded RNA into mono- or oligo-nucleotides with generally little sequence 
specificity (Deshpande and Shankar, 2002). DNase II is an endonuclease that cleaves 
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double-stranded DNA with low sequence specificity (Evans and Aguilera, 2003). 
Turnover of DNA and RNA molecules produces nucleotides that are further catabolized 
to nucleosides as catabolic end-products. Recycling of nucleosides is important for the 
‘salvage’ pathway, required for the synthesis of new nucleic acids (Möhlmann et al., 
2010). In human and mouse, ENT3 (equilibrative nucleoside transporter 3) protein 
promotes the export of nucleosides from the lysosomal lumen (Baldwin et al., 2005).  
 
1.4 Phospholipase	D	family	
The phospholipase D (PLD) lipid-signaling enzyme superfamily has long been studied for 
its role in cell communication and a wide range of cell biological processes. The most 
commonly studied PLD activity entails hydrolysis of phosphatidylcholine (PC), the most 
abundant membrane phospholipid, to yield choline and the second messenger signal lipid 
phosphatidic acid (PA) (Peng and Frohman, 2012). However, other members of this 
family, like the Vaccinia	virus protein KL4, can function as endonucleases (Huang et al., 
2011; Voigt et al., 2012). A large subset of enzymes with PLD activity share a conserved 
HxKxxxDx6GSxN motif (HKD), or a variation thereof, which is involved in mediating 
catalytic activity (Figure 5) (Koonin, 1996; Ponting and Kerr, 1996). HKD enzymes 
sharing this conserved catalytic domain have a similar structural core that contributes to 
the hydrolysis of phosphodiester bonds with a similar reaction mechanism for a range of 
substrates (Liscovitch et al., 2000; Selvy et al., 2011).  
 
 Enzymes	with	PLD	activity	
PLD family members are found in organisms ranging from viruses to bacteria, yeast, 
plants and animals (Jenkins and Frohman, 2005). In mammals, PLD1 and PLD2, two 
isoforms attached to the cytosolic leaflet of the membranes via palmitoyl anchors (Figure 
5), are responsible for the PC-hydrolyzing activity described above (Peng and Frohman, 
2012). PLD1 and PLD2, which are 50 % identical in protein sequence and have almost the 
same protein domain organization, are widely expressed in different tissues and cell 
types that are activated by a variety of signaling molecules (Colley et al., 1997; Du et al., 
2000; Jenkins and Frohman, 2005). The two HKD motifs are essential for PLD enzymatic 
activity (Sung et al., 1997), while the other consensus domains like the phox sequence 
1. Introduction 12 
 
 
(PX) and the pleckstrin homology (PH) domain (Figure 5) are lipid binding domains that 
regulate PLD subcellular localization (Du et al., 2003; Jang et al., 2012). PLD1 and PLD2 
modulate many cell signaling-driven processes, such as regulated exocytosis, 
endocytosis, Golgi-ER trafficking, proliferation, cell migration, autophagy and apoptosis 
(Brown et al., 1998; Hughes and Parker, 2001; Nelson and Frohman, 2015). PLD1 and 
PLD2 polymorphisms, as well as upregulated activity levels, have been linked to 
development of cancer, cardiovascular, neurodegenerative and infectious diseases, 
making these proteins of high interest as therapeutic targets (Frohman, 2015). 
Several viral and bacterial proteins are known to exert PLD activity. They are involved in 
a range of different processes including bacterial invasion, survival enhancement, host 
cell invasion and increased infectivity (Selvy et al., 2011). For example, a protein of the 
Vaccinia	 virus, named p37, is known to have lipase activity and PC specificity. This 
enzymatic activity is important to facilitate viral trafficking to the host cell plasma 
membrane and release at the extracellular enveloped virus (EEV) (Eckert et al., 2005; 
Hiller et al., 1981). Yersinia	pestis, an enteric Gram-negative bacterium, encodes in its 
genome the cytosolic protein Ymt which belongs to the PLD superfamily and consist of 
two HKD motifs (Ponting and Kerr, 1996). In	 vitro	 characterization of this enzyme 
revealed its capability of hydrolyzing PC, phosphatidylethanolamine (PE) and other 
phospholipids (Rudolph et al., 1999).  
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▲Figure	5	|	Domain	alignment	of	different	PLD	superfamily	enzymes.		The HKD motifs responsible of 
the PLD catalytic activity are conserved among different family members and species. PLD1 and PLD2 are 
attached to the membrane via palmitoyl anchors. PLD3, PLD4 and PLD6 contain a transmembrane domain, 
although with different topology. K4L is found in the viral core, while Nuc is localized in the cytosol of 
bacteria. aa, amino acid; PX, phox sequence, PH, pleckstrin sequence; TMD, transmembrane domain; IMS, 
mitochondrial intermembrane space.		
 
 PLD	nucleases	
Several proteins that do not act as phospholipases belong to the PLD family because they 
contain one or two HKD motifs (Figure 5). PLD6, also named MitoPLD, functions as an 
endonuclease (via phosphodiesterase action) to generate microRNAs (miRs) known as 
piwi-interacting RNAs, which are critical during spermatogenesis (Huang et al., 2011; 
Voigt et al., 2012). The genome of the Vaccinia	virus also encodes a protein named K4L, 
containing two HKD motifs (Figure 5). K4L was reported to exhibit nuclease and viral 
DNA condensation function (Eckert et al., 2005). Subsequently, the K4L gene product was 
also determined to be the previously described nick-joining enzyme (DeMasi et al., 2001; 
Reddy and Bauer, 1989). The plasmid DNA of Salmonella	typhimurium	and Escherichia	
coli encodes a protein called Nuc, an ATP-independent, non-specific endonuclease. 
Crystal structure studies revealed that Nuc contains one HKD motif that forms a 
homodimer (Figure 5) (Stuckey and Dixon, 1999). Nuc endonucleases non-specifically 
hydrolyzes internal phosphodiester bonds within the backbone of single and double-
stranded duplex DNA and RNA (in	vitro and in	vivo) in the bacterial periplasm during DNA 
conjugation (Winans and Walker, 1983).   
 
 Phospholipase	D3	(PLD3)	
The mammalian enzyme PLD3 is another member of the PLD family. The human PLD3 
gene is localized in the long arm (q) of chromosome 19 at position 13.2 (19q13.2), and it 
is expressed as a 488 amino acid protein. PLD3, also known as Hu-K4, has a type II 
transmembrane protein orientation with a short N-terminal tail of 38 amino acids 
exposed to the cytosol, and a large C-terminus with multiple predicted glycosylation sites 
(Munck et al., 2005). The C-terminus contains two HxKxxxD/E motifs, where the 
aspartate of one motif is mutated to glutamate (Figure 5).  
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PLD3 was first identified as a human homolog of the K4L protein of Vaccinia virus 
mentioned before, sharing a significant sequence homology (48 %). Yet, K4L is a 
nonessential protein in the life cycle of the virus and its viral function remains unclear. 
On the other hand p37, encoded by the same virus, shares 25 – 30 % of homology with 
PLD3, being p37 the closest relative with known function (Cao et al., 1997). The 
conservation of the HKD motifs and the high similarity between PLD3 and the proteins 
K4L and p37 suggests that these viral proteins have evolved from one or more eukaryotic 
genes that were involved in similar cellular processes (Cao et al., 1997). However, the 
closest homologues of PLD3 are found in other mammals, were the murine protein 
(denoted as SAM9) has 93 % identical amino acid residues. More distantly related 
proteins are found in Xenopus (54 %) and Drosophila (48 %).  
The mechanism of action or any type of catalytic activity exerted by PLD3 are unknown. 
Initial studies have suggested that PLD3 is localized to the ER and the secretory pathway 
(Munck et al., 2005). However, PLD3 was identified as a direct target of the CLEAR 
(Coordinated Lysosomal Expression and Regulation) gene network, together with a 
partial overlapping localization of PLD3 with lysosomes in HeLa cells (Palmieri et al., 
2011). Moreover, PLD3 was identified as a glycoprotein that may contain mannose 6-
phosphate (M6P) as a target for lysosomal delivery (Sleat et al., 2013). PLD3 has been 
also reported in granules in an insulin pancreatic β-cell line (Brunner et al., 2007). 
Additionally, PLD3 was shown to play a role in myogenesis during myotube formation, 
potentially in the events involving ER reorganization (Osisami et al., 2012).  
1.5 Alzheimer’s	disease		
Alzheimer’s disease (AD) is a chronic progressive neurodegenerative disease and 
represents the most common form of age-related dementia (Bertram and Tanzi, 2005). 
Genetically, the disease is divided into familial cases and sporadic cases. The familial form 
(~5 % of total AD cases) is due to mutations in three major genes: amyloid precursor 
protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) (Bekris et al., 2010; Varvel 
et al., 2008). In contrast, many genetic and environmental factors may contribute to 
determining the sporadic AD cases (Piaceri et al., 2013). Dementia in AD is characterized 
by progressive neurodegeneration of the central nervous system that eventually leads to 
gradual decline of cognitive functions (DeKosky and Scheff, 1990; DeKosky et al., 1996). 
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This is accompanied by the extracellular accumulation of amyloid-β (Aβ) deposits and 
intracellular aggregation of neurofibrillary tangles in the brain (Bertram and Tanzi, 
2005). Accumulation of Aβ peptide, which is derived from proteolysis of the amyloid 
precursor protein (APP), is the result of an imbalance between the levels of Aβ 
production, aggregation and clearance (Crews and Masliah, 2010). APP is proteolytically 
processed at several different subcellular sites (Chow et al., 2010; Weidemann et al., 
1989). Three major proteases, termed α-, β- and γ-secretase, are involved in these 
processing steps, which give rise to two independent pathways, the non-amyloidogenic 
and the amyloidogenic pathway (Haass, 2004). In the first pathway, sequential cleavage 
of α- and γ-secretase, release a soluble sAPPα fragment and a short P3 peptide, shown to 
have synaptotrophic and neuroprotective functions (Nikolaev et al., 2009; Turner et al., 
2003). In the amyloidogenic pathway, sequential cleavage of β- and γ-secretase, generate 
a soluble sAPPβ ectodomain and the Aβ peptide (Müller and Zheng, 2012). Both pathway 
also lead to the generation of an APP intracellular domain (AICD) which is released into 
the cytosol and it may function in intracellular signaling (Cao and Südhof, 2001; von Rotz 
et al., 2004). Aβ is then liberated and found in intracellular fluids such as plasma and 
cerebrospinal fluid (Seubert et al., 1992). APP is transported throughout the constitutive 
secretory pathway. Once it reaches the plasma membrane (PM), it is rapidly internalized 
and subsequent trafficked to endocytic and recycling organelles, transported back to the 
PM or retrogradely to the TGN. A small fraction is also degraded in lysosomes (Haass et 
al., 2012). 
 
 PLD3	and	Alzheimer’s	disease	
PLD3 is highly expressed in the brain, including mature neurons of the forebrain, 
hippocampus and cortex (Cruchaga et al., 2014; Hawrylycz et al., 2012; Lein et al., 2007). 
Rare coding variants in the PLD3 gene have been associated with late onset AD in 14 
families of European ancestry and African Americans (Cruchaga et al., 2014). More 
specifically, a putative loss-of-function polymorphism (V232M) was proposed to increase 
the secretion of the amyloid peptide (Aβ), hence increasing the risk of late-onset AD 
development. In addition, PLD3 was found to interact with APP after transfection of both 
plasmids in HEK293T cells (Cruchaga et al., 2014). PLD3 protein expression is 
downregulated in AD brains (Kong et al., 2009; Satoh et al., 2014) and in cortical 
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membrane lipid rafts prepared from the 3xTgAD murine model of AD (Chadwick et al., 
2010). Notably, PLD3 was found to be constitutively expressed in cortical neurons, 
hippocampal pyramidal granular neurons but not in microglia. A high accumulation of 
PLD3 immunoreactivity was also observed in neuritic plaques of AD brains (Satoh et al., 
2014). Other groups were not able to successfully reproduce the genetic association of 
PLD3 polymorphisms with late-onset AD (Heilmann et al., 2015; Hooli et al., 2015; van 
der Lee et al., 2015). Moreover, loss-of-function of Pld3 in the background of an AD mouse 
model (Appki	Pld3ko), did not show any alterations on APP expression and processing 
(Fazzari et al., 2017). Thus, the genetic link between PLD3 and AD is still under debate. 
 
1.6 PLD3	and	spinocerebellar	ataxia	
Autosomal dominant cerebellar ataxias (ADCA) are hereditary neurodegenerative 
disorders that are known as spinocerebellar ataxias (SCA) in genetic nomenclature 
(Schöls et al., 2004). The term SCA has been used to denote recessive and sporadic 
disorders characterized from patients that suffer from coordination, loss of balance, gait 
abnormalities and slurred speech (Durr, 2010; Klockgether, 2011). In 2017, Nibbeling et 
al., through a combination of exome sequencing in genetically undiagnosed families, 
reported PLD3 as a novel ataxia gene, more specifically, they identified the PLD3 variant 
p.Leu308Pro (Nibbeling et al., 2017). Further cell-based analysis suggested that this 
overexpressed PLD3 variant localized to the endoplasmic reticulum (ER). However, no 
alterations on protein stability were observed. Moreover, Nibbeling et al. reported that 
the PLD3 L308P variant led to a reduction of phospholipase D activity, based on a 
colorimetric assay. These results proposed a role of PLD3	in the etiology of SCA. 
 
1.7 Aim	of	the	study	
Lysosomes are the main organelles responsible of the catabolism of a number of 
macromolecules. Several studies support an increasing emergence of undescribed 
lysosomal hydrolases and lysosomal membrane proteins. The phospholipase D3 (PLD3) 
protein has been identified as a type II transmembrane protein mainly localized in the 
endoplasmic reticulum. However, independent proteomic analyses suggested that PLD3 
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is a lysosomal protein. An aim of the present study was to perform a detailed biochemical 
and cell biological characterization of PLD3 with a special focus on its subcellular 
localization, intracellular transport, post-translational modifications and intracellular 
proteolytic cleavage. Another objective of this thesis was to analyze PLD3 expression in	
vivo in different organs and cell types. To investigate how the absence of PLD3 affects the 
physiology of the mouse, a phenotype analysis of a Pld3-deficient mouse model was 
performed. Due to the linkage of PLD3 variants with the development of late-onset 
Alzheimer’s disease (AD), the influence of in	vivo	PLD3 deletion, especially on the brain 
phenotype, should be evaluated. Since PLD3 downregulation was found to promote 
increased amyloid-β release, the effect of Pld3 deficiency on APP proteolysis in the 
background of the 5xFAD AD mouse model was also investigated. 
PLD3 is part of the phospholipase superfamily because it contains two HKD motifs. 
However, no canonical PLD activity or substrate has been specified. Interestingly, during 
the course of this project, PLD3 and PLD4 were described to have 5’-exonuclease in the 
spleen responsible of cleaving single-stranded DNA  (Gavin et al., 2018). We hypothesized 
that this nuclease activity might be tissue-specific, thus a thorough in	vitro	and in	vivo	
description of PLD3 nuclease activity was performed.  
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2 MATERIAL AND METHODS  
2.1 Material	
 Laboratory	chemicals	
The chemicals not listed on Table 1 were purchased with the purity grade pro	analysi	(p.a.)	
from the firma Carl Roth. 
 
Table	1.	List	of	laboratory	chemicals	
 
Chemical	 Reference	 
DABCO Sigma-Aldrich 
DAPI Sigma-Aldrich 
Glutaraldehyde Merck 
LE Agarose Biozym 
Mowiol 4-88 Calbiochem 
NP-40 Calbiochem 
Triton X-100 Sigma-Aldrich 
 
 Frequently	used	solutions	and	buffers	
LB medium 
 1 % (w/v) Trypton / Pepton  
 0.5 % (w/v) Yeast extract 
 1 % (w/v) NaCl 
 pH 7.0 
LB agar 
1.5 % (w/v) Agar-agar 
In LB medium 
0.1 M Phosphate buffer (PB) 
 84 mM Na2HPO4 
 16 mM KH2PO4 
 pH 7.2 – 7.4  
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10X Phosphate-buffered saline (PBS) 
 100 mM Na2HPO4 
 18 mM KH2PO4 
 1.37 M NaCl 
 27 mM KCl 
 pH 6.8 
10X Tris-buffered saline (TBS) 
 200 mM Tris/HCl pH 7.0 
 1.5 M NaCl 
Mounting solution 
 1x PBS pH 7.4 
 17 % (w/v) Mowiol 4-88 
 33 % (v/v) Glycerol 
 20 mg/ml 1,4-Diazabicyclo-[2.2.2]-octane (DABCO) 
 
 Reagents,	solutions,	media	and	buffers	
Table	2.	List	of	reagents,	solutions,	media	and	buffers	
 
Name	 Reference	
5x Phusion HF/GC Buffer Thermo Fisher Scientific 
6x DNA Loading Dye Thermo Fisher Scientific 
10 x DreamTaq Buffer Thermo Fisher Scientific 
Albumin Fraction V Roth 
Bafilomycin A1 Sigma-Aldrich 
B-27TM Supplement (50X), serum free Thermo Fisher Scientific 
Bovine serum albumin (BSA)  Carl Roth 
Brefeldin A Sigma-Aldrich 
Chloroquine Sigma-Aldrich 
DirectPCR® Lysis Reagent (Mouse Tail) Viagen Biotech 
Dynabeads Protein G Thermo Fisher Scientific 
cOmpleteTM Protease Inhibitor Cocktail Roche 
DNaseI  Roche 
dNTP Mix, 10 mM each Thermo Fisher Scientific 
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Dulbecco´s Modified Eagle Medium (DMEM) Gibco 
DMEM (with D-Glucose and Sodium Pyruvate) Gibco 
DMEM/F-12, HEPES Gibco 
E64D Enzo 
Endoglycosidase H Roche 
Fetal bovine serum (FBS) Biochrom 
GlutaMAXTM Supplement Thermo Fisher Scientific 
Glutathione Sepharose 4B Thermo Fisher Scientific 
GW4869 Sigma-Aldrich 
Hank´s Balanced Salt Solution (HBSS) Gibco 
INTERFERin® siRNA transfection reagent Polyplus  
Ketamine 10 %  Bremer Pharma 
Leupeptin  Enzo 
NeurobasalTM-A Medium Thermo Fisher Scientific 
N-glycosidase F Roche 
Silencer® Select Pre-designed siRNA  Life Thecnologies  
Penicillin/Streptomycin  Thermo Fisher Scientific 
Pepstatin A Enzo 
PMSF Sigma-Aldrich 
Polyethylenimin Max (PEI) Polysciences 
Poly-L-Lysine Sigma-Aldrich 
Rompun 2 % Bayer 
Sodium Pyruvate (100 mM) Thermo Fisher Scientific 
SYBRTM Gold Nucleic Acid Gel Stain Thermo Fisher Scientific 
Trypsin/EDTA Sigma-Aldrich  
Wortmannin Sigma-Aldrich 
 
 Cell	lines	
Table	3.	List	of	cell	lines	
 
Cell	line	 Description	
HeLa	 Human cervical cancer cell line  
Pld3	KO	HeLa	 PLD3-deficient human cervical cancer cells  
Neuro2a	 Mouse neuroblastoma cell line 
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SH‐SY5Y	 Human neuroblast-like subclone  
MEF	 Mouse embryonic fibroblasts  
BV‐2	 Mouse microglia cell line 
 
 Transgenic	mouse	lines	
Table	4.	List	of	transgenic	mouse	lines	
 
Mouse	strain	 Mouse	strain	(full	name)	 Source	 Refererence	
Pld3 KO Pld3tm1e(EUCOMM)Wtsi EUCOMM Skarnes et al., 
2011 
5XFAD  B6SJL-Tg  
(APPSwFlLon,PSEN1*M146L*L286
V) 6799Vas/Mmjax 
The Jackson Lab Oakley et al., 2006 
TLR9 Tlr9‐/‐	
	
Dr. Shizuo Akira 
and Dr. Melanie 
Brinkmann 
Hemmi et al., 2000 
 
 Bacterial	strains		
Amplification of plasmid DNA was conducted using the Escherichia	coli XL1-blue strain 
(Agilent Technology). 
Genotype: recA1	endA1	gyrA96	thi‐1	hsdR17	supE44	relA1	lac [F ́ proAB	lacIqZΔM15 Tn10 
(Tetr)]. 
 
 Antibodies	
Table	5.	List	of	primary	antibodies	
 
Antigen	 Clonality	 Host	 Dilution	 Reference	
APP (22C11) Monoclonal Mouse 1:5000 (WB) eBioscience 
APP (A8717) Polyclonal Rabbit 1:1000 (WB) Sigma-Aldrich 
APP (6E10) Monoclonal Mouse 1:500 (IHC) BioLegend 
β-glucocerebrosidase Monoclonal - 1:100 (WB) Johannes Aerts 
Bace1 (D10E5) Monoclonal Rabbit 1:1000 (WB) Cell Signaling 
Cathesin D - Rabbit 1:200 (IF) 
1:1000 (WB) 
Andrej Hasilik 
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CD68 (FA 11) - Rat 1:500 (IHC) BioLegend 
Doublecortin Polyclonal Goat 1:50 (IHC) Santa Cruz  
EEA1 Monoclonal Rabbit 1:100 (IF) Cell Signaling 
GAPDH (FL-335) Polyclonal Rabbit 1:5000 (WB) Santa Cruz  
GFAP (G-A-5) Monoclonal Mouse 1:500 (IF, IHC) Sigma-Aldrich 
GFP (D5.1) Monoclonal Rabbit 1:500 (IF) 
1:1000 (WB) 
Cell Signaling 
GST (P1A12) Monoclonal Mouse 1:500 (WB) Hybridoma Bank 
HA (3F10) Monoclonal Rat 1:1000 (WB) Roche 
Hrs (A-5) Monoclonal Mouse 1:500 (WB) Enzo Life Science 
Iba1 (GTX100042) Polyclonal Rabbit 1:500 (IHC) GeneTex 
Ki67 Monoclonal Rat 1:300 (IHC) eBioscience 
LAMP1 - Mouse 1:500 (EM) Pharmingen 
LAMP1 (1D4B) Monoclonal Rat 1:500 (IF, IHC) 
1:100 (WB) 
Hybridoma Bank 
LAMP2 (H4B4) Monoclonal Mouse 1:500 (IF, IHC) 
1:100 (WB) 
Hybridoma Bank 
LBPA (6C4) - Mouse 1:50 Jean Gruenberg 
MAP2 (HM-2) Monoclonal Mouse 1:500 (IHC) Sigma-Aldrich 
Myc (9B11) Monoclonal Mouse 1:1000 (WB) Cell Signaling 
NeuN (MAB377) Monoclonal Mouse 1:200 (IF) Merck 
Pld3 (N-term) Polyclonal Rabbit 1:500 (IF) 
1:3000 (WB) 
Pineda Service 
Pld3 (HPA012800) Polyclonal Rabbit 1:400 (IF) 
1:300 (WB) 
Sigma-Aldrich 
     EM: electron microscopy, IF: immunofluorescence, IHC: immunohistochemistry, WB: Western blot 
	
Table	6.	List	of	secondary	antibodies	
 
Antigen	 Coupled	to	 Host	 Dilution	 Reference	
Anti-mouse Horseradish-
Peroxidase 
Goat 1:10000 Dianova 
Anti-rabbit Goat 
Anti-rat Goat 
Anti-mouse AlexaFluor® 
488, 594, 647 
Goat/donkey 1:500 Cell Signaling 
Technology Anti-rabbit Goat 
Anti-rat Goat 
Anti-rabbit Protein A gold - 1:500 G. Posthuma, 
University 
Medical 
Center Utrecht 
Anti-mouse 
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 Protein	and	DNA	standards	
Table	7.	List	of	protein	and	DNA	standards	
 
Name	 Reference	
PageRulerTM Prestained Protein Ladder Thermo Fisher Scientific 
GeneRulerTM Ultra Low Range DNA Ladder Thermo Fisher Scientific 
GeneRulerTM 100 pb Plus DNA Ladder Thermo Fisher Scientific 
Albumin Standard  Thermo Fisher Scientific 
 
 Enzymes	
Table	8.	List	of	enzymes	
 
DreamTaqTM	DNA	Polymerase	 Thermo	Fisher	Scientific	
Phusion DNA Polymerase Thermo Fisher Scientific 
DreamTaq DNA Polymerse Thermo Fisher Scientific 
Proteinase K Roche 
DpnI Thermo Fisher Scientific 
HindIII Thermo Fisher Scientific 
XbaI Thermo Fisher Scientific 
 
 
 Substrates	for	lysosomal	enzyme	activity	
Table	9.	List	of	artificial	substrates	for	lysosomal	enzyme	activity	
 
Substrate	 Enzyme	 Reference	
p-nitrophenyl-N-acetyl-β-D-glucosaminide β-hexosaminidase Sigma-Aldrich 
2-nitrophenyl-β-D-glucopyranoside β-glucocerebrosidase Sigma-Aldrich 
p-nitrophenyl-α-D-glucoronidase β-glucuronidase Sigma-Aldrich 
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 Plasmids	
Table	10.	List	of	plasmids	
	
Plasmid	 Resistance	 Reference		
pcDNATM3.1/Hygro(+) Ampicillin Huang, Morielli and Peralta, 1993 
pEGFP-C1 Kanamycin T. T. Yang et al., 1988 
pCMV  Ampicillin Matsuda T, Cepko CL 2004 
pFrog Ampicilin - 
pCMV-Cas9-GFP Kanamycin Sigma-Aldrich 
 
	
Table	11.	List	of	expression	constructs	
	
Construct	 Vector	 Reference	
Dynamin-WT pCR3.1 Juan Bonifacino & Stephan Storch 
Dynamin-K44A pCR3.1 Juan Bonifacino & Stephan Storch 
Hrs-GFP pEGFP-C1 Sylvie Urbe & Andreas Kallinos 
hPLD3-WT pcDNATM3.1/Hygro(+) Sebastian Jagdmann 
hPLD-K2R pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-K4R pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-M6R pcDNATM3.1/Hygro(+) Generated in this work 
hPLD3-Y7A pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-K11R pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-K30R pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-K34R pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-K35R pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-G63S pcDNATM3.1/Hygro(+) Cedric Cappel 
hPLD-P76A pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-G92A pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-L93A pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-D94A pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-F95A pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-P96A pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-N97A pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-N102A pcDNATM3.1/Hygro(+) Generated in this work 
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hPLD-N132A pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-K228R pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-V232M pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-N236A pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-N236S pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-N284A pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-N284S pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-L308P pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-N387A pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-K418R pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-E423A pcDNATM3.1/Hygro(+) Cedric Cappel 
hPLD-T426A pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-N432A pcDNATM3.1/Hygro(+) Generated in this work 
hPLD-K1-6R pcDNATM3.1/Hygro(+) Generated in this work 
Rab5-WT pFrog Michael Schwake 
Rab5-Q79L pFrog Michael Schwake 
Ubiquitin-HA pcDNATM3.1/Hygro(+) Jan Riemer 
Vps4a-WT-3XFlag pCMV Nobuyuki Tanaka 
Vps4a-E228Q-3Xflag pCMV Nobuyuki Tanaka 
Vps4a-WT-GFP pEGFP-C1 John McCullough 
Vps4a-K173Q-GFP pEGFP-C1 John McCullough 
 
 Oligonucleotides	
Table	12.	Oligonucleotides	used	for	genotyping	
 
Oligonucleotide	name	 Length	(Nt.)	 5’		3’	sequence	
Pld3 forward  19 GGGGCCTCAAGGGAGAGTC 
Pld3 WT reverse  24 CAAGCTCTCACTGAGTTCTTCTGG 
Pld3 CAS R1 20 TCGTGGTATCGTTATGCGCC 
TLR9 WT2  28 GTGGAGGGACTTTTGGCCACATTCTATA 
TLR9 extra 27 GCAATGGAAAGGACTGTCCACTTTGTG 
TLR9 Neo  27 ATCGCCTTCTATCGCCTTCTTGACGAG 
5XFAD transgene forward 20 AGGACTGACCACTCGACCAG 
5XFAD transgene reverse  19 CGGGGGTCTAGTTCTGCAT 
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5XFAD internal positive control 
forward 
24 CTAGGCCACAGAATTGAAAGATCT 
5XFAD internal positive control 
reverse 
25 GTAGGTGGAAATTCTAGCATCATCC 
 
 
Table	13.	Oligonucleotides	used	for	site	directed	mutagenesis	
 
Amino	acid	
change	position	
Length	
(nt.)	
	 5’	3’	sequence	
hPLD-K2R 
 
42 Forward ACATCAGTTTAGGCCTCATAAGCTTAAGTTTAAACGCTAGCC 
Reverse GGCTAGCGTTTAAACTTAAGCTTATGAGGCCTAAACTGATGT 
hPLD-K4R 37 Forward GCTCCTGGTACATCAGTCTAGGCTTCATAAGCTTAAG 
Reverse CTTAAGCTTATGAAGCCTAGACTGATGTACCAGGAGC 
hPLD-M6R 35 Forward CCTTCAGCTCCTGGTACCTCAGTTTAGGCTTCATA 
Reverse TATGAAGCCTAAACTGAGGTACCAGGAGCTGAAGG 
hPLD3-Y7A 38 Forward GGCACCTTCAGCTCCTGGGCCATCAGTTTAGGCTTCAT 
Reverse ATGAAGCCTAAACTGATGGCCCAGGAGCTGAAGGTGCC 
hPLD-K11R 30 Forward TGCAGGCACCCTCAGCTCCTGGTACATCAG 
Reverse CTGATGTACCAGGAGCTGAGGGTGCCTGCA 
hPLD-K30R 31 Forward CTTTTCCGCAGCCCTCCACGCCTCAATCTCA 
Reverse TGAGATTGAGGCGTGGAGGGCTGCGGAAAAG 
hPLD-K34R 29 Forward CCCAGCGGGCTTTCCTTTCCGCAGCCTTC 
Reverse GAAGGCTGCGGAAAGGAAAGCCCGCTGGG 
hPLD-K35R 30 Forward CCAGCGGGCTCTCTTTTCCGCAGCCTTCCA 
Reverse TGGAAGGCTGCGGAAAAGAGAGCCCGCTGG 
hPLD-G63S 38 Forward CAAAGAGATGCAAGTCGCTGTATTCCCATAGAAACAGC 
Reverse GCTGTTTCTATGGGAATACAGCGACTTGCATCTCTTTG 
hPLD-P76A 25 Forward GGTCATAGCAGGCGGCTGGGCGCTG 
Reverse CAGCGCCCAGCCGCCTGCTATGACC 
hPLD-G92A 27 Forward GGGGAAGTCCAGGGCCTCAGGAATGCT 
Reverse AGCATTCCTGAGGCCCTGGACTTCCCC 
hPLD-L93A 32 Forward GCATTGGGGAAGTCCGCGCCCTCAGGAATGCT 
Reverse AGCATTCCTGAGGGCGCGGACTTCCCCAATGC 
hPLD-D94A 27 Forward GGCATTGGGGAAGGCCAGGCCCTCAGG 
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Reverse CCTGAGGGCCTGGCCTTCCCCAATGCC 
hPLD-F95A 30 Forward TGGAGGCATTGGGGGCGTCCAGGCCCTCAG 
Reverse CTGAGGGCCTGGACGCCCCCAATGCCTCCA 
hPLD-P96A 27 Forward GTGGAGGCATTGGCGAAGTCCAGGCCC 
Reverse GGGCCTGGACTTCGCCAATGCCTCCAC 
hPLD-N97A 28 Forward CCCCGTGGAGGCAGCGGGGAAGTCCAGG 
Reverse CCTGGACTTCCCCGCTGCCTCCACGGGG 
hPLD-N102A 28 Forward GCTGGTGGAAGGGGCCCCCGTGGAGGCA 
Reverse TGCCTCCACGGGGGCCCCTTCCACCAGC 
hPLD-N132A 34 Forward CTGGACCCTCACCAACGCTGACACCCACACGCAG 
Reverse CTGCGTGTGGGTGTCAGCGTTGGTGAGGGTCCAG 
hPLD-K228R 27 Forward GCCCAGCTCCCTGACCTGGGTCAGTGA 
Reverse TCACTGACCCAGGTCAGGGAGCTGGGC 
hPLD-V232M 33 Forward CAGTTGTACATGACCATGCCCAGCTCCTTGACC 
Reverse GGTCAAGGAGCTGGGCATGGTCATGTACAACTG 
hPLD-N236A 32 Forward GCCAGGCAGCTGCAGGCGTACATGACCACGCC 
Reverse GGCGTGGTCATGTACGCCTGCAGCTGCCTGGC 
hPLD-N236S 29 Forward CCAGGCAGCTGCAGCTGTACATGACCACG 
Reverse CGTGGTCATGTACAGCTGCAGCTGCCTGG 
hPLD-N284A 36 Forward CCAGAGCAGGGGTTCCAGCGAGGCAGATCTCCATTG 
Reverse CAATGGAGATCTGCCTCGCTGGAACCCCTGCTCTGG 
hPLD-N284S 33 Forward CAGGGGTTCCACTGAGGCAGATCTCCATTGGTG 
Reverse CACCAATGGAGATCTGCCTCAGTGGAACCCCTG 
hPLD3-L308P 29 Forward TGAGTAGAGCCTTCGGGTCTGGAGTGCGG 
Reverse CCGCACTCCAGACCCGAAGGCTCTACTCA 
hPLD-N387A 32 Forward TCAGAGTGGGTATGGGCGTCACGCAGGGCAGC 
Reverse GCTGCCCTGCGTGACGCCCATACCCACTCTGA 
hPLD3-K418R 35 Forward GTTCAGTCACCATGTACCTGTTGTGGTTGACACGG 
Reverse CCGTGTCAACCACAACAGGTACATGGTGACTGAAC 
hPLD-E423A 33 Forward GATGTAGGTGGCGCGTGCAGTCACCATGTACTT 
Reverse AAGTACATGGTGACTGCACGCGCCACCTACATC 
hPLD-T426A 29 Forward GGTTCCGATGTAGGCGGCGCGTTCAGTCA 
Reverse TGACTGAACGCGCCGCCTACATCGGAACC 
hPLD-N432A 36 Forward AGTAGTTGCCAGACCAGGCGGAGGTTCCGATGTAGG 
Reverse CCTACATCGGAACCTCCGCCTGGTCTGGCAACTACT 
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Table	14.	Oligonucleotide	used	for	nuclease	activity	assay	
 
Name	 Length	
(Nt.)	
5’		3’	sequence	
5´-ssDNA 55 ACCATGACGTTCCTGATGCTAAGTATGCACTTCATCGTCAAGCAATGCTATG*C*A*T 
* indicates internucleotide phosphorothioate (PS) modifications 
 
 Equipment	
Table	15.	List	of	equipment		
 
Name	 Description		 Reference	
Blot Imager Odyssey FC LI-COR 
Cell culture centrifuge Universal 32  Hettich Zentrifugen 
Cell incubator HERA cell 150  Thermo Electron Corporation 
Cold centrifuge Centriguge 5415R Eppendorf 
Confocal Microscope FV1000D Olympus 
Confocal Microscope lens UPLSAPO 100x Olympus 
Electron Microscope EM902 Zeiss 
Electron Microscope camera MegaViewIII A. Tröndle, Moorenweis 
Flow Cytometer FACSAria BD Biosciences 
Gel Imager Amersham 680 GE Healthcare Life Sciences 
Gel Imager LAS 4000 GE Healthcare Life Sciences 
Homogenizer - B. Braun 
Light microscope LEICA DMi8 Leica 
Light microscope camera DFC7000T Leica 
Microplate reader Synergy HT BioTek 
Orbital shaker - Edmund Bühler 
PCR machine FlexyCycler2 analytic jena 
Perfusion pump 11 Plus Harvard Apparatus 
SDS-PAGE chamber - BIO-RAD 
Sliding microtome SM 2000R Leica 
Sonifier Branson 450 Emerson Industrial Automation 
Table centrifuge Centrifuge 5424 Eppendorf 
Thermo block TherMixer F1.5 Eppendorf 
Ultracentrifuge  OptimaTM LE-89IL Beckmann 
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Ultracentrifuge OptimaTM TLX Beckmann 
UV transilluminator UV-Systeme Intas® 
Water bath (37 °C) - GFL® 
 
 
 Software	
Table	16.	List	of	software	
	
Software		 Version		 Reference	
FV10-ASW Version 4.2 Olympus 
GraphPad Prism Version 7.04 GraphPad Software Inc.  
ImageJ (Fiji) Version 1.8.0_66 Wayne Rasband / BioVoxxel 
Odyssey Image Studio Version 4.0 LI-COR 
 
 Other	material			
Table	17.	List	of	consumables	
 
Name	 Reference	
Carbon-Formvar-coated nickel grids  Science Services GmbH, Germany 
C-chip disposable hemocytometer NanoEntek 
Cell culture plates and dishes  SARTEDT  
Cell scraper SARTEDT 
Cryogenic freezing tubes  SARTEDT 
Falcon tubes SARTEDT 
Needles (20G & 26G) Fine-Ject 
Microscope Cover Glasses 13 mm Asistent 
Nitrocellulose membrane  GE Healthcare Life Sciences 
Pasteur pipettes Assistant 
Scalpel B. Braun 
Serological pipettes  SARTEDT 
Syringe B. Braun 
Whatman blotting paper GE Healthcare Life Sciences 
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2.2 Molecular	biology	methods	
 Commercial	kits	
Table	18.	List	of	commercial	kits	
 
Name	 Reference	
ECL AdvancedTM Western Blotting Detection Kit GE Healthcare 
GeneJET Plasmid Miniprep Kit Thermo Fisher Scientific 
PierceTM BCA Protein Assay Kit Thermo Fisher Scientific 
Pure YieldTM Plasmid Midiprep System   Promega 
HighPure PCR Product Purification Kit?? Roche 
  
 Site	directed	mutagenesis	
In order to address the effect of different point mutations, amino acid changes were 
generated by site directed mutagenesis. Primer sequences were design using the online 
QuickChange Primer Design tool from Agilent. With the PLD3 WT sequence as a template, 
a Polymerase Change Reaction (PCR) was performed by mixing 1x GC or HF buffer, 6.4 
µM dNTPs, 3% DMSO, 0.2 µM forward and reverse primers, 10 ng plasmid DNA and 0.02 
units of Phusion Polymerase in a total reaction volume of 50 µl. The PCR program was set 
as: (1) 5 min of initiation at 98 °C, (2) 30 s of denaturation at 98 °C, (3) 30 s of annealing 
at 68 °C, (4) 2000 bp/min of elongation at 72 °C and (5) a final elongation of 10 min at 72 
°C; steps 2 to 4 were repeated 35 times. The PCR product was further incubated with 1 µl 
DpnI enzyme (10 U/µl) for 1 h at 37 °C to digest the parental methylated DNA, which does 
not contain the newly introduced mutation.  Further, a transformation was performed by 
incubating 5 µl of the digested PCR product with 50 µl chemo-competent E. coli XL1 blue 
bacteria for 20 min on ice, followed by a heat shock for 45 s at 42 °C. The bacteria/PCR 
product mixture was then incubated with 300 µl LB-media without antibiotics for 1 h at 
37 °C, shaking at 125 rpm. The bacteria suspension was spun down for 1 min at 8000 rpm 
at room temperature (RT), 200 µl of the media was discarded and the pellet was 
resuspended with the remaining volume and plated on a LB-agar plate containing 
ampicillin (50 µg/ml) and incubated upside-down overnight at 37 °C. For further 
purpose, the plate was stored at 4 °C.  
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 Isolation	of	plasmid	DNA	(MiniPrep)	
A single colony was inoculated in 3 ml LB-media containing ampicillin (100 µg/ml) and 
incubated overnight at 37 °C in a rotor. Isolation of plasmid DNA was done following the 
manufacture´s protocol (GeneJET Plasmid MiniPrep Kit, Thermo Fischer Scientific). 
Plasmid DNA concentration was measured (section 2.2.4) and sent for sequencing 
(Eurofins Genomic). 
 
 Determination	of	nucleic	acid	concentration	
DNA concentration was measured photometrically (Synergy HT, BioTek) in a microplate 
reader. The maximal absorption of nucleic acids is 260 nm. An absorbance of 1.0 reflects 
a concentration of 50 ng/µl of double stranded DNA and a concentration of 40 ng/µl for 
RNA. An absorbance of 280 nm was used to measure the purity of the nucleic acid 
preparation with respect to protein contaminants; a A260/280 ratio should range 
between 1.7 and 2.0.  
 
 Purification	of	plasmid	DNA	
In order to obtain higher concentrations of the plasmid DNA, chemo-competent E. coli 
XL1 blue bacteria were transformed as described in section 2.2.1. Instead, the bacteria-
plasmid mixture was inoculated in 200 ml of LB-media containing ampicillin (50 µg/ml) 
and incubated overnight at 37 °C. The plasmid DNA was later purified following the 
manufacture´s protocol described by the PureYieldTM Plasmid Midiprep System 
(Promega). Nucleic acid concentration was measured as described in section 2.2.4. 
 
 Agarose	gel	electrophoresis		
50x Tris-acetate-EDTA (TAE) buffer 
2 M Tris/HCl pH 8.0 
5.5 % (v/v) acetic acid 
50 mM EDTA  
For the visualization and separation of DNA, an agarose gel electrophoresis was 
performed. Hence, nucleic acid samples where mix with 6x DNA loading dye (Thermo 
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Fisher Scientific) to adjust the sample density and track the migration during the 
electrophoresis. Agarose gels were cast in 1x TAE buffer with a final concentration 
between 1 % and 3 % (w/v) and 500 ng/ml ethidium bromide. Separation was done by 
using a voltage of 120 V. The length of the separated products was compared with a 
standard DNA ladder (GeneRulerTM 100 pb Plus DNA Ladder, Thermo Scientific). 
Detection of DNA was achieved using UV light (λ = 312 nm) and documented with a Gel 
Jet Imager (Intas®). 
 
2.3 Cell	biology	methods		
 Maintenance	of	cell	lines	 	
Culture medium 
 DMEM (containing 4 mM L-glutamine and 4.5 g/l D-glucose) 
 10 % (v/v) FBS 
 1x Penicillin/Streptomycin 
All cell lines used during this study were kept at 37 °C in a humidified atmosphere at 5 % 
(v/v) CO2. Handling of cells and sterile material was always performed under a laminar 
flow clean bench. HeLa, Neuro-2a (N2a) and MEF cells were cultivated in fresh culture	
medium and maintained by two passages per week at 100 % confluency. Where indicated, 
SH-SY5Y cell were differentiated to neuronal-like cells with 20 mM retinoic acid for 4 
days. Medium including retinoic acid was changed every two days. Therefore, cells were 
rinsed once with phosphate-buffered saline (PBS) and incubated with 1 ml trypsin/EDTA 
(0.5 mg/ml – 0.22 mg/ml in PBS) for 3 min at 37 °C for cell detach. Cells were dissociated 
in fresh medium by pipetting several times up and down and seeded onto new culture 
dishes in a dilution between 1:5 and 1:30 depending on the cell type and cell growth.  
 Cryo‐preservation	of	cell	lines		
Freezing medium 
 DMEM (containing 4 mM L-glutamine and 4.5 g/l D-glucose) 
 20 % (v/v) FBS 
 10 % DMSO  
All cell lines were cryo-preserved on liquid nitrogen. Accordingly, cultured cells with 
confluence between 60 – 80 % were first detach with trypsin/EDTA (section 2.3.1), 
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resuspended in fresh medium and transferred into a 15 ml Falcon tube for further 
centrifugation at 800 rpm for 5 min at RT. The supernatant was removed and cell pellet 
was resuspended in 1ml freezing	medium and pipetted into cryogenic freezing tubes. 
Tubes were frozen at -80 °C and for longer storage cells were kept on a liquid nitrogen 
container at -196 °C.  
 
 Transient	transfection	of	cells	with	Polyethylenimine	(PEI)	
For the evaluation of transient gene expression, cells were transfected with 
polyethylenimine (PEI). Therefore, cells must have an approximate confluency of 60 – 
80% at the moment of transfection. An incubation was performed for 20 min at RT by 
mixing 300 µl DMEM medium without any additive, 1 mg/ml PEI (3 µl / µg of DNA) and 
plasmid DNA. The complete mixture was added to the cells containing fresh culture 
medium and incubated at 37 °C for up to 5 h. Culture medium was changed again and cell 
harvesting (section 2.5.1) was performed 24 h or 48 h post-transfection.  
 
 siRNA	transfection	
Transfection of siRNA (Thermo Fisher Scientific) was performed with Interferin (VWR). 
Briefly, 5 nM siRNA was mixed with DMEM without additive and Interferin, incubated for 
20 min at RT and added to the cells. The specific amount of transfection reagents are 
listed on Table 19. After 48 h, a second siRNA transfection was performed and 24 h 
afterwards cells were further analyzed by immunocytochemistry (ICC, section 2.3.9) or 
harvested (section 2.5.1). 
 
 
Table	19.	siRNA	transfection	volumes	per	dish/well	
 
 6‐well	plate	 6	cm	dish	
DMEM only 200 µl 400 µl 
siRNA  5 nM (5,5 µl) 5 nM (11 µl) 
Interferin 5 µl 10 µl 
Medium total 2 ml 4 ml 
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 Generation	of	stable	PLD3	knockout	cell	line	(CRISPR‐Cas9)	
FACS buffer 
PBS 
0.5% (w/v) BSA 
2 mM EDTA 
Generation of Pld3	 knockout (KO) in HeLa cells was performed by CRISPR-Cas9 
technology (Clustered Regularly Interspaced Short Palindromic Repeats). Cells were 
transfected with the vector U6gRNA-Cas9-2A-GFP (Sigma-Aldrich) containing the target 
site ACGCCTCAATCTCATTCATGGG, located on exon 4 of Pld3	 (Figure 6). Isolation of 
clonal cell population from transfected cells was performed by fluorescence-activated 
cell sorting (FACS) at the Institute of Immunology (University Hospital Schleswig-
Holstein), were cell pellets were resuspended in FACS	buffer filtered with a cell strainer, 
sorted in 96 well plates with a FACSAria high speed flow cytometer (BD Bioscience) and 
expanded for 2-3 weeks in culture medium supplemented with 10 % conditioned 
medium. When reaching 60% confluency, cells were passaged into a 24-well plate and 
functional testing was performed by Sanger sequencing (GATC Biotech) and Western blot 
(section 2.5.8).   
 
Figure	6	| Schematic representation of CRISPR-Cas9 plasmid for the generation of stable PLD3-deficient 
HeLa cells.  
 
 Isolation	of	mouse	embryonic	fibroblast	(MEFs)	
For the preparation of mouse embryonic fibroblasts, pregnant female mice were 
sacrificed at day E13.5 post	coitum. Embryos were placed in a Petri dish containing sterile 
PBS. The placenta and the amniotic sac of each embryo was taken out, together with the 
heart, the liver and other red organs. A washing step with PBS was performed to remove 
the blood. The head of the embryos was used for further genotyping (section 2.6.4), if 
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necessary. The remaining tissue of each embryo was incubated for 15 min at 37 °C with 
2 ml trypsin/EDTA after prior cell dissociation with the help of a scalpel. The mesh was 
resuspended and mixed with 13 ml warm culture medium (DMEM, 10 % FBS and 1x 
Penicillin/Streptomycin) and cells were centrifuged at 800 rpm for 5 min at RT. 
Supernatant was discarded and cell pellet was resuspended in 10 ml fresh culture 
medium. When cells reached a confluence of approximately 60 %, a transient transfection 
was performed with a SV40 Large T antigen plasmid as described on section 2.3.3, in 
order to immortalize the cells.  
 
 Coating	of	culture	dishes	with	Poly‐L‐Lysine	(PLL)	
A PLL stock solution (10 mg/ml) was prepared in autoclaved ddH2O, aliquoted and stored 
at -20 °C. Working solution (0.1 mg/ml) was freshly prepared in autoclaved ddH2O. The 
solution was added in the 24-well plates (for ICC experiments) or cell cultures dishes (for 
protein biochemistry) and incubated for 4 h under the bench at RT. Next, 5x washing 
steps with ddH2O were performed, DMEM/F12 medium was added and plates or culture 
dishes were kept in the incubator at 37 °C for up to 1 week for further preparation of the 
primary mix co-culture (section 2.3.8).  
 
 	Preparation	of	primary	mix	co‐culture	from	mouse	hippocampi	
Dissociation medium 
 0.025 % trypsin/EDTA in 1X HBSS 
Plating medium 
 DMEM (containing 25 mM D-Glucose and 1 mM Sodium Pyruvate) 
 1X Penicillin/Streptomycin 
 10 % FBS 
Growing medium 
 Neurobasal A 
 1X B-27TM Supplement  
 1X GlutaMAXTM Supplement  
 1 mM Sodium Pyruvate 
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For the preparation of hippocampal co-culture of neurons, microglia and astrocytes, 1-
day-old mice were used. Therefore, embryos were transferred to a Petri dish containing 
1X Hank´s Balanced Salt Solution (HBSS) placed on ice and the head was cut using a 
scissor. The head was fixed by piercing the eyes with the tips of a curved forceps and the 
skin, the skull and meninges were cut with the help of a straight forceps. The brain was 
removed and the hippocampus was isolated as described on Figure 7. Hippocampi were 
collected in a tube containing 500 µl 1X HBSS. After isolation was completed, dissociation	
medium	was added and incubated for 20 min at 37 °C mixing in between every 5 min. 
Afterwards, 2x washes with HBSS were followed and tissue were resuspended in 1 ml 
warm plating	medium.	Tissue were gently triturated using two different needles (yellow 
20G and brown 26G) with the help of a 2 ml syringe until big clumps of tissue were not 
observed (3 – 4 times each, dropwise). Cells were counted using a Neubauer chamber (C-
chip, Biochrom) and desired amount of cells (80.000 cells/ml for immunofluorescence 
analysis) were resuspended in the required volume of plating	medium. Hippocampal 
neuron suspension was plated in PLL-coated (section 2.3.7) 18 mm diameter coverslips 
placed in a 24-well-plate. Culture plates were incubated for 1 h at 37 °C and media was 
changed with growing	medium. Cells were further processed at DIV 15.  
 
 
 
 
 
 
 
 
Figure	7	|	Isolation	of	hippocampus	and	cortex. a, brain was removed by cutting the skin, the skull. b, 
brain was cut in half; c. half brain was placed with the cortex to the upper part. d, the meninges was 
removed. e, cortex was separated from the rest of the brain. f,	g	and	h, cortex was placed upside down and 
hippocampus was isolated. I	and	j, hippocampus was get rid of remaining meninges. From: (Melling and 
Westermayer, 2011). 
 
 Immunocytochemistry	(ICC)	
Semi-confluent cultures of cells grown on coverslips were fixed with 99% (v/v) p.a cold 
Methanol (Roth) or 4% (w/v) paraformaldehyde solution (PFA; Roth) for 20 min at RT. 
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Cells were permeabilized with 0.2% (w/v) Saponin (Roth) in PBS and natural 
fluorescence was reduced by adding 0.12% (w/v) Glycine (Roth) in 0.2% Saponin/PBS. 
Cells were blocked for 1 h with 10% FBS in 0.2 % Saponin/PBS. Coverslips were 
incubated overnight at 4 °C with 40 µl of the indicated primary antibody diluted in 0.2% 
Saponin/PBS. The secondary antibody (1:500 in 0.2% Saponin/PBS) coupled to Alexa-
Fluor-488/594/647 (Thermo Fisher Scientific) was added for 1 h at RT, followed by 
embedding of coverslips in 17% (w/v) Mowiol 4-88 mounting Solution (Calbiochem) 
containing 20 mg/ml DABCO (1,4-Diazabicyclo-[2.2.2]-octane; Sigma-Aldrich) and 5 
µg/ml DAPI (Sigma-Aldrich) for nuclear staining. 
 
2.4 Histological	methods	
 Fluorescence	staining	of	mouse	tissue	(Immunohistochemistry)	
Blocking solution  
0.1 M PB (phosphate buffer)  
0.5 % (v/v) Triton X-100  
4 % goat serum 
Washing buffer 
0.1 M PB 
0.25 % (v/v) Triton X-100 
Tissue sections were obtained from mice previously perfused with 4 % (w/v) PFA 
(section 2.6.5). The Sliding Microtome (Leica SM  2000 R) was pre-cooled with dry ice 
and tissue was placed on a thin layer of 5 % sucrose and further embedded with a 30 % 
sucrose solution using a brush. Tissue sections were cut in 35 µm and stored in a 24-well 
plate containing 0.1 M PB / 0.02 % (w/v) sodium azide. For antibody staining, sections 
were first incubated in blocking	solution for 2 h followed by overnight primary antibody 
incubation at 4 °C. For staining of Pld3 with the commercial C-terminal antibody, antigen 
retrieval was performed by incubation of sections in pre-heated (85 °C) sodium citrate 
buffer (10 mM, pH 8.5) for 30 min, washed 2x with 0.1 M PB (10 min each) and incubated 
overnight with primary antibody. Next, sections were washed 3x with washing	buffer (10 
min each) and incubated 2 h with Alexa-coupled secondary antibody (1:500) prepared in 
washing	buffer and protected from the light.	After the incubation time, sections were 
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washed 3x with washing	buffer	(10 min each), where the second washing step was used 
for nuclear staining with DAPI. Finally, sections were carefully transferred to a 
microscope slide and embedded with a 17 % (w/v) Mowiol mounting solution containing 
20 mg/ml DABCO.  
 
 X‐gal‐staining	of	brain	sections	
Permeabilization solution 
0.01 % Na-deoxycholate 
0.02 % NP40 in PBS 
X-gal staining solution 
 5mM K3Fe(CN)6 
 5mM K4Fe(CN)6 
 2 mM MgCl2 
 1 mg/ml X-gal in PBS 
Free floating sections (35 µm) were washed with 1x PBS and incubated for 10 min at RT 
with permeabilization	solution. Sections were further washed with 1x PBS for 10 min at 
RT and stained overnight at 37 °C with X‐gal	 staining	 solution protected from light. 
Sections were washed twice with PBS, 10 min each. Finally, brain sections were 
embedded with a 17 % (w/v) Mowiol mounting solution containing 20 mg/ml DABCO.  
 
2.5 Protein	biochemistry	methods	
 Generation	of	cell	lysates	for	protein	extraction		
Cell lysis buffer 
 1x cOmplete protease inhibitor  
 1 % (v/v) Triton X-100  
 1x PBS 
In order to prepare protein lysates from cells, a lysis was performed with a buffer 
containing the non-ionic surfactant (Triton X-100) which disrupt the lipid barrier and 
solubilize the integral membrane proteins. The corresponding culture dishes with 
transfected cells were first washed 2x with cold PBS and cells were detached with the 
help of a cell scraper and resuspended in 500 µl 1xPBS containing 1x cOmplete protease 
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inhibitor. Cells were centrifuged down at 3.000 rpm for 10 min at 4 °C. Supernatant was 
discarded and cell pellet was resuspended in 100 – 300 µl cell	lysis	buffer, sonicated 3x 20 
s and incubated on ice for 1 h. To spin down the cell debris, a centrifugation step was 
performed at 13.000 rpm for 10 min at 4 °C. The supernatant (cell lysate) was transferred 
into a new Eppendorf and protein concentration was determined (section 2.5.3). Lysates 
were kept at -20 °C for long term storage.  
 
 Preparation	of	tissue	homogenates		
Cell lysis buffer 
 1x cOmplete protease inhibitor  
 1 % (v/v) Triton X-100  
 1x TBS (tris buffered saline) 
Protein extraction from mouse tissue was achieved by homogenization. Therefore, 
organs were weighed and homogenized in 6x volumes of cell	lysis	buffer using 10 up-and-
down strokes (1.000 U/min, B. Braun), sonicated 3x 20 s and incubated on ice for 30 min 
(with vortex in between). A centrifugation step was followed at 13.000 rpm for 10 min at 
4 °C and the soluble fraction was further quantified (section 2.5.3) and analyzed by 
Western blot (section 2.5.8). 
 
 Determination	of	protein	concentration	with	a	Bicinchoninic	acid	(BCA)	assay	
Protein concentration was measured using the PierceTM BCA Protein Assay according to 
the manufacturer’s instructions. The assay relies on the formation of Cu2+-protein 
complexes under alkaline conditions, followed by the reduction of Cu2+ from the copper 
sulfate (CuSO4) to Cu1+. This reduction occurs via cysteine, tryptophan, tyrosine and 
peptide bonds. Thus, the amount of reduction is proportional to the protein amount. BCA 
will form a purple-colored complex with Cu1+ in an alkaline environment, thus providing 
a basis to monitor the reduction of Cu2+ by proteins at a wavelength of 562 nm.  Briefly, 
diluted (1:10) samples were mixed with 200 µl of the BCA assay mixture and incubated 
at 37 °C for 20 min and measured photometrically with a Synergy HT (BioTek) microplate 
reader. Sample absorption values were related to a calibration curve based on Albumin 
standard concentrations ranging from 0 to 2 mg/ml to determine the protein amount.   
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 Membrane	separation	
Lysis buffer 
 10 mM Tris pH 7,5 
 140 mM NaCl 
 250 mM sucrose 
 1x cOmplete protease inhibitor 
Cell pellets (generated as described on section 2.5.1) were resuspended in 500 µl lysis	
buffer, passed 10 times through a 27G x 3/4‘‘ gauge needle (0.4 x 20 mm, FineJet) using a 
1 ml syringe (Omnifix, B. Braun Medical Inc.) and sonicated 3x 10 s. From the cell 
suspension, 200 µl were further processed to generate the cell lysate as described above. 
The remaining 300 µl were sonicated 3x 10s and centrifuged for 1 h at 55.000 rpm at 4°C 
(Beckmann OptimaTM TLX Ultracentrifuge, rotor TLA 55) and supernatant was collected 
(soluble fraction). Same procedure was repeated by resuspension of the pellet on 200 µl 
lysis	buffer, and both soluble fractions were mixed. The pellet was resuspended in 100 µl 
lysis buffer containing 1% (v/v) Triton X-100 and 0.5 % (w/v) SDS and sonicated to 
obtain the membrane fraction. Further analysis was performed by Western blot (section 
2.5.6 and 2.5.8). 
 
 Co‐immunoprecipitation	(CO‐IP)		
EBC buffer (pH 7.4) 
 120 Mm NaCl 
 50 Mm Tris 
 0.5 & NP-40 
 1x cOmplete protease inhibitor 
After 48 h of transfection, cell pellets were resuspended in EBC	buffer at 4 °C, and cell 
lysates were generated as described above (section 2.5.1). For the IP, 800 – 1.000 mg of 
protein was incubated overnight with 1.5 mL of the indicated antibody at 4 °C. Dynabeads 
Protein G (Thermo Fisher Scientific) were blocked in 3% Albumin Fraction V (Roth) in 
EBC	buffer, and 50 mL of the magnet beads were added to the cell lysate and incubated 
for 2 h at RT. The beads were finally washed with EBC	buffer, proteins were eluted with 
Lämmli buffer, heated for 30 min at 60 °C and separated on a SDS-PAGE (section 2.5.7). 
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 Tandem	ubiquitin‐binding	entities	(TUBES)	
Cell lysis buffer  
 50 mM Tris/HCl pH 7.5 
 0.15 M NaCl 
 1 mM EDTA  
 1 % (v/v) NP-40 
 10 % (v/v) Glycerol 
 1x cOmplete protease inhibitor (added fresh) 
Resin wash buffer 
 20 mM Tris/HCl pH 8.0 
 0.15 M NaCl 
 0.1 % (v/v) Tween-20 (TBS-T) 
 1x cOmplete protease inhibitor 
Glutathione Affinity Resin (GSH beads) 
 Glutathione Sepharose 4B slurry 
For the analysis of PLD3 ubiquitination, a GST-TUBE approach was performed as 
previously described by Hjerpe et al., 2009. After 48 h of transfection (section 2.3.3), 300 
µl of cell	 lysis	buffer containing 100 mg GST-TUBE or 100 mg GST only (as a negative 
control) were added to the cells, resuspended and incubated for 30 min on ice. Cell 
suspension was centrifuged at 13.000 rpm for 10 min at 4 °C and the supernatant was 
further mixed with 100 µl slurry of glutathione	affinity	resin	and incubated overnight at 
4 °C. GSH beads were collected by centrifugation at 2.000 rpm for 5 min at 4 °C, 
supernatant (unbound fraction) was discarded and beads were washed 3x with resin	
wash	buffer	for 10 min in a rotator, collecting the beads by low centrifugation as described 
above. All liquid was carefully aspirated and beads were resuspended in 40 µl 1X Lämmli 
buffer containing 1 % (v/v) 2-Mercaptoethanol at 95 °C for 10 min and further analyzed 
by Western blot (section 2.5.8). 
 
 SDS‐polyacrylamide	gel	electrophoresis	(SDS‐PAGE)	
5x Lämmli loading buffer 
 1% (w/v) SDS  
 10 % (v/v) glycerol 
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 125 mM Tris 
 1 % 2-Mercaptoethanol  
 Bromophenol blue 
Separating gel buffer 
 1.5 M Tris/HCl pH 8.8 
 0.4 % (w/v) SDS 
Stacking gel buffer 
 0.5 M Tris/HCl pH 6.8 
 0.4 % (w/v) SDS 
10X SDS gel electrophoresis running buffer 
 0.25 M Tris 
 2M Glycine  
 1 % (w/v) SDS 
In order to perform the electrophoretic separation of proteins, cell lysates were 
previously denatured by the addition of the anionic detergent sodium dodecyl sulfate 
(SDS) to add a negative charge to the linearized proteins, which will move towards the 
positive pole through a polymer of acrylamide monomers. Therefore, 20 µg of protein 
(cell lysates) was mixed with Lämmli	loading	buffer to get a 1X final concentration and 
denatured at 95 °C for 5 min. Proteins were separated by SDS-PAGE (10 – 15 %, Table 
20) in a vertical chamber containing 1X SDS	gel	electrophoresis	running	buffer applying a 
current between 80 – 100 V (BIO-RAD). A protein ladder (PageRulerTM Prestained Protein 
Ladder, Thermo Fisher Scientific) was included next to the samples as known-size-
standards to monitor the progress of the electrophoresis and estimating the approximate 
size of separated proteins.  
 
Table	20.	Composition	of	SDS	polyacrylamide	gels	
 
  Separating	gel	 	
  10	%	 12.5	%	 15	%	 Stacking	gel	
Separating/stacking gel buffer [µl] - - - 675 
30 % (w/v) Acrylamide / 
bisacrylamide Rotiphorese Gel 
30 (37,5:1) 
[ml] 3.3 4.2 5.0 0,8 
Water [ml] 4.0 3.1 2.3 3.4 
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10 % (w/v) APS [µl] 60 60 60 30 
TEMED [µl] 30 30 30 15 
APS, ammonium persulfate 
 
 Western	blotting	and	immunodetection		
10X Transfer buffer 
 250 mM Tris 
 2 M Glycine 
 add 20 % (v/v) MeOH  
10X Tris-buffered saline (TBS) 
 200 mM Tris/HCl pH 7.0 
 1.5 M NaCl 
TBS-T 
 1X TBS 
0.1 % (w/v) Tween® 20  
Detection solution A 
0.1 M Tris/HCl pH 8.6 
0.025 % (w/v) Mowiol  
Detection solution B 
 0.11 % (w/v) p-Coumaric acid 
 In DMSO 
For the specific immunodetection of proteins via Western blot, an immunoblotting into a 
nitrocellulose membrane (GE Healthcare Life Sciences) was performed. Therefore, two 
sheets of Whatman® blotting paper, a nitrocellulose membrane, the SDS polyacrylamide 
gel and another two sheets of Whatman® blotting paper (all equilibrated in 1X transfer	
buffer) were mounted on a semi-dry transfer chamber, beginning at the anode and sealed 
with the cathode. The transfer was performed at a constant current of 1.5 mA per cm2 of 
nitrocellulose membrane for 120 min. The membranes were further probed overnight at 
4 °C with the indicated antibodies diluted in 5% (w/v) milk powder prepared in TBS‐T. 
Membranes were washed 3x with TBS‐T	(10 min each), incubated with HRP-conjugated 
secondary antibodies (1:10.000, prepared in 5% milk powder / TBS‐T) for 1 h at RT and 
washed again 3x with TBS‐T. Immunodetection of horseradish peroxidase was performed 
by mixing 100 µl of each solution provided on the ECL Advanced™ Western Blotting 
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Detection Kit (GE Healthcare Life Sciences), 1 ml detection	solution	A, 100 µl detection	
solution	B	and 3.5 µl H2O2. Image acquisition was performed with the ImageQuant LAS 
4000 Analyzer or the Amersham Imager 680 (GE Healthcare Life Sciences). Signal 
intensities were quantified with the ImageJ software (section 2.8.) 
 
 Percoll	density	gradient	centrifugation		
Buffer I 
 250 mM sucrose 
3 mM Imidazole pH 7.4 
Buffer P 
 90 % (v/v) Percoll (GE Healthcare Life Sciences) 
2.5 M sucrose 
30 mM Imidazole pH 7.4 
Subcellular fractionation of PLD3 transfected cells was performed with a 30% (v/v) 
Percoll density gradient. Cell pellet (corresponding to 10 mg total protein) was 
resuspended in 600 µl buffer	I, passed 10 times through a 27G x 3/4‘‘ gauge needle (0.4 x 
20 mm, Fine-Jet) using a 1 ml syringe (Omnifix, B. Braun Medical Inc.) and homogenate 
was centrifuged 10 min at 1000 x g. Supernatant (post-nuclear fraction; PNS) was 
transferred to a new Eppendorf tube and procedure was repeated by resuspension of 
pellet with 400 µl buffer	I. Both PNS fractions were mixed. 0.9 ml of PNS was mixed with 
1.98 ml buffer	P and 6.12 ml buffer	I, followed by centrifugation for 90 min at 18100 rpm 
(Beckman, OptimaTM LE-89K Ultracentrifuge, rotor 70TI/70.1TI). From the total 
volume, 12 fractions (750 µl each) were taken, 1% (v/v) Triton X-100 was added to each 
fraction and incubated for 30 min. Fractions were either mixed with 1X Lämmli buffer for 
Western blot analysis (section 2.5.8) or further used for measurement of β-
hexosaminidase activity (section 2.5.11). 
 
 Enzymatic	deglycosylation		
To a final volume of 10 µl, cell lysates (20 µg) were digested with 0.5% (w/v) SDS and 
0.25 M β-mercaptoethanol followed by incubation at 95 °C for 5 min. Cell lysates were 
cooled down at RT and 0.25 M Tris/HCl, 100 mM EDTA (pH 7.4), 2.5 mM Phenylmethane-
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sulphonylfluoride protein inhibitor (PMSF; Sigma-Aldrich) and either 1 unit of N-
Glycosidase F (PNGFase, Roche) or 0.05 units of Endoglycosidase H (EndoH, 
Roche) were added. Samples were incubated overnight at 37°C in an orbital shaker at 125 
rpm. The reaction was stopped by heating the samples for 5 min at 95 °C. Further analyses 
were performed by Western blot (section 2.5.8). 
 
 In	vitro	measurement	of	lysosomal	hydrolase	activity	
For the measurement of lysosomal hydrolase activity, 10 µl of brain lysate was mixed 
with 100 µl substrate solution (10 mM) listed on Table 9 and incubated for 30 min (β-
hexosaminidase) or 3 h (β-glucocerebrosidase and β-glucuronidase) at 37 °C in an orbital 
shaker (125 rpm). As a blank value, samples were incubated without substrate. The 
reaction was stopped by addition of 1000 μl 0.4 M glycine/NaOH pH 10.4. Absorbance of 
each sample was measured at 405 nm using a Synergy HT spectrometer (Biotek) and 
percentage of enzyme activity was further calculated. 
 
 Nuclease	activity	assay	
MES buffer 
 50 mM MES, pH 4.5 
 100 mM NaCl 
10X TBE buffer  
 1 M Tris 
 1 M Boric acid 
 0.02 M EDTA  
Pld3 nuclease activity was analyzed by denaturing polyacrylamide gel electrophoresis as 
previously described by Gavin et al., 2018. Therefore, 50 µg of lysate (section 2.5.1) was 
incubated with 5 µM ssDNA (Table 14) in MES buffer pH 4.5 for the indicated time at 37 
°C. Nuclease reaction was deactivated by incubation at 95 °C for 5 min and sample was 
mixed with 6X DNA loading dye. DNA was separated on a vertical chamber using a 20 % 
denaturing polyacrylamide gel in 1X Tris-Borate-EDTA (TBE	buffer)	applying a current of 
60 V for 6 h. To monitor the progress of the electrophoresis, a GeneRuler Ultra Low Range 
DNA Ladder was used. DNA gel was either incubated at RT in 1X SYBRTM Gold Nucleic 
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Acid Gel Stain for 5 min or in an Ethidium Bromide (EtBr) bath for 30 min. For EtBr 
staining, gels were visualized under UV light. For SYBR Gold staining, acquisition was 
performed with the Odyssey® FC Imaging system at 600 nm and visualized with the 
Image Studio Software (LI-COR). 
 
2.6 Animal	experimentation	
 Animal	housing		
Animal housing was established at the “Victor-Hensen-Haus” at the University of Kiel 
under the special care of animal keepers. All mice were kept in individually ventilated 
cages (IVC) to generate a pathogen free environment. The temperature of the room was 
maintained between 19 – 22 °C with a humidity of 45 – 60 % and conditions of 12 hours 
with light followed by 12 hours of darkness. Animal handling and care was performed in 
agreement with the German animal welfare law according to the guidelines of the 
Christian Albrecht University of Kiel. Experiments with mice were approved by the 
Ministry of Energy, Agriculture, Environment and Rural Areas of Schleswig Holstein 
under the reference numbers V242-4255/2018 (mice with deficient lysosomal proteins 
and proteases) and V242-18325/2016 (generation of KO lysosomal proteins in the 
5XFAD Alzheimer mouse model).  
 
 Breeding	strategies	
The Pld3-deficient mouse used for this study was purchased from the Wellcome Trust 
Sanger Institute, corresponding to the allele Pld3tm1e(EUCOMM)Wtsi. The knockout (KO) 
strategy is based in gene trap technology, by the insertion of a reporter-tagged cassette 
in intron 9 containing an artificial 5´-splice acceptor (SA) followed by an IRES:lacZ	
reporter coding for β-galactosidase (Figure 8). Splicing from the splice donor sites in the 
chromosomal gene to the splice acceptor sites in the reporter gene results in the fusion 
of Pld3 upstream exon sequences to the reporter gene, disrupting the gene function. Pld3 
KO mice were already available when this study was initiated.  
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Figure	8	| Schematic representation of the gene-trap cassette for the generation of Pld3 KO mice.  
 
 
Generation	of	5xFAD	Pld3‐/‐	mice	
The 5xFAD mouse (Tg6799 line) was purchased from The Jackson Laboratory. These 
transgenic mice overexpress mutant human APP(695) with the Swedish (K670N, 
M671L), Florida (I716V), and London (V717I) Familial Alzheimer's Disease (FAD) 
mutations along with human PS1 harboring two FAD mutations, M146L and L286V. Both 
transgenes are regulated by the mouse Thy1	promoter to dive overexpression in the brain 
(Oakley et al., 2006). Schematic representation of 5xFAD Pld3-/- is shown in Figure 9. 
 
 
Figure	9	|	Schematic representation of 5xFAD Pld3-/- mice. 
 
To maintain the breeding colony with the desired phenotype of the mice used for this 
study, a one-to-one long term mating was performed until pregnancy. After birth, the 
litters were weaned three weeks after and an ear or tail biopsy was taken for further 
genotyping (section 2.6.3). 
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 Tail	or	ear	biopsy	and	isolation	of	genomic	DNA		
For mice genotyping, either a tail or an ear biopsy was taken. Tail biopsy was collected 
between weeks 4 and 6 after birth. Ear biopsies were taken at any time point after 
weaning. The tissue was digested overnight in DirectPCR® Lysis Reagent Tail (Viagen 
Biotech) containing 0.3 mg/ml proteinase K at 55 °C and vigorous shaking. The next day, 
inactivation of proteinase K was performed at 85 °C for 45 min and debris was pelleted 
by centrifugation at 13.000 rpm for 2 min. Isolated genomic DNA was directly used for 
genotyping (section 2.6.4).  
 
 Genotyping	by	polymerase	chain	reaction	(PCR)	
In order to distinguish between the mutant and the wild-type alleles of Pld3, TLR9	and 
5xFAD, genotyping of the different mouse lines used in this study were analyzed by 
polymerase chain reaction (PCR). Therefore, isolated genomic DNA (section 2.6.3) was 
incubated with specific oligonucleotides (Table 12) and a heat-stable DNA polymerase 
(Table 21 and Table 22) and PCR product was further visualized by agarose gel 
electrophoresis (section 2.2.6).  
 
Table	21.	PCR	components	for	genotyping	determination	
 
	
	
	
 
Pld3	 µl  TLR9	 µl  5xFAD µl 
10X DreamTaqTM buffer 5  10X DreamTaqTM buffer 5  10X DreamTaqTM buffer 5 
dNTP Mix  (10 mM) 1.25  dNTP Mix  (10 mM) 1.25  dNTP Mix  (10 mM) 1 
Fw primer  (20 µM) 0.95  WT2 primer (10 µM) 0.5  Transgene fw (20 µM) 2.5 
WT rev. primer (20 µM) 0.63  Extra primer (10 µM) 0.5  Transgene rev. (20 µM) 2.5 
CAS R1 primer (20 µM) 0.63  Neo primer (10 µM) 0.5  Internal pos. control fw 1.3 
Template DNA  2  Template DNA  1  Internal pos. control rev 1.3 
DreamTaqTM (5 U/µl)  0.38  DreamTaqTM (5 U/µl)  0.38  Template DNA  3 
H2O ad 50 µl 39.2  H2O ad 50 µl 40.9  DreamTaqTM (5 U/µl)  0.33 
	   	   H2O ad 50 µl 33.2 
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Table	22.	PCR	cycle	conditions	applied	for	genotyping	
 
 
 
 Mice	perfusion	for	organ	extraction	and	euthanasia	
Mice perfusion was performed in order to rapidly and uniformly preserve the tissues in 
a life-like state. Accordingly, mice were anesthetized via intraperitoneal injection (30G, 
0.3 mm x 8 mm, BD Micro-FineTM ) with a Ketamin/Rompun mixture (10 % Ketamine and 
2 % Rompun) prepared in 0.9 % (w/v) NaCl and mice received a dosage of 10 µl per g 
body weight. Once the animal reached a surgical plane of anesthesia, an incision was done 
through the abdominal wall and further through the diaphragm to expose the pleural 
cavity. The rips were cut along the sides and the sternum was lifted away to provide a 
major view of the heart. The perfusion needle was passed through the left ventricle and 
finally and incision was made to the animal’s right atrium using a scissor. Mouse was first 
perfused with 20 ml of 0.1 M PB and further fixed with 30 ml of fresh prepared 4 % PFA 
with a rate of 5 ml/min (11 Plus, Harvard Apparatus). After proper fixation, desired 
tissues were collected and post-fixed for 4 h with 4 % PFA at RT and later stored at 4 °C. 
For fluorescence staining, tissues were incubated overnight with a 30 % sucrose solution 
at 4 °C and protocol was followed as described (section 2.4.1). For the analysis of tissue 
biochemistry, mice were sacrificed by cervical dislocation.  
 
 Behavioral	studies	
Motor coordination and equilibrium were tested on an accelerating rotarod (MED 
Associates Inc., St. Albans, Vermont, US). A training with constant speed (4 rpm, 2 min) 
was performed, followed by four 5-min trials with 10-min intertrial intervals. Rotaring 
 Pld3 	 TLR9	 	 5xFAD	
Step ° C t (s)    ° C t (s)    ° C t (s)   
Initiation	 94 180   94 180   94 180  
Denaturation	 94 30 
35 x 
 94 30 
35 x 
 94 30 
35 x Annealing	 62 40  62 40  52 60 
Extension	 72 40  72 40  72 60 
Final	extension	 72 180   72 180   72 120  
Hold		 4 ∞   4 ∞   4 ∞  
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rod was accelerated from 4 to 40 rpm in 5 min, and the time until they dropped from the 
rod was recorded. Additionally, the standard deviation of standardize drop latencies for 
each animal was calculated to evaluate the variability of performance. All behavioral 
studies were performed in collaboration with Dr. Stijn Stroobants.  
 
2.7 Microscopy	
 Confocal	and	fluorescence	microscopy	
Cell images were analyzed with an Olympus FV1000D Laser Scanning Confocal 
Microscope (Model: FV10-292-115, inverted microscope) with a 100x lens (UPLSAPO 
100x NA: 1.40) and 2.5% zoom. Acquisition was performed with the FV10-ASW 
4.2 Viewer software (Olympus Europa GmbH, Germany). Tissue images were analyzed 
with the Inverted Microscope Leica DMi8 (20x lens) and acquisition was performed with 
the LAS X Software (Leica). 
  
 Electron	microscopy		
Cells were first fixed with warm 8% paraformaldehyde (PFA) and 0.2% glutaraldehyde 
(GA, Merck KGaA) in PB solution (pH 7.4). After 5 min, fixative was replaced with 4% PFA 
and 0.1% GA solution in PB for 1 h. Cells were washed with PBS, scratched with a cell 
scraper, transferred to an Eppendorf tube and centrifuged at 1.000 rpm. Supernatant was 
replaced with 2% PFA solution. Further sample processing was performed with the 
collaboration of Michaela Schweizer at the Center of Molecular Neurobiology, University 
Medical Center Hamburg-Eppendorf. In brief, for post-embedding double immunogold-
labeling, small pieces of cryoprotected cell pellets (2.3 M sucrose) were mounted on 
specimen holders and immersed in liquid nitrogen. Ultrathin sections (70 nm) were cut 
and labeled according to Slot and Geuze, 2007. Briefly, sections were collected on Carbon-
Formvar-coated nickel grids (Science Services GmbH, Germany). Antibodies, mouse anti-
LAMP1 (Pharmingen) and rabbit anti PLD3, were detected with 15 nm and 10 nm large 
protein A gold secondary antibodies (G. Posthuma, University Medical Center Utrecht), 
respectively. Ultrathin sections (60 nm) were examined in an EM902 (Zeiss, Germany). 
Pictures were taken with a MegaViewIII digital camera (A. Tröndle, Moorenweis, 
Germany). 
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2.8 Quantification	of	Western	blot	bands	and	immunocytochemistry	
/immunohistochemistry	images	
Pearson	correlation	coefficient	(PCC)		
Co-localization analyses with different intracellular markers were quantified by Pearson 
correlation coefficient (PCC) using the Olympus FV10-ASW 4.2 Viewer software.  
Western	blot	analysis	by	densitometry	
For Western blot analyses by densitometry, the integrated density was calculated with 
ImageJ. Raw values were used for the quantification of the respective ratios of the 
proteolytic fragments, and the average of the untreated cells was set as 100% and 
represented as 1 in each independent experiment (untreated; n = 3). The ratio of the 
treated cells is shown relative to the untreated cells. 
Quantification	of	microglial/astrocytes	markers	in	brain	sections	
CD68 and GFAP intensity quantification was analyzed by Fiji, with special plugins 
provided by Dr. Jan Brocher, BioVoxxel 2017-2018. Therefore, all pictures were taken 
with the same acquisition parameters as described on section 2.7.1. Image processing 
was performed by applying the following steps: (1) The region of interest was drawn 
using the freehand selection tool, (2) >Filter Menu >Median…(radius=2 pixels), (3) 
>Process >Subtract background…(Rolling ball radius=100 pixles), (4) >Process >Enhance 
contrast…(saturated pixels=0.1 %, normalize active), (5) >Adjust Menu >Auto Threshold 
(method=Intermodes white), (6) Measure (Area, Mean). The <Area> and <Mean> output 
values were multiplied and further normalized to the wild-type.  
 
2.9 Statistical	analyses	
All experiments were repeated at least three times and data analyses were performed 
with unpaired, two-tailed t-test using the GraphPad Prism 7.04. Significant values were 
considered at p < 0.05. Values are expressed as mean ± SEM, and significance is 
designated as *p < 0.05, **p < 0.005, and ***p < 0.0001. 
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3 RESULTS	
3.1 Cellular	and	biochemical	 characterization	of	phospholipase	D3	
(PLD3)	
Due to the structural similarities with phospholipase D-related proteins, including the 
presence of two conserved HKD motifs, PLD3 has been grouped as a member of the 
phospholipase D family. PLD3 was characterized as a type II transmembrane protein 
associated with the endoplasmic reticulum (Munck et al., 2005; Osisami et al., 2012), but 
no canonical substrate has been identified. Independent genetic and proteomic 
approaches have identified PLD3 as a lysosomal protein (Sleat et al., 2008; Lübke et al., 
2009; Palmieri et al., 2011; Sleat et al., 2013). Therefore, we first aimed to make a detail 
description of PLD3 at the cellular and biochemical level. 
 PLD3	is	a	lysosomal	protein		
In order to analyze the expression and subcellular distribution of PLD3, an antibody was 
generated against an N-terminal peptide of murine PLD3 (mPLD3) encompassing the 
amino acids between position 1 and 20 (referred along the text as N-terminal specific 
PLD3 antibody, Figure 10A, upper panel). Additionally, a commercial antibody raised 
against the luminal domain of human PLD3 (hPLD3) was used (referred along the text as 
luminal specific PLD3 antibody, Figure 10A, lower panel). To check for PLD3 expression, 
HeLa cells and Neuroblastoma 2a (Neuro2a) cells were transfected with either human 
PLD3 (hPLD3) or mouse PLD3 (mPLD3)	and further analyzed by Western blot using both 
described antibodies. Untransfected cells were used as a negative control to test for 
antibody specificity (Figure 10B). With the N-terminal specific anti-PLD3 antibody, a 
signal was observed at around 70 kDa, with a double band pattern corresponding to the 
full-length (fl) protein, probably caused by different glycosylation forms. A signal with a 
lower molecular weight (~12 kDa) was detected with the same antibody (designated as 
“nt”). Using the PLD3 antibody directed against the luminal domain, a similar signal was 
observed at ~70 kDa (fl PLD3, Figure 10B). Interestingly, another PLD3-specific 
polypeptide appeared at ~50 kDa (designated as “soluble”). The same protein pattern is 
recognized with both mouse and human PLD3 as well as in both cell types. It should be 
noted that, the 12 kDa signal is slightly lower for mPLD3	compared to hPLD3 transfected 
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cells, which might be due to three amino acid changes within the N-terminal sequence 
possibly leading to a lower migration. These differential protein pattern observed with 
both antibodies suggest that PLD3 is proteolytically processed and/or modified by 
posttranslational modifications, like glycosylation.  
 
 
	
Figure	10	|	Western	blot	analysis	of	PLD3	transfected	cells. A, Schematic representation of the epitope 
binding sites of PLD3 antibodies. hPLD3, human PLD3; mPLD3, mouse PLD3. B, human and murine PLD3	
cDNA were transiently transfected in HeLa or Neuro2a cells followed by detection with the antibodies 
directed against the N-terminal and luminal domain of PLD3. Specific PLD3 signals are indicated with black 
arrowheads. * indicates nonspecific signal. fl, full-length; nt, N-terminus; TM, transmembrane domain; HKD, 
HxKxxxxD motif; Ab, antibody; AA, amino acids. GAPDH is presented as a loading control. 
 
 
 
Next, the subcellular distribution of PLD3 was analyzed. To this end, HeLa cells were 
transfected with hPLD3 and immunolabeled with both N-terminal and luminal specific 
PLD3 antibodies together with antibodies against proteins from the endoplasmic 
reticulum (KDEL), Golgi apparatus (GM130), early endosomes (EEA1), late endosomes 
(LBPA) and lysosomes (LAMP2). Quantification of co-localization was determined by 
Pearson correlation coefficient (PCC) as a degree of linear relationship between the 
localization of PLD3 and each marker (Figure 11). 
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Figure	11	|	PLD3	localizes	to	late	endosomes	and	lysosomes. HeLa cells were transiently transfected 
with hPLD3 and co-stained with the indicated PLD3 antibodies against the N-terminal and luminal domain 
of PLD3 (green) and different markers against intracellular proteins (anti-KDEL, anti-GM130, anti-EEA1, 
anti-LBPA and anti-LAMP2 antibodies, red). The nucleus was stained with DAPI (blue). Insets show 
enlarged regions of the cell. In the graphs, the Pearson correlation coefficient (PCC) was calculated for each 
PLD3 specific antibody staining and each corresponding intracellular marker. Error bars represent SEM. 
***p < 0.001; unpaired Student´s t test (n = 12). Scale bar, 10 µm.  
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Confocal images and its respective quantification (PCC) revealed only minor co-
localization of both PLD3 specific antibody staining with the endoplasmic reticulum (ER) 
and Golgi organelle markers (Figure 11). A partial co-localization with early endosomes 
(EE) was observed only with the anti-PLD3 N-terminal antibody, which was higher in 
comparison with the staining of antibody against the PLD3 luminal domain. In contrast, 
an increase in co-localization between the staining of the luminal specific anti-PLD3 
antibody and late endosomes was detected, which was even more pronounced with the 
lysosomal marker (PCC ~0,8). These results suggest that PLD3 has a differential vesicular 
distribution in subcellular compartments. While full-length and N-terminal PLD3 are 
localized to early and late endosomes, a possible soluble fraction of PLD3 is preferentially 
localized to lysosomes. 
To validate the PLD3 localization at the endogenous level, cells from the neuroblastoma 
cell line SH-SY5Y (Figure 12A) or human brain sections (Figure 12B) were stained with 
the luminal specific anti-PLD3 antibody and the lysosomal marker anti-LAMP1 antibody. 
No endogenous staining with the PLD3 specific N-terminal antibody was detected (data 
not shown). Confocal microscopy images and PCC quantification confirm that PLD3 is 
found in lysosomes under endogenous conditions (Figure 12A). Interestingly, in the 
stained cortical human brain region, PLD3 was mostly found in neuronal-like cells (in 
accordance with their cellular shape (Figure 12B).  
 
 Proteolytic	processing	of	PLD3	
3.1.2.1 PLD3	is	proteolytically	processed,	yielding	a	stable	soluble	form		
The distinctive PLD3 signal patterns observed with the different N-terminal and luminal 
specific antibodies (Figure 10B) suggest that posttranslational modifications are 
implicated. To test if the 50 kDa PLD3 signal detected with the luminal specific antibody 
correspond to a possible N-glycosylated polypeptide or if it is derived from proteolytic 
processing, lysates of hPLD3 transfected HeLa cells (Figure 13A) or mouse brain tissue 
(Figure 13B) were treated with either endoglycosidase H (EndoH), which cleaves 
asparagine-linked mannose rich oligosaccharides, or with N-glycosidase F (PNGaseF), 
which cleaves all types of N-linked (Asn-linked) glycans generated in the Golgi apparatus 
(O’Neill, 1996). 
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Figure	12	|	Endogenous	PLD3	localizes	to	lysosomes. PLD3 was co-stained endogenously in SH-SY5Y 
cells (A) and human brain (B) with the antibody against the luminal domain of PLD3 and an antibody 
against the intracellular lysosomal marker (LAMP2).  A, neuroblastoma SH-SY5Y cells were differentiated 
for 4 days with retinoic acid (20 µM) and co-stained with the luminal PLD3 antibody (red) and the 
lysosomal marker LAMP2 (green). Scale bar, 10 µm. B, immunofluorescence of human brain sections 
(cerebral cortex) shows co-localization of endogenous PLD3 (green) and LAMP2 (red). Staining of human 
brain sections was performed by Christian Bernreuther (Institute of Pathology, UKE, Hamburg, Germany). 
Pearson correlation coefficient (PCC) is shown in the graph.  
 
 
 
Western blot analyses of EndoH-treated samples revealed that only a partial shift of full-
length but not of the luminal (50 kDa) PLD3 was detected using the N-terminal specific 
anti-PLD3 antibody. In contrast, a complete shift of full-length and soluble PLD3 were 
observed in samples treated with PNGaseF, detected with both antibodies. As a positive 
control of glycosidase treatment, an antibody against β-glucocerebrosidase (β-GC) was 
used, which is known to be modified by both complex– and high– mannose– type glycans 
(Erickson et al., 1985).  This experiment led to the conclusion that the 50 kDa-form of 
PLD3 is derived from proteolytic processing and that PLD3 is mainly modified with 
complex-type glycans.  
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Figure	13	|	PLD3	is	N‐glycosylated. PLD3	transfected HeLa cells (A) and mouse brain (B) were treated 
with the glycosidases EndoH and PNGaseF followed by immunodection with both N-terminal and luminal 
specific anti-PLD3 antibodies (specific signals are shown with arrowheads). β-glucocerebrosidase (β-GC), 
known to be modified with both complex – and high – mannose – type glycans, is included as a positive 
control of glycosidase treatment. * indicates a signal derived from previous incubation with the luminal 
antibody and inefficient stripping of the membrane. GAPDH is presented as a loading control.  
 
 
 
To gain a deeper insight which positions are N-glycosylated, single PLD3 mutants were 
generated by substitution of each asparagine amino acid to alanine. Sequence analysis 
predicts 7 consensus N-glycosylation sites in the full-length PLD3 protein (N97, N102, 
N132, N236, N284, N387and N432). Accordingly, HeLa cells were transfected with either 
PLD3	WT	or with each of the single glycosylation mutants (PLD3	N97A,	PLD3	N102A,	PLD3	
N132A,	 PLD3	N236A,	 PLD3	N284A	 and PLD3	N432A). In addition, a PNGaseF treated 
sample was included as a positive control of complete glycan cleavage (Figure 14). 
Western blot analyses showed that the full-length and soluble PLD3 signals of several N-
glycosylation mutants shifted to a slightly lower molecular weight, except for the PLD3	
N102 expressing mutant. Different molecular weight signals of full-length PLD3 were also 
observed with both antibodies, suggesting that PLD3 is not only N-glycosylated at 
multiple sites, but that different combinations of N-glycosylation might occur at different 
asparagine positions (Figure 14). Of note, in a longer exposed membrane, several mutants 
showed an additional signal at ~40 kDa, peptide that also shifted with the PNGase-treated 
sample, arguing for a possible, less pronounced, alternative cleavage site for PLD3. For 
the N236 and N432A mutants, PLD3 cleavage was strongly reduced, suggesting that these 
amino acids are highly conserved and important for proper PLD3 folding and subsequent 
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proteolytic processing. It is worth mentioning that the PLD3 N-terminal peptide did not 
shift for any of the N-glycosylation mutants and neither after PNGaseF-treatment. This 
observation suggests that PLD3 cleavage occurs before amino acid 97, leading to the 
generation of an N-terminal peptide with a theoretical molecular weight of ~11 kDa.  
 
 
 
Figure	14	 |	PLD3	 is	N‐glycosylated	at	multiple	sites. Western blot analysis of HeLa cells transiently 
transfected with PLD3	WT	and different N-glycosylation mutants where the asparagine (N) amino acid was 
mutated to alanine (A). Additionally, PLD3 transfected cells were treated with PNGaseF as a positive control 
cleaving all protein glycans. Immunodetection was performed with both N-terminal and luminal specific 
anti-PLD3 antibodies (specific signals are shown with arrowheads). Open arrowheads represent possible 
alternative cleavage site of PLD3. * indicates unspecific signal. GAPDH is presented as a loading control. fl, 
full-length PLD3; sol., soluble PLD3; long exp., long exposure.  
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To investigate if the N-terminus of PLD3 is linked to the soluble domain via disulfide 
bonds, lysates of hPLD3 transfected HeLa cells were analyzed by immunoblot under 
reducing and non-reducing conditions (with/without β-mercaptoethanol, β-ME) (Figure 
15). After detection with both PLD3 specific antibodies, only a small shift of full-length 
and luminal PLD3 was observed, which might be explained by different denatured 
conformations of the protein or intramolecular disulfide bonds with or without the 
reducing agent. This experiment led to the conclusion that the N-terminal and C-terminal 
PLD3 peptides are not linked via disulfide bonds and that mostly proteases are involved 
in the generation of the PLD3 cleavage products.  
 
 
 
Figure	15	|	Reducing	conditions	do	not	affect	the	generation	of	PLD3	cleavage	products. Western blot 
analysis of PLD3	transfected HeLa cells treated with or without β-mercaptoethanol (β-ME) do not reveal 
major changes on the generation of PLD3 fragments. Arrowheads indicate the PLD3 signal with both N-
terminal and luminal anti-PLD3 specific antibodies. GAPDH is presented as a loading control.  
 
 
To address the distribution of PLD3 in more detail, hPLD3 transfected lysates of HeLa 
cells were fractionated using ultracentrifugation to separate them into a membrane and 
cytoplasmic (soluble) cell fraction. Immunoblot analyses revealed that full-length and N-
terminal PLD3, both containing the transmembrane domain, are enriched in the 
membrane fraction, but no signal of these peptides was observed in the soluble fraction 
(left panel, Figure 16). On the other hand, the immunoblot incubated with the luminal 
PLD3 specific antibody (right panel, Figure 16) shows an enrichment of soluble PLD3, 
although a smaller signal was also detected in the membrane fraction. Antibodies against 
LAMP2 and GAPDH were used as a positive control of membrane bound- and cytosolic-
proteins, respectively, indicating a suitable fractionation procedure.  
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Figure	16	|	Membrane	separation	of	PLD3	transfected	HeLa	cells. Transiently transfected PLD3	HeLa 
lysates were subjected to membrane separation by ultracentrifugation into soluble and membrane proteins 
fractions and further immunoblotted using the N-terminal (A) or luminal (B) PLD3-specfic antibodies. 
Arrowheads indicate PLD3-specific signals. GAPDH was used as a loading control and control for soluble 
proteins. LAMP2 is represented as a membrane protein control.  
 
 
These findings were corroborated by immunofluorescence analysis of HeLa cells 
transfected with hPLD3	and either myc-tagged Rab5‐WT	or Rab5‐Q79L. Cells were further 
co-stained with specific antibodies against PLD3 and antibodies against the intracellular 
membrane proteins myc (to recognize Rab5, Figure 17A) or against LAMP2 (Figure 17B). 
Rab5-Q79L represents a dominant active form of Rab5 known to impair the maturation 
of early endosomes, leading to an enlargement of endo-/lysosome-positive vesicles upon 
overexpression, allowing better to distinguish between membrane-bound and cytosolic 
protein localization (Stenmark et al., 1994). A weak co-localization between PLD3 and 
Rab5-WT was observed (Figure 17A, upper panels). In cells co-transfected with Rab5-
Q79L, PLD3 staining was mainly found in membrane-bound vesicles positive for Rab5 
(Figure 17A) and LAMP2 (Figure 17B), when labeled with the N-terminal specific PLD3 
antibody. On the other hand, labeling with the PLD3 specific luminal antibody led to a 
homogenous soluble staining within the enlarged vesicles. 
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Figure	17	|	Membrane‐bound	and	soluble	PLD3	show	different	compartmentalization	in	lysosomes. 
A,	confocal microscopy of transfected HeLa cells with PLD3	and myc-Rab5	WT	(upper panel) or the negative 
dominant Rab5 mutant myc-Rab5	Q79L (lower panel, red), followed by co-staining with the N-terminal and 
luminal PLD3-specific antibodies (green). Nuclei are stained with DAPI (blue). Inset 1: staining of 
membrane-bound PLD3 with the N-terminal specific antibody. Inset 2: additional intraluminal vesicle-like 
staining is observed with the PLD3 specific luminal antibody. For the vesicles labeled with a white line, 
profile plots are shown from a sequence of equi-spaced vertical spikes (µm) corresponding to each 
indicated antibody. F, fluorescence; a.u., arbitrary units. B	and	C, PLD3	and Rab5 co-transfected HeLa cells 
were stained using both PLD3-specific antibodies (green) and LAMP2 as a membrane-bound positive 
control (B) or CD63 as a marker of intraluminal vesicles (C). Scale bar, 10 µm. 
 
 
Of note, in addition to membrane-bound staining of PLD3 with the PLD3 specific N-
terminal antibody, a distinctive punctate staining was also detected, which is clearly 
different from that observed with the PLD3 specific luminal antibody, also shown in the 
profile plots (Figure 17A, right panel). This particular staining looks similar to 
intraluminal vesicles (ILVs), structures that are formed by membrane deformation and 
scission on the surface of endosomes (Henne et al., 2011). Indeed, after co-staining of 
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PLD3 with an anti-CD63 antibody (marker for intraluminal vesicles), a high level of co-
localization was detected (Figure 17C). Percoll density centrifugation and subsequent 
analysis of hPLD3 transfected HeLa cells confirmed the subcellular distribution of PLD3 
(Figure 18). Western blot analyses of a series of Percoll fractions reveal that soluble PLD3 
is progressively enriched in the later fractions (fractions 8 – 12), corresponding to 
lysosomal fractions, as observed by activity measurement of the β-hexosaminidase 
hydrolase (Figure 18, lower panel). Little co-fractionation was observed between the 
PLD3 luminal domain and the endoplasmic reticulum marker protein disulfide isomerase 
(PDI).  In contrast, full-length PLD3 is distributed along the different fractions (fractions 
1 – 10), except the lysosomal ones. These data suggest that membrane-bound PLD3 
(either full-length or N-terminal PLD3 fragment) and its luminal domain are differentially 
distributed in the cell.   
 
 
 
Figure	 18	 |	 PLD3	 shows	 distinct	 subcellular	 distribution	 as	 visualized	 by	 Percoll	 density	
centrifugation	experiment. PLD3-transfected HeLa cells were subjected to Percoll density centrifugation 
for organelle fractionation and further analyzed by immunoblotting using the PLD3-specific luminal 
antibody. The endoplasmic reticulum marker was detected with an antibody against PDI.  PNS, post-nuclear 
supernatant.  
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3.1.2.2 Proteolytic	processing	of	PLD3	is	mediated	by	acidic	cysteine	proteases	
To investigate in more detail the proteolytic processing of PLD3, different inhibitors 
affecting cellular sorting, acidification and proteolysis were added to the media of hPLD3‐
transfected HeLa cells and analyzed by Western blot. Further quantification of the 
luminal / full-length PLD3 ratio (Figure 19) as well as immunofluorescence analyses were 
performed (Figure 20). When applying inhibitors of intracellular trafficking like Brefeldin 
A and monensin, known to restrain the transport from endoplasmic reticulum to Golgi 
apparatus (Misumi et al., 1986) and from Golgi to early endocytic compartments 
(Tartakoff et al., 1978), respectively, a significant decrease of PLD3 cleavage products was 
observed using both PLD3-specific antibodies (Figure 19A). This result argues that 
protease cleavage occurs after PLD3 has left the ER.  
 
 
Figure	19	 |	Proteolytic	processing	of	PLD3	 is	mediated	by	acidic	cysteine	proteases. Western blot 
analysis of PLD3-transfected cells treated with different inhibitors of intracellular transport monensin and 
brefeldin A (A), inhibitors interfering with lysosomal acidification chloroquine, NH4Cl and bafilomycin (B) 
and protease inhibitors E64D, leupeptin and pepstatin A (C) followed by immunodetection with the PLD3-
specific N-terminal and luminal antibodies (specific PLD3 signal is shown with arrowheads). * indicates 
unspecific signal. GAPDH is shown as a loading control. For each inhibitor, the ratio between the luminal 
domain and the full-length (fl) PLD3 is presented after densitometric quantification (lower panel). Error 
bars represent SEM. ***p < 0.001; **p < 0.01; unpaired Student´s t test (n = 3). ns, not significant. 
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A similar effect was observed with the different inhibitors of lysosomal acidification 
chloroquine, ammonium chloride (NH4Cl) and Bafilomycin A (Poole and Ohkuma, 1981), 
indicating that an acidic environment is required for the protease(s) involved in PLD3 
cleavage, and that this process takes place in post-Golgi compartments (Figure 19B). To 
narrow down which classes of protease(s) are responsible for PLD3 cleavage, more 
specific inhibitors were used (Figure 19C). As shown by Western blot and its respective 
quantification, an effect on PLD3 proteolytic processing was only observed after addition 
of E64D, a potent cysteine protease inhibitor (Tamai et al., 1981) and leupeptin, a 
reversible and competitive  inhibitor of cysteine, serine and threonine proteases (Aoyagi 
et al., 1969; Zimmerman and Schlaepfer, 1982). No changes on PLD3 processing were 
observed with pepstatin A, an aspartate protease inhibitor (Greenbaum and Sutherland, 
1983). Interestingly, levels of the PLD3 N-terminus did not change upon incubation with 
E64D or leupeptin, suggesting that proteases of these classes are involved in the 
degradation of this short peptide. Analysis by immunofluorescence with the specified 
inhibitors revealed PLD3 retention in the ER after treatment with Brefeldin A (Figure 20). 
As expected, a decrease in the co-localization of PLD3 and LAMP2 was detected in 
Bafilomycin A-treated HeLa cells. A higher co-localization between PLD3 and LAMP2 was 
observed in cells treated with E64D (Figure 20). 
 
3.1.2.3 Degradation	of	the	PLD3	N‐terminus	is	mediated	by	Cathepsin	B	and	L		
As observed in Western blot analyses of E64D- and Leupeptin-treated HeLa cells (Figure 
19C), there seems to occur a stabilization of the PLD3 N-terminus. To further address this 
observation, brain lysates of mouse strains deficient for the most abundant cysteine 
proteases cathepsin B (CtsB), cathepsin H (CtsH), cathepsin L (CtsL), legumain and the 
aspartate protease cathepsin D (CtsD) were analyzed by immunoblot (Figure 21A). Using 
both anti-PLD3-specific antibodies for detection, a cleavage of PLD3 could still be 
observed, even in the absence of the different proteases. However, only for the mouse 
brain lysates deficient for both cathepsin B and L, a striking increase of the PLD3 N-
terminus was observed, together with a less pronounced increase of the luminal and full-
length PLD3 (Figure 21A, lower panel, arrowheads), suggesting that these proteases 
might degrade the N-terminal short peptide.  
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Figure	 20	 |	 Confocal	 images	 of	 PLD3‐transfected	 HeLa	 cells	 with	 different	 inhibitors. PLD3-
transfected cells were co-stained with the PLD3-specific N-terminal and luminal antibodies (green) and an 
antibody against the lysosomal marker LAMP2 (red) after overnight treatment with the indicated 
inhibitors. DMSO was used as a negative control. Nuclei are stained with DAPI (blue). Insets show enlarged 
regions of the cell. Scale bar, 10 µm. 
 
After transfection of hPLD3	in wild-type (WT) or CtsB-, CstL- or CtsB/L-deficient mouse 
embryonic fibroblast (MEF) cells, a cleavage of the luminal PLD3 domain was detected, 
along with an increase of the PLD3 N-terminus in CtsB/L KO MEFs. These data indicate 
that cathepsin B and L are involved in the degradation of the PLD3 N-terminus, but not in 
the initial PLD3 cleavage or luminal peptide turnover, which is more stable and resistant 
to lysosomal proteolysis.  
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Figure	21	|	Degradation	of	PLD3	N‐terminus	is	mediated	by	cathepsin	B	and	L. A, Western blot analysis 
of brain lysates of WT and mouse strains deficient for different cysteine proteases (CtsB, CtsL, CtsB/L, CtsH, 
CstD and Legumain) were immunodetected with the PLD3-specific antibodies. B,	Western blot analysis of 
wild-type (WT), cathepsin B, cathepsin L and cathepsin B/L mouse embryonic fibroblasts (MEF) 
transfected with hPLD3 followed by detection with the indicated PLD3-specific antibodies. GAPDH is 
represented as a loading control. Arrowheads shown specific PLD3 signal. * indicates unspecific signals.  
 
 Intracellular	transport	of	PLD3	
3.1.3.1 PLD3	is	partially	sorted	to	the	plasma	membrane	(PM)	before	reaching	lysosomes	
We further investigated if PLD3 is transported en route to lysosomes through the plasma 
membrane (PM). Different membrane proteins are transported through the PM mediated 
by the interaction with adaptor proteins (AP), which recognize sorting signals contained 
within the cytosolic domain of the proteins. One of the very well conserved motifs is the 
tyrosine-based sorting signals, with the consensus motif YXXΦ (Canfield et al., 1991; 
Marks et al., 1997).  
Alignment of the cytosolic tails of PLD3 homologs and LAMP1, reveal a similar tyrosine 
motif for PLD3 (Figure 22A). Therefore, a PLD3 tyrosine mutant was generated by its 
substitution to alanine at position 7. Immunoblots analyses of HeLa cells transfected with 
the hPLD3	Y7A mutant showed normal PLD3 proteolytic processing. An absence of the 
PLD3 N-terminus and a decrease of full-length PLD3 might be due to a lower binding 
strength of the antibody due to the epitope change in the very N-terminal region (Figure 
22B). Nonetheless, confocal images of the tyrosine mutant revealed an increased staining 
of PLD3 at the PM using both PLD3-specific antibodies (Figure 22C).  
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Despite of its transient appearance at the PM, PLD3 is still able to reach lysosomes, as 
revealed by its co-localization with the marker LAMP2, indicating that PLD3 is partially 
transported throughout the plasma membrane. As an indirect approach, electron 
microscopy analyses of hPLD3‐transfected HeLa cells, labeled with the luminal PLD3-
specific antibody followed by secondary antibody immunogold labeling, detected several 
gold particles at the PM (Figure 22D). These data support the idea that PLD3 is partially 
transported though the PM, but independent trafficking pathways may also be involved 
in its direct transport from the Golgi to late endosomal and lysosomal compartments.  
 
Figure	22	|	PLD3	is	partially	sorted	to	the	plasma	membrane	(PM). A, Schematic representation of the 
PLD3 protein and alignment of the N-terminal amino acids (1-20) of different orthologues of PLD3 and the 
C-terminus of LAMP1 showing the highly conserved tyrosine sorting motif (boxed). B,	western blot analysis 
of HeLa cells transfected with hPLD3	WT	 and hPLD3	 Y7A	 and further immunodetected with both N-
terminal-specific and luminal-specific PLD3 antibodies. GAPDH is presented as a loading control. C, 
immunofluorescence images of HeLa cells transfected with the PLD3	Y7A	tyrosine mutant and co-labeled 
with the indicated anti-PLD3-specific antibodies and the lysosomal marker (anti-LAMP2 antibody). Scale 
bar, 10 µm. D,	electron microscopy image showing the plasma membrane of PLD3-transfected HeLa cells 
followed by immunogold labeling with the luminal-specific PLD3 antibody (15 nm gold particles). Scale bar, 
500 nm. 
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3.1.3.2 PLD3	is	sorted	into	intraluminal	vesicles	(ILVs)	of	multivesicular	bodies	(MVBs)	in	
a	PtdIns(3)P‐dependent	manner		
Having observed that PLD3 is localized in ILV-positive vesicles upon transfection of the 
Rab5 mutant Q79L (Figure 17C), the possible sorting of PLD3 into this structures was 
analyzed. hPLD3	transfected HeLa cells were analyzed by electron microscopy using both 
PLD3-specific antibodies and co-immunolabeled with an anti-LAMP1 antibody (Figure 
23). Immunogold staining with the PLD3-specific N-terminal antibody showed 
localization of PLD3 in intraluminal vesicles (ILVs) of multivesicular bodies (MVBs, 
Figure 23, I) or at the limiting membrane of lysosomes where it co-localized with LAMP1-
positive gold particles (Figure 23, II). It is important to consider that with this antibody it 
is not possible to distinguish between the full-length PLD3 or the N-terminal peptide of 
PLD3. Gold particles stained with the PLD3 luminal-specific antibody showed similar 
localization to ILVs of MVBs (Figure 23, III), whereas most of the soluble peptide was 
found in the lumen of lysosomes (Figure 23, IV). In contrast, LAMP1 labeling was 
exclusively found at the limiting membrane of lysosomes. These data indicate that the 
full-length and the N-terminal peptide of PLD3 are localized into ILVs of MVBs, where 
possible processing might occur before the delivery of the luminal domain of PLD3 into 
lysosomes. 
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▲Figure	23	|	PLD3	is	localized	to	ILVs	of	MVBs.	Co-immunogold labeling of PLD3-transfected HeLa cells 
with the N-terminal-specific (I and II) and luminal-specific (III and IV) PLD3 antibodies (10 nm gold 
particles, white arrowheads) and LAMP1 (15 nm gold particles, black arrowheads) showing its localization 
in lysosomes and intraluminal vesicles (ILVs) of multivesicular bodies (MVBs). Scale bar, 500 nm. Electron 
microscopy images were performed in collaboration with Dr. Michaela Schweizer at the Center of 
Molecular Neurobiology (ZMNH), Hamburg.  
 
Three mechanisms have been reported regarding the sorting of proteins into ILVs: (1) 
involvement of the tetraspanin CD63 (Theos et al., 2006; van Niel et al., 2011), (2) 
utilization of the sphingolipid ceramide (Trajkovic et al., 2007) and (3) transport through 
the ESCRT pathway (Odorizzi et al., 1998; Nickerson et al., 2010). To narrow down which 
of these mechanisms is involved in the transport of PLD3 into ILVs, wild-type (WT) or 
CD63-deficient MEF cells (Schröder et al., 2009) were transfected with hPLD3 and further 
analyzed by immunofluorescence. CD63 deficiency did not abrogate the proper transport 
of PLD3 to lysosomes, as revealed by co-localization of PLD3 with an anti-LAMP1 
antibody (Figure 24). To analyze if PLD3 is transported to ILVs via the sphingolipid 
ceramide, hPLD3	transfected HeLa cells were treated with the neutral sphingomyelinase 
(nSMase) inhibitor GW4869 (Trajkovic et al., 2007). As shown by Western blot analysis 
and immunofluorescence experiments, normal processing and lysosomal localization of 
PLD3 was observed (Figure 25, A and B).  
	
	
Figure	24	|	PLD3	reaches	lysosomes	in	CD63	deficient	MEFs. Confocal images of WT (upper panel) and 
CD63-deficient (lower panel) mouse embryonic fibroblast (MEF) cells transfected with hPLD3	and further 
co-stained with the luminal-specific PLD3 antibody (green) and the lysosomal marker (anti-LAMP1 
antibody). Staining with an anti-CD68 antibody is depicted as a control of appropriate CD63 knockout. Scale 
bar, 10 µm. 
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Figure	25	|	Effect	of	the	ceramide	inhibitor	GW4869	on	the	processing	and	localization	of	PLD3. HeLa 
cells were transfected with hPLD3	and treated with the ceramide inhibitor GW4869 or DMSO as a negative 
control. A, Western blot analysis was performed using the indicated anti-PLD3 specific antibodies showing 
the respective cleavage products (arrowheads). B, confocal images of HeLa cells were generated by co-
staining with the PLD3 luminal-specific antibody (green) and the anti-LAMP2 lysosomal antibody (red). 
Scale bar, 10 µm. 
 
The third mechanism through which PLD3 may be delivered to ILVs is the ESCRT 
pathway. Four large protein complexes are involved in ESCRT sorting (ESCRT-0, ESCRT-
I, ESCRT-II and ESCRT-III; Katzmann et al., 2001; Babst et al., 2002a, 2002b). Several steps 
during this process critically depend on phosphatydilinositol 3-phosphate (PtdIns3P or 
PIP3) - and its derivative PtdIns(3,5)P2, products of the class III phosphatidylinositide 3-
kinase Vps34 (Gill et al., 2007). hPLD3 transfected HeLa cells were treated with the fungal 
metabolite Wortmannin, an inhibitor of Vps34 (Brown et al., 1995). This metabolite 
induces the swelling of vesicles and further inhibits the invagination and/or pinching off 
of ILVs. In cells treated with Wortmannin, PLD3 was exclusively found in the limiting 
membrane of endosomes and not in ILVs (Figure 26A), similar to CD63 (Figure 26B), used 
as a positive control. These results suggest that transport of PLD3 to ILVs of MVBs is 
PtdIns(3)P- and PtdIns(3,5)P2-dependent and that members of ESCRT machinery are 
involved.   
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Figure	26	|	PLD3	is	transported	to	MVBs	dependent	on	PtdIns(3)P.	A and B,	hPLD3‐transfected HeLa 
cells were treated with DMSO (negative control) or wortmannin and co-stained with the PLD3-specific 
antibodies (green) and antibodies against the lysosomal marker anti-LAMP2 (A)	or the ILV marker anti-
CD63 (B)	depicted in red. Insets of wortmannin-treated cells in A and B show enlarged vesicles with a white 
line further represented in a profile plot between fluorescence (F) in arbitrary units (a.u.) and distance 
(µm). Scale bar, 10 µm.  
A 
B 
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3.1.3.3 PLD3	transport	to	lysosomes	is	ESCRT‐dependent		
From the previous results, it can be hypothesized that PLD3 is transported to MVBs using 
the ESCRT machinery for final delivery of the luminal peptide to lysosomes. A straight 
forward approach to address this assumption is by interfering with the function of some 
key components of this machinery, either by overexpression or knock down experiments. 
Hrs plays a key role in the initiation of the MBV pathway, not only because it binds to the 
ubiquitinated cargo, but it also recruits the ESCRT-I complex (Schmidt and Teis, 2012). 
Overexpression of Hrs prevents efficient formation of ILVs, therefore preventing the 
sorting of cargo proteins to MVBs. Increased recruitment of clathrin leads to the 
formation of enlarged endosomes (Bishop et al., 2002; Urbé et al., 2003), making this Hrs 
overexpression approach suitable for the distinction between intracellular signal and 
localization at the limiting membrane of endosomes.  
Using both anti-PLD3-specific antibodies, PLD3 was found in the limiting membrane of 
endosomes when co-transfected with GFP-tagged Hrs. No obvious PLD3 staining in the 
lumen was observed (Figure 27, upper panel). Additionally, no co-localization between 
PLD3 and LAMP2 was detected, arguing for its retention in enlarged endosomes and no 
further transport to lysosomes (Figure 27, lower panel). Immunoblot analyses revealed 
that co-transfection of hPLD3 with eEGFP‐C1‐Hrs	led to decreased proteolytic cleavage of 
PLD3, shown also by quantification (Figure 28). This result is in agreement with the 
altered delivery of PLD3 to lysosomes, suggesting that cleavage takes place in a later step 
after MVB formation.  
To independently prove the contribution of the ESCRT machinery on PLD3 delivery to 
ILVs, HeLa cells were co-transfected with hPLD3 and dominant-negative forms of Vps4a, 
a AAA(+) ATPase protein required for the final step of MVB vesicle formation by 
dissociation of the ESCRT-III complex (Babst et al., 1997). Overexpression of both the 3x-
FLAG-tagged Vps4a‐E228Q and the GFP-tagged Vps4a‐K173Q led to significant reduction 
of PLD3 delivery to lysosomes (Figure 29A) and abrogated PLD3 cleavage (Figure 30). Of 
note, overexpression of the Vps4a mutants did not abolish the transport to lysosomes of 
the soluble protein cathepsin D (CtsD) (Figure 29B) and neither affected its maturation 
or proteolytic processing (Figure 30).  
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Figure	27	|	PLD3	is	retained	in	intracellular	membranes	upon	co‐expression	of	Hrs. HeLa cells were 
co-transfected with PLD3	and the ESCRT-0 member Hrs‐GFP and further co-stained with N-terminal and 
luminal anti-PLD3-specific antibodies (red) and an antibody against the lysosomal marker LAMP2 (green). 
Insets represent enlarged lysosomes. Scale bar, 10 µm.  
 
 
Figure	28	|	PLD3	processing	is	altered	upon	co‐expression	with	Hrs.	HeLa cells co-transfected with 
PLD3	and eGFP‐C1‐Hrs	were further immunoblotted and detected with the N-terminal and luminal PLD3 
specific antibodies. GFP is depicted as a positive control of transfection and GAPDH as loading control. 
Arrowheads represent PLD3 specific signals. The ratio of PLD3 luminal domain and full-length PLD3 of 
eEGFP and eEGFP-Hrs is shown in a graph after densitometric quantification. Error bars represent SEM. 
***p < 0.001; **p < 0.01; unpaired Student´s t test (n = 3). 
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Figure	 29	 |	 PLD3	 transport	 to	 lysosomes	 is	 altered	 upon	 co‐expression	 with	 Vps4a. 
Immunofluorescence analysis of HeLa cells co-transfected with PLD3 and a WT or a 3x-FLAG –tagged 
dominant negative mutant (E228Q) of the ESCRT-III member Vps4a. A,	cells were co-labeled with indicated 
anti-PLD3-specific antibodies (green) and an anti-LAMP2 lysosomal antibody (red). B,	as a control for 
normal lysosomal delivery, cells were co-stained with antibodies against cathepsin D (CtsD) and LAMP2. 
Scale bar, 10 µm. The Pearson correlation coefficient (PCC) between LAMP2 and the different transfection 
plasmids is presented in a graph. Error bars represent SEM. ***p < 0.001; **p < 0.01; unpaired Student´s t 
test (n = 12). ns, not significant.	
 
 
 
 
 
 
The effect of PLD3 proteolytic cleavage and localization was also evaluated by 
knockdown of Hrs. An almost 80 % reduction of Hrs gene expression by transient 
transfection of Hrs siRNA reduced the levels of the processed forms of PLD3 (Figure 31A 
and B). In addition, PLD3 was mostly found in the limiting membrane of vesicle-like 
structures after Hrs siRNA transfection (Figure 31C). Our data indicate that PLD3 
transport to lysosomes is ESCRT-dependent, in contrast to the conventional trafficking of 
lysosomal membrane proteins (e.g. LAMP2) or soluble enzymes (e.g. cathepsin D).   
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Figure	30	|	PLD3	processing	is	altered	upon	co‐expression	with	Vps4a. HeLa cells were co- transfected 
with PLD3 and the WT and dominant negative mutants (E228Q and K173Q) of Vps4a and further 
immunodetected with both anti-PLD3-speficic antibodies (shown with arrowheads). Antibodies against 
cathepsin D and GAPDH are depicted as positive control or loading control, respectively. The ratio of the 
luminal domain and full-length PLD3 of the different Vps4a mutants is presented as a graph after 
densitometric quantification. Error bars represent SEM. ***p < 0.001; *p < 0.1; unpaired Student´s t test (n 
= 3). 
 
 
 
3.1.3.4 Sorting	of	PLD3	into	ILVs	is	ubiquitin‐dependent							
Cargo proteins sorted via the ESCRT pathway require its prior ubiquitination. Therefore, 
PLD3 might be post-translationally modified with ubiquitin molecules covalently linked 
to the protein. A co-immunoprecipitation (CO-IP) assay by overexpression of hPLD3 with 
a hemagglutinin (HA)-tagged ubiquitin (Ub‐HA) construct was performed. Transfected 
cell lysates were incubated with the PLD3 N-terminal-specific antibody and further 
immunoblotted with a HA antibody, where a specific signal of ubiquitinated full-length 
PLD3 is observed (Figure 32A, upper panel, lane 8). As a negative control, cells were 
transfected with either Ub‐HA (lane 6) or PLD3 (lane 7) constructs alone or an isotype 
control antibody (cAb, lane 9). In all cases, no PLD3-specific signal was detected.   
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Figure	31	 |	PLD3	processing	and	 localization	is	altered	upon	Hrs	knockdown. A, PLD3-transfected 
HeLa cells were transfected with scrambled (Scr) siRNA or Hrs siRNA and analyzed by Western blot by 
immunodetection with the PLD3-specific N-terminal and luminal antibodies (shown with arrowheads). An 
anti-Hrs antibody was used as a positive control to show the Hrs knockdown. GAPDH was presented as a 
loading control. B, the graphs show the ratio of Hrs / GAPDH for the control and Hrs knockdown (left) and 
ratio of luminal domain / FL PLD3 (right) from the blots shown in A. Error bars represent SEM. ***p < 
0.001; **p < 0.01; unpaired Student´s t test (n = 3). C, immunogold labeling of siRNA-mediated knockdown 
of Hrs in PLD3-transfected cells using the luminal PLD3-specific antibody (15 nm gold particles, white 
arrowheads). Scale bar, 500 nm. Electron microscopy image was performed in collaboration with Dr. 
Michaela Schweizer at the Center of Molecular Neurobiology (ZMNH), Hamburg.  
 
 
 
 
 
To corroborate PLD3 ubiquitination, immunoprecipitation was also performed in the 
opposite direction, i.e.	by incubation of cell lysates with a HA antibody and additional 
immunodetection with the PLD3 N-terminal specific antibody. Similarly, a signal of 
ubiquitinated full-length PLD3 was detected using the anti-PLD3 specific N-terminal 
antibody (Figure 32B, lower panel, lane 8). For the control of proper transfection of 
indicated constructs, both antibodies (anti-HA and anti-PLD3 N-terminal) were used.  
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Figure	32	 |	PLD3	 is	ubiquitinated. HeLa cells transfected with PLD3	and/or ubiquitin‐HA and further 
immunoprecipitated (IP) with the N-terminal PLD3-specific antibody (A) or an anti-HA antibody (B). 
Membranes were immunoblotted with the indicated antibodies.	Lines	1	to	4, 4 % of indicated transfected 
lysates were loaded. Lines	5	to	8,	 immunoprecipitated lysates. Black arrowhead indicates the full-length 
PLD3-specific ubiquitinated signal. Open arrowheads show the signal of immunoglobulin G (IgG). cAb, 
control antibody (lane 9).  
 
 
 
PLD3 contains six lysine resides (K2, K4, K11, K30, K34, K35) which can be modified with 
a single ubiquitin (Ub) in a single lysine (mono-ubiquitination) or a single Ub on multiple 
lysines (multi-ubiquitination). These positions are conserved among different species 
(Figure 33A). To analyze which position(s) undergo ubiquitination, single lysine mutants 
were generated by substitution with an arginine residue to keep the positive charged side 
chains. Additionally, a mutant of all lysine residues (K1-6R) was generated to avoid any 
lysine conjugation of ubiquitin molecules. Following the same co-immunoprecipitation 
(CO-IP) approach, each single and full lysine mutants were co-expressed with Ub‐HA	
(Figure 33B). For all mutants, a normal PLD3 processing was observed. Interestingly, a 
3. Results 79 
 
 
slight increase of full-length PLD3 was detected for the K11R mutant, an observation that 
was consistent in independent experiments, although not significant (data not shown). 
After immunoprecipitation (IP) with the anti-HA antibody, a signal of ubiquitinated PLD3 
was observed for all mutants. However, no signal at the same molecular weight was 
detected for the K1-6R mutant, indicating that PLD3 is multi-ubiquitinated.   
 
 
 
 
Figure	33	|	PLD3	is	ubiquitinated	at	multiple	lysine	(K)	residues. A,	alignment of the PLD3 cytosolic N-
terminal sequencing (amino acids 1-38) from different species, highlighting the lysine (K) residues for 
possible ubiquitination events. B, HeLa cells were co-transfected with ubiquitin‐HA	and	PLD3	WT, PLD3	K1‐
6	(full lysine mutant) or the indicated single lysine mutants (K2R,	K4R,	K11R,	K30R,	K34R,	K35R). Cell lysates 
were analyzed by Western blot with the N-terminal and luminal PLD3-specific antibodies, either for the 
input lysates (two upper blots) or the immunoprecipitated lysate (lower blot). Black arrowheads indicate 
PLD3 specific signal. White arrowhead indicates immunoglobulin G (IgG).  
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To test for an indirect pathway of PLD3 ubiquitination, we applied the tandem-repeated 
ubiquitin-binding entities (TUBEs)-based assay. This approach is based on the generation 
of a construct with four tandem ubiquitin-associated (UBA) domains of ubiquilin 1, fused 
to glutathione S-transferase (GST; Hjerpe et al., 2009). Thus, ubiquitin-modified proteins 
will interact with higher affinity to GST-TUBE. After GST-pulldown with a Glutathione 
Sepharose resin, ubiquitinated proteins can be detected. As expected, for the hPLD3	
transfected cell lysates, a specific signal of ubiquitinated PLD3 was observed but not in 
the lane with GST-only (Figure 34A), used as a negative control, indirectly proving that 
PLD3 is post-translationally modified with ubiquitin molecules.  
 
 
 
 
Figure	34	|	PLD3	ubiquitination	is	altered	after	mutation	of	all	N‐terminal	lysine	(K)	residues.	A,	
Ubiquitination assay using tandem ubiquitin-binding entity (TUBE). HeLa cells were transfected with 
either PLD3	WT	or the full lysine mutant PLD3	K1‐6R, followed by the addition of GST or GST-TUBE. Cell 
lysates or affinity purified protein with a glutathione resin (GST) were further immunoblotted with the 
PLD3-specific luminal antibody or an anti-GST antibody as a positive control of the pulldown. B,	the ratio 
of the GST-pulldown and lysate is shown. C, electron microscopy image of HeLa cells transfected with the 
full lysine mutant PLD3	K1‐6R immunolabeled with the PLD3-specific luminal antibody coupled to 15 nm 
gold particles.  
3. Results 81 
 
 
A weaker signal was detected in the GST-pulldown of hPLD3	 K1‐6R	 transfected cell 
lysates, arguing for an abrogation of PLD3 ubiquitination (Figure 34A, GST-pulldown and 
Figure 34B). A blot with the PLD3-specific N-terminal antibody is not shown due to amino 
acid changes in the PLD3 epitope. Moreover, the full lysine mutant was still cleaved 
(Figure 34A, luminal) and found in MVBs (Figure 34C), indicating that processing does 
not depend on ubiquitination and that alternative sorting pathways than lysine 
ubiquitination are involved. Mutation of each single lysine residue only had a little effect 
on the overall PLD3 ubiquitination. Of note, an increase in full-length PLD3 (Figure 35, 
upper panel) and a slight decrease of ubiquitination (Figure 35, lower panel) was 
observed for the PLD3 K11R mutant, suggesting that this residue is a key player of PLD3 
ubiquitination, however the signal was not completely abrogated.  
Altogether, our data indicate that PLD3 is ubiquitinated and transported through the 
recruitment of the ESCRT-0 complex and formation of MVBs to finally reach lysosomes. 
 
 
 
 
Figure	 35	 |	 Lysine	 residue	 11	 (K11)	might	 be	 a	 key	 residue	 of	 PLD3	 ubiquitination.	 GST-TUBE 
pulldown of HeLa cell lysates transfected with PLD3	WT	and the single lysine mutants (K2R,	K4R,	K11R,	
K30R,	K34R,	K35R) and further analyzed by Western blot with the anti-PLD3 specific antibodies. GST only 
was used as a negative control. 
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3.2 Pld3	 expression	 in	mouse	 tissues	 and	 characterization	 of	 the	
Pld3tm1e(EUCOMM)Wtsi	mouse	model	
Having provided a detail the intracellular transport of PLD3 in cells, we wanted to further 
investigate PLD3 expression and function in	vivo. Is PLD3 expressed ubiquitously or is 
PLD3 expression tissue- and cell-type dependent? To address these question and further 
analyze possible functions, we generated a Pld3-deficient mouse strain 
(Pld3tm1e(EUCOMM)Wtsi), based on a targeted non-conditional mutant strategy (see section 
2.6.2, Material and Methods), where the lacZ-tagged allele reports expression of the 
endogenous PLD3 promoter, leading to a null allele.  
 
 Pld3	is	abundantly	expressed	in	the	brain		
Northern blot analyses have shown a strong hybridization signal for PLD3 mRNA in brain 
tissues of adult mice, but not with RNA purified from non-nervous tissues (Pedersen et 
al., 1998). In order to investigate if a similar Pld3 expression pattern occurs at the protein 
level and to validate Pld3 deficiency, different mouse tissues from wild-type (WT) and 
Pld3 knockout (KO) mice were evaluated. Western blot analysis revealed a strong Pld3-
specific signal in the mouse brain lysate at ~70 kDa (indicated with the black arrowhead, 
Figure 36). Additionally, a specific but weaker Pld3 signal was detected in the spleen, 
bone marrow (BM) and lungs. Very faint Pld3 signals were also observed in the kidney 
and the liver, but not in the heart.  
 
 
Figure	36	|	Pld3	is	highly	expressed	in	the	brain.	Cell lysates of different mouse tissues from WT (+/+) 
and Pld3-deficient mice (-/-) were analyzed by Western blot and immunodetected with the anti-Pld3-
specific N-terminal antibody. Black arrowhead represents specific full-length Pld3 signal. * indicates 
unspecific signal. GAPDH is presented as a loading control.  
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As a control for the antibody specificity and validation of Pld3 deficiency, no signal at 70 
kDa was detected in the Pld3 -/- tissue lysates (Figure 36). Fluorescence histology images 
of Pld3 expression in visceral tissues only revealed a Pld3-specific signal in the spleen, 
especially in the red pulp and in a small population of cells in the white pulp (Figure 37). 
No specific Pld3 staining was observed in the kidney, liver, lung and the heart (data not 
shown). These results indicate that Pld3 is mainly expressed in the brain, but also a 
significant expression is observed in the spleen.  
 
 
 
Figure	37	|	Pld3	is	expressed	in	the	spleen. Immunohistochemistry images of spleen of Pld3 WT (+/+) 
and Pld3 KO (-/-) sections labeled with the Pld3-specific luminal antibody. Prior to Pld3 labeling, heat-
induced antigen retrieval was performed (see section 2.4.1, Material and Methods). The main regions of the 
spleen are listed. Scale bar, 50 µm. 
 
 
 
 Pld3	is	mainly	expressed	in	the	cortex	and	hippocampus		
After comparing different tissues, Pld3 is highest expressed in the brain. Therefore, Pld3 
distribution in this organ was analyzed in more detail. The brain of WT mice was 
dissected in different regions, including the cerebellum, the medulla, the olfactory bulb, 
the hippocampus and the cerebral cortex. Western blot analysis of lysates from the main 
brain regions and further immunoblotting with the anti-PLD3-specific N-terminal 
antibody revealed that Pld3 is expressed highest in the hippocampus and the cerebral 
cortex, but at low levels in the cerebellum. Quantification of the relative Pld3 levels are 
shown in Figure 38A.  
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Figure	38	|	Pld3	is	mainly	expressed	in	the	cortex	and	the	hippocampus. A, Pld3 full-length protein 
levels of different brain regions were analyzed via Western blot by immunoblotting with the N-terminal 
specific Pld3 antibody. GAPDH is presented as a loading control. Relative PLD3 levels of independent 
biological replicates (n = 3) is shown. Values were normalized to Pld3 levels in the cerebral cortex. B, 
Immunohistochemistry images of β-galactosidase activity in the cerebral cortex, the hippocampus and the 
cerebellum, using X-gal as a colorimetric substrate. The layers of the cerebral cortex (I-VI) are labeled. CA3, 
Cornu	Ammonis	area 3; GCL, granular cell layer; PCL, Purkinje cell layer; GL, granular layer; ML, molecular 
layer.  
 
 
X-gal staining, used to detect the reporter lacZ gene expression, also confirmed this result 
(Figure 38B). In this assay, β-galactosidase cleaves X-gal into galactose and 5-bromo-4-
chloro-3-hydroxyindole; this second compound is then oxidized into 5,5’-dibromo-4,4’-
dichloro-indigo (Burn, 2012). As its name suggest, the final product is blue in color, as 
seen in Figure 38B, where X-gal staining was distributed along the cerebral cortex and 
the hippocampus, particularly in the dentate gyrus and the CA3 region. In contrast, barely 
any staining was observed in the cerebellum. Of note, within the hippocampus, Pld3 is 
predominantly expressed in cells distributed along the granular cell layer (gcl). To get a 
broader overview of the Pld3 expression within the brain, an immunofluorescence 
staining was performed. Analysis of PLD3 expression by immunofluorescence of brain 
sections showed showed an increased Pld3 immunoreactivity along the different layers 
of the cerebral cortex and in the hippocampus (Figure 39). Additionally, Pld3-specific 
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fluorescence signal was observed in sub-regions of the hypothalamus, the striatum, the 
medulla and the anterior olfactory nucleus (AON, Figure 39). The presence of Pld3 in 
these sub-regions might explain the lower Pld3 protein signal observed in the Western 
blot analysis compared to the cortex and the hippocampus (Figure 38A), probably 
derived from a sub-population of specific cell types.  
 
 
	
	
Figure	39	|	Image	stitching	of	Pld3	expression	in	the	brain. Paraffin embedded WT brain sections (9 
months old) were stained with the luminal-specific Pld3 antibody and more than 300 single fluorescence 
images were acquired to generate a full picture of the brain by stitching overlapping image tiles. A high Pld3 
expression is observed in the hippocampus and cerebral cortex. All main brain regions are named. AON, 
anterior olfactory nucleus. 
 
 
 Pld3	is	a	neuronal	protein	
The central nervous system (CNS) contains a large variety of cell types, each with a unique 
morphology, physiology and function (Lein et al., 2007). Within the CNS, the two main 
types of cells are neurons and glia cells. Within the neuronal population, it has been 
reported that 50 – 250 neuronal sub-cell types exist (Ascoli et al., 2007; Kandel et al., 
2012; Dimou and Götz, 2014). On the other hand, glia cells make up about 90 % of cells 
within the CNS. Astrocytes, oligodendrocytes and microglia are the major cell types. 
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Considering the cell morphology, immunohistochemistry images of human brain sections 
suggests that Pld3 is expressed mainly in neurons (Figure 12A). To confirm this 
observation, mouse brain sections were co-stained with the luminal Pld3-specific 
antibody and a neuronal nuclear marker (anti-NeuN antibody). Fluorescence images of 
Pld3-stained brain regions with the highest immunoreactivity (hippocampus and cortex) 
revealed that Pld3 is expressed in NeuN positive cells (Figure 40). Within the 
hippocampus, Pld3 is mostly concentrated in cells of the Striatum Pyramidale (CA3 
region) and in the hilus of the dentate gyrus. Although Pld3 was expressed in all cerebral 
cortical layers (Figure 39), a stronger staining was observed in layers II and III, which 
might be due to the presence of a population of large pyramidal cells (Figure 40).  
For Pld3 staining in tissue sections, heat-induced antigen retrieval is required (see 
section 2.4.1, Material and Methods). Therefore, only co-staining with the NeuN marker 
was possible. Thus, no co-staining of Pld3 with glia markers was viable. To investigate if 
Pld3 is expressed in other cell types, a primary co-culture of neurons, astrocytes and 
microglia was prepared from newborn WT mouse embryos. Accordingly, Pld3 localized 
to MAP2- (microtubule-associated protein 2) positive cells, used as a neuronal marker 
(Figure 41). However, no co-localization of Pld3 was observed in cells positive for the 
marker proteins expressed in astrocytes (anti-GFAP antibody, glial fibrillary acidic 
protein) or in microglial cells (anti-CD68 antibody). This result confirms that Pld3 is 
exclusively expressed in neurons. Additionally, Pld3 protein levels of WT and Pld3 KO 
mouse brain lysates were directly compared with BV-2 WT cells (Figure 42). This murine 
cell line (BV-2) has been previously generated by infecting primary microglia cell cultures 
with a v-raf/v-myc oncogene carrying retrovirus (J2), resulting in the generation of a cell 
line exhibiting morphological, phenotypical and functional properties of active microglial 
cells (Blasi et al., 1990). 
Western blot analysis revealed a faint signal in BV-2 cells at the size of Pld3, especially 
with the luminal Pld3-specific antibody (Figure 42). No Pld3 was detected by 
immunofluorescence analysis of BV-2 cells (data not shown). In brief, these data indicate 
that Pld3 is a neuronal protein, although a low expression in microglia cells cannot be 
excluded.  
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Figure	40	 |	Pld3	 is	mainly	expressed	 in	neuronal	cells. Fluorescence images of the CA3 region and 
dentate gyrus of the hippocampus and the cerebral cortex (layers numbered). Sections were treated with 
heat-induced antigen retrieval and further co-labeled with the Pld3-specific luminal antibody (green) and 
the neuronal nuclear protein marker anti-NeuN (red). SO, Stratum Oriens; SP, Stratum Pyramidale; SR, 
Stratum Radiatum; h,hilus; gcl, granular cell layer. Scale bar, 50 µm. 
 
 
 
 
▼Figure	41	|	Pld3	is	highly	expressed	in	neurons. Mixed co-culture of neuronal, astroglia and microglia 
cells co-stained with the luminal Pld3-specific antibody (green) and antibodies against the microtubule-
associated protein 2 (MAP2, neuronal dendrites marker), the glial fibrillary acidic protein (GFAP, astrocyte 
marker) and the cluster of differentiation protein 68 (CD68, microglia marker) depicted in red (upper 
panel). The lower panels correspond to enlarged regions for each cell type (dashed square). Images of 
astrocytes and microglia cells were acquired at the same region. Scale bar, 10 µm.  
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Figure	42	|	Pld3	is	hardly	expressed	in	microglia	
cells. Western blot analysis of Pld3 WT and KO brain 
lysates compared to BV-2 WT microglia cell lysate. 
Pld3 signal detected with the N-terminal and luminal 
Pld3-specific antibodies is indicated with black 
arrowheads. * denotes unspecific signal. MAP2 is 
presented as a positive control of neuronal cell 
specificity. GAPDH was used as a loading control.  
 
 
 Pld3‐deficient	mice	exert	subtle	changes	in	the	activity	of	lysosomal	enzymes	
Lysosomes are the primary degradative compartment of the cell, containing more than 
50 hydrolases with utilize specific substrates (Saftig and Klumperman, 2009). In order to 
test if Pld3 deficiency leads to changes in the activity of lysosomal enzymes, e.g. due to 
higher number of lysosomes, the activities of three different lysosomal enzymes (β-
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hexosaminidase, β-glucuronidase and β-glucocerebrosidase) were analyzed (Figure 43). 
Considering that Pld3 may have phospholipase D activity, its deficiency could lead to the 
accumulation of specific substrates and subsequent alteration of other lysosomal 
hydrolases. β-Hexosaminidase catalyzes the hydrolysis of  β-glycosidically linked N-
acetylglucosamine and N-acetylgalactosamine residues from the non-reducing end of a 
number of glycoconjugates (Wendeler and Sandhoff, 2009). β-glucuronidase catalyzes 
the hydrolysis of β-D-glucuronic acid residues from the non-reducing termini of 
glycosaminoglycans (Fratz-Berilla et al., 2017). β-glucocerebrosidase catalyzes the 
hydrolysis of glucosylceramide to form ceramide and glucose (Motabar et al., 2012). All 
assays used to analyze the activity of these enzymes were based on the use of 
chromogenic artificial substrates, thereby producing a product that can be detected 
spectrophotometrically at 405 nm to determine enzymatic activity. These analyses were 
performed using brain lysates of 3 months old and 6 months old WT and Pld3 KO mice. 
For most of the enzymes evaluated, a significant decrease of the specific activity (mU/mg 
protein) was observed in the lysates of Pld3 KO mice when compared to WT lysates 
(Figure 43). 
 
 
 	Pld3	deficiency	leads	to	a	localized	microgliosis	in	the	dentate	gyrus	(DG)		
As described above, Pld3 is highly expressed in neuronal cells of the hippocampus and 
the cortex (3.2.1, 3.2.2 and 3.2.3). Moreover, PLD3 variants have been associated as risk 
factors for the development of Alzheimer’s disease (AD) (Cruchaga et al., 2014). 
Neuoinflammation is proposed as one of the mechanisms by which AD pathology leads to 
neuronal death and dysfunction (Griffin, 2006).  
Microglia cells are the resident immune cells of the brain and play a major role in the 
neuroinflammatory response in AD (Hopperton et al., 2018). Despite low expression of 
Pld3 in microglia, Pld3 WT (+/+) and KO (-/-) brain sections were stained with an 
antibody against CD68 to analyze any sign of neuroinflammation (Figure 44). Although 
there is some expression of CD68 in resting microglia (Lee et al., 2002), it is commonly 
considered a maker for activated phagocytic microglia (Walker and Lue, 2015). 
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Figure	 43	 |	 Pld3	 KO	mice	 have	 reduced	 lysosomal	 enzyme	 activity. The lysosomal enzymes β-
hexosaminidase, β-glucoronidase and β-glucocerebrosidase were analyzed in two cohorts of 3 months and 
6 months old Pld3 WT versus Pld3 KO mice using total brain lysate. The absolute specific activity (mU/mG 
protein) for each enzyme was measured. Error bars represent SEM. ***p < 0.001; *p < 0.1; unpaired 
Student´s t test (n = 4 – 5). ns, not significant. 
 
 
 
 
Immunohistochemistry for CD68 revealed increased microglia immunoreactivity in the 
dentate gyrus of Pld3 KO mice when compared to WT sections (Figure 44). This 
observation was more evident on brain sections of adult mice (6 months old) and old 
mice (21 months old).   
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Figure	44	 |	Pld3	KO	mice	show	 localized	microglia	activation	 in	 the	dentate	gyrus. Dentate gyrus 
fluorescence images of 1.5, 3, 6 and 21 months old WT versus Pld3 KO mice. Sections were labeled with an 
anti-CD68 antibody as a marker of activated microglia, CD68 (green). Nuclei are stained with DAPI (blue). 
Scale bar, 50 µm.  
 
 
To confirm these results, brain sections of 12 months old WT and Pld3 KO mice were 
labeled with anti-CD68 and anti-GFAP antibodies. An increased microglia activation in 
the sections of Pld3 KO mice was not only observed in the dentate gyrus (DG) of the 
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hippocampus, but also in the subventricular zone (SVZ, Figure 45A), known to be the 
largest germinal zone of the adult mammalian brain and were adult neurogenesis takes 
place (Doetsch and Alvarez-Buylla, 1996).  
Quantification of CD68 revealed significantly higher CD68 immunoreactivity in these two 
areas (DG and SVZ), as well as in the corpus callosum (CC) and the cerebellum (CB, Figure 
45B). Although not significant, a tendency of increased CD68 labeling was also observed 
in the cerebral cortex (CX).  
 
 
Figure	45	|	Pld3	KO	mice	have	increased	immunoreactivity	of	microglia	and	astrocytes	markers. A, 
12 months old Pld3 WT and KO brain sections were labeled with the microglia marker (anti-CD68) or the 
astrocyte marker (anti-GFAP). Fluorescence images show the subventricular zone and the dentate gyrus of 
the hippocampus. B,	Relative CD68 immunoreactivity was quantified in different brain regions. C,	GFAP 
immunoreactivity was quantified in the dentate gyrus. Error bars represent SEM. **p < 0.01; *p < 0.1; 
unpaired Student´s t test (n = 3). ns, not significant. LV, lateral ventricle; DG, dentate gyrus; CC, corpus 
callosum, SVZ, subventricular zone; CB, cerebellum; CX, cortex. Scale bar, 50 µm. 
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Immunofluorescence images of anti-GFAP staining in the DG (Figure 45A, lower panel) 
and further quantification (Figure 45C), revealed a tendency towards increased GFAP 
immunoreactivity. This marker is commonly used for the activation of astrocytes 
following injury or stress in the central nervous system (Zhang et al., 2017). Taken 
together, these data suggest that Pld3 deficiency leads to a subtle neuroinflammatory 
phenotype, especially in reported regions were new neurons are constantly and 
spontaneously born: the subgranular zone of the hippocampus (Altman and Das, 1965) 
and the subventricular zone (Altman, 1969).  
We therefore hypothesized that Pld3 deficiency might alter neurogenesis in any of these 
described regions. Due to a higher rate of neuronal cell division in the first stage of mouse 
development (0 – 4 weeks), brain sections of 3 weeks old WT (+/+) and Pld3 KO (-/-) 
mice were co-labeled with fluorescence antibodies against Ki67 (neuronal mitotic 
marker) and doublecortin (DCX, marker of immature neurons). Immunohistochemistry 
images of the dentate gyrus and the subventricular zone did not reveal apparent 
differences in the staining of these two markers between WT and Pld3 KO sections 
(Figure 46). In the subgranular zone (sgz) of the dentate gyrus, less cells positive for Ki67 
were observed in Pld3 -/-, yet this observation was not consistent when other brain 
sections were stained (data not shown). Additionally, staining against the CD68 antibody 
did not show increased immunoreactivity in the DG and SVZ as previously observed in 
older mice (Figure 44 and Figure 45). Nonetheless, a tendency of increased CD68 staining 
in Pld3 -/- sections was detected in the cerebellum, especially in the white matter (WM).  
In summary, these experiments suggest that Pld3 deficient mice develop a localized 
microgliosis in different brain regions, but this inflammatory phenotype does not seem 
to occur as a consequence of neurodegeneration.  
 
 
 
▼Figure	46	|	Pld3	KO	mice	show	normal	neurogenesis	and	cell	proliferation. Brain sections of 3 weeks 
old Pld3 WT and KO mice were co-labeled with markers of neurogenesis and cell proliferation 
(Doublecortin and Ki67) or with markers of microglia (Iba1 and CD68). Florescence images were acquired 
in different region including the dentate gyrus of the hippocampus (A), the subventricular zone (B) and the 
cerebellum (C). For the dentate gyrus and the cerebellum main structures are listed. h, hilus; sgz, 
subgranular zone; gcl, granular cell layer; ml or ML, molecular layer; PCL, Purkinje cell layer; IGL, internal 
granular layer; WM, white matter. Scale bar, 50 µm.  
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 Pld3	deficient	mice	show	a	depression‐like	behavior		
As a result of the increased CD68 immunoreactivity observed in brain regions of the Pld3 
deficient mice, we wanted to address if this inflammatory response has any effect on the 
behavior of Pld3 KO mice. A large variety of rodent behavioral tests have been designed 
to evaluate traits such as sensory-motor function, social interactions, anxiety-like and 
depression-like behavior, substance dependence and various forms of cognitive functions 
(Hånell and Marklund, 2014). In collaboration with Dr. Stijn Stroobants from the 
University of Leuven (Belgium) different tests, including cage activity, grip strength, 
rotarod and open field, were used to test the locomotor activity and neuromuscular 
function in 5 months old WT (+/+), Pld3 heterozygous (+/-) and Pld3 KO (-/-) mice. 
Moreover, the exploratory activity was also evaluated. No differences appeared between 
the groups for cage activity (Figure 47A), grip strength (Figure 47B) and rotarod (Figure 
47C), indicating similar neuromotor function. The groups showed comparable 
exploration in the open field test in terms of total activity (Figure 47D, left) and 
exploration of the center (Figure 47D, right). In the elevated plus maze, no changes 
between the groups were observed for total exploratory activity (Figure 47E). Passive 
avoidance test and water maze probe trials were used to evaluate learning and memory. 
All three groups performed successful passive avoidance learning (increase of step-
through latencies (Figure 47F). During the water maze probe trials, long-term retention 
of the platform location is tested. However, spatial preferences cannot be evaluated 
reliably when mice are highly immobile. Indeed, similar trends of increased immobility 
were observed in the probe trials. Therefore, all mice showing more than 15 % 
immobility were excluded to evaluate spatial preference. From the remaining animals, no 
differences were observed (Figure 47G). The Morris water maze is the most common test 
to evaluate cognitive functions related to learning and memory (Nunez, 2008). During 
water maze acquisition, Pld3 KO mice tended to show increased escape latencies (Figure 
48A, upper left), but did not travel more distance to reach the platform (Figure 48A, upper 
right). In fact, Pld3 KO mice showed reduced swimming velocity depending on the time 
point of acquisition. When acquisition weeks were analyzed separately, knockout mice 
showed a progressive reduction of swimming velocity during the first week, in contrast 
to wildtype and heterozygous mice, which remained stable during the second week 
(Figure 48A, lower left).  
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▲Figure	47	 |	Pld3	KO	mice	show	normal	neuromotor	and	cognitive	 function. Locomotor activity, 
anxiety and willingness for the mice to explore was measured by cage activity, grip strength, rotarod, open 
field and elevated plus maze behavioral tasks. Passive avoidance and water maze probe trials were used to 
evaluate learning and memory. A total of  31 animals (5 months old) were analyzed for these trials (9 wild-
type, 11 heterozygous, 11 Pld3 knockout). Error bars represent SEM. All tests were performed in 
collaboration with Dr. Stijn Stroobants at the Laboratory of Biological Phycology in Leuven (Belgium). 
 
 
 
 
 
Figure	48	|	Pld3	KO	mice	show	a	depression‐like	behavior. Spatial learning, memory and depression-
like phenotype were evaluated by water maze acquisition, tail suspension and Y-Maze. A total of 31 animals 
(5 months old) were analyzed for these trials (9 wild-type, 11 heterozygous, 11 Pld3 knockout). All tests 
were performed in collaboration with Dr. Stijn Stroobants at the Laboratory of Biological Phycology in 
Leuven (Belgium). Error bars represent SEM. *p < 0.1. 
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This reduction of swimming velocity appeared to be due to increased floating behavior in 
the majority of knockout mice (=immobility in the water). Similar to the related velocity 
graph, knockout mice showed a progressive increase of immobility during the first week 
of acquisition, with floating behavior remaining at similar levels during the second week 
(Figure 48A, lower right). These results indicate an increased susceptibility for 
behavioral despair in knockout mice. To confirm a depression-like phenotype, a tail 
suspension test was performed. There were significant differences between the groups 
for the time spent immobile when suspended from the tail. Pld3 KO mice spent more time 
immobile than WT mice (Figure 48B). However, during Y-maze exploration, all groups 
showed a similar alternation behavior (Figure 48C, left) and similar amount of arm visits 
(Figure 48C, right), indicating intact working memory. All behavioral tests were re-tested 
in the same animals at 9 months of age, showing the same results and tendencies 
observed when tested at 5 months old (data not shown). These data indicate that Pld3 
deficient mice have normal locomotor activity and no alterations in cognitive function 
related to memory and learning. However, Pld3 KO mice seems to develop a depression-
like behavior.  
 
 
3.3 Functional	analysis	of	PLD3	
 	Pld3	deficient	mice	show	subtle	alterations	in	lipid	species	
PLD3 has been grouped to the phospholipase D family members due to the presence of a 
conserved HKD motif. Enzymes belonging to this family, like PLD1 and PLD2 catalyze the 
hydrolysis of phosphatidylcholine (PC) to phosphatidic acid (PA) and choline (Hanahan 
and Chaikoff, 1947; Heller, 1978; Oude Weernink et al., 2007). In order to indirectly test 
for PLD activity, a high-throughput lipidomics analysis was performed. This analysis was 
carried out in collaboration with Dr. Dominik Schwudke from the Research Center 
Borstel, Germany. Due to the predominant Pld3 expression observed in the brain (section 
3.2.1), especially in neuronal cells (section 3.2.3), wild-type (WT) and Pld3-deficient (KO) 
whole brain lysates were used for methyl-tert-butyl ether (MTBE) -based lipid extraction 
(Matyash et al., 2008) and further analyzed by mass spectrometry. A total of 220 lipid 
species divided in 13 classes were reported (Supplementary Table 23). From all the lipids 
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analyzed, only significant differences for ceramides (Cer) species were observed (Figure 
49). However, for most of the detected species, the lipid content was too low, making it 
difficult to interpret. Moreover, no major differences were detected for phosphatidic acid 
(PA) as a classical end product of PLD enzyme activity. These data suggest that PLD3 does 
not have typical phospholipase D activity.  
 
 PLD3	is	a	5´‐exonuclease		
To further analyze possible functions for PLD3 at the cellular level, a stable PLD3-
knockout (KO) HeLa cell line was generated by CRISPR-Cas9 technology (clustered 
regularly interspaced short palindromic repeats, see section 2.3.5). To this end, HeLa cells 
were transfected with a pCMV-Cas9-GFP vector (Figure 6), containing a 22 bp target 
region of exon 4 of the human PLD3 gene (Figure 50). The RNA-guided Cas9 promotes 
genome editing by stimulation of DNA-double stranded breaks at the target genomic 
locus (i.e. PLD3 target region) (Hsu and Zhang, 2012; Urnov et al., 2010). This region is 
associated with a protospacer adjacent motif (PAM), necessary for Cas9 to cleave the 
sequence (Barrangou et al., 2007; Brouns et al., 2008).  
 
 
Figure	49	|	High‐throughput	lipidomics	analysis	of	WT	and	KO	Pld3	mice. Lipid extraction of whole 
brain lysates of 4 WT vs. 4 Pld3 KO mice were performed via methyl-tert-butyl ether- (MTBE) and further 
analyzed by mass spectrometry. The graph shows significant values of different ceramide (Cer) species 
denoted as [carbon atoms:double bonds]. Error bars represent SD. *p < 0.05, **p < 0.05; unpaired Student´s 
t test (n = 4).  
3. Results 100 
 
 
 
Figure	50	|	Schematic	representation	of	sgRNA	target	site	of	the	human	PLD3	gene.	A sgRNA target 
region located in exon 4 of PLD3 gene was used for the generation of PLD3-deficient HeLa cells using the 
CRISPR-Cas9 technology. The protospacer adjacent motif (PAM) is highlighted in orange.  
 
 
Different clonal cell populations from the GFP-positive transfected HeLa cells were 
isolated by FACS and further validated. Primers were designed for PCR amplification of a 
394 bp long product encompassing exon 4. Agarose gels of the PCR products for clones 
#16 and #19 revealed large genetic deletions (Figure 51A). Sanger sequencing 
chromatograms shows that PLD3 KO clones #10, #16 and #19 carry heterozygous 
mutations, where double peaks are observed after the target sequence, indicating 
different allelic mutations. For the PLD3 KO clone #20, a single nucleotide was inserted 
between the target sequence, leading to a homozygous frameshift mutation (Figure 51B). 
Additionally, PLD3 KO clones were validated by Western blot with both PLD3-specific N-
terminal and luminal antibodies, showing an absence of PLD3 full-length and PLD3 
cleavage products, when compared to the parental HeLa cell line (Figure 51C). For further 
analyses, only the PLD3 KO clone #20 was used.  
With the aim to get better insight if PLD3 deficiency could cause any morphological 
alterations in subcellular structures (e.g. enlarged lysosomes), PLD3 KO HeLa cells were 
stained with different antibodies against intracellular proteins of the endoplasmic 
reticulum (KDEL), Golgi-apparatus (GM130), early endosomes (EEA1), late endosomes 
(LBPA) and lysosomes (LAMP2, Cathepsin D and CD63). Immunofluorescence analysis 
did not show any evident alterations in the size, positioning or morphology of the 
evaluated intracellular organelles (Figure 52). 
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Figure	 51	 |	Validation	 of	HeLa	 CRISPR‐Cas9	 clones. Four different HeLa CRISPR-Cas9 clones were 
generated and validated for PLD3 deficiency. A, agarose gel analyses of PLD3 CRISPR-Cas9 clones 
amplifying by PCR a region of 394 bp long fragment covering exon 4 of WT PLD3 using genomic DNA as 
template. Clones #16 and #19 show large genetic deletions. B, Sanger sequencing chromatograms of all 
four PLD3 CRISPR-Cas9 clones and the corresponding sequence of the wild-type (WT) locus. Target region 
and protospacer adjacent motif (PAM) are indicated. C, Western blot analysis of three selected clones 
immunoblotted with PLD3-specific N-terminal and luminal antibodies. Comparison with the HeLa WT 
parental cell line is shown. Specific signals are labeled with black arrowheads. GAPDH is presented as a 
loading control.  
 
 
Recently, in collaboration with the group of Dr. David Nemazee from The Scripps 
Research Institute, it was published that PLD3 and PLD4 (another homolog of the 
phospholipase D family) are lysosomal 5´ single stranded acid exonucleases (Gavin et al., 
2018). Pld3 protein expression analyses in different mouse organs (Figure 36 and Figure 
37) showed that the spleen is the organ with second highest Pld3 expression. However, a 
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10-fold higher Pld3 expression was detected in the brain. Thus, we hypothesized that, if 
PLD3 and PLD4 have the same functions and/or similar physiological substrates, they 
might be tissue and/or cell-type specific.  
Two different assays were established in order to investigate PLD3 nuclease activity. 
Both assays consisted on the in	 vitro incubation of cell or mouse organ lysates with 
specific 30 – 55 nucleotides long single-stranded deoxyribonucleic acid (ssDNA) in an 
acidic buffer condition. In the first (qualitative) assay, reaction products were separated 
in a DNA polyacrylamide gel electrophoresis (DNA-PAGE), stained with intercalating DNA 
agents and further visualized (for details, see section 2.5.12). In the second (quantitative) 
assay, ssDNA substrates were synthesized with a 5´-fluorescin amidite (FAM) dye and a 
3´-BMN-Q530 quencher. Due to the low proximity between the dye and the quencher, 
FAM fluorescence is quenched; if 5´ cleavage is occurring, FAM will be released from the 
sequence, allowing further quantification by spectrophotometry. We decided to name 
this assay as EFQO (End-Labeled Fluorescence-Quenched Oligonucleotide), assay that 
has been further developed and standardized by the MD student Cedric Cappel. The 
results that are discussed below are referred to the gel-based (qualitative) assay. 
Importantly, to make sure that no 3´ exonuclease cleavage takes place in the reaction, the 
last 3´ nucleotides of the sequence were modified with phosphorothioate (PS) bond 
modifications, which is known to render the internucleotide linkage resistance to 
degradation of most nucleases (Fisher et al., 1993).  
First, PLD3 nuclease activity was studied at the cellular level by incubation of ssDNA as a 
substrate with lysates of WT HeLa or PLD3 KO HeLa cells. Analysis of the incubation 
products by DNA-PAGE revealed degradation of the substrate when incubated with WT 
HeLa cells lysates (Figure 53A). Degradation is evident by disappearance of the 50 nt 
ssDNA signal and appearance of smaller fragments. In contrast, similar to the negative 
control, where no lysate was added, limited substrate degradation was detected when 
incubated with PLD3 KO HeLa lysates (Figure 53A).  
 
 
Figure	 52	 |	 PLD3	 KO	 HeLa	 cells	 do	 not	 show	 any	 morphological	 alterations	 in	 intracellular	
organelles.	Immunofluorescence images of PLD3 KO HeLa cells vs. WT HeLa cells stained with antibodies 
against marker proteins of the endoplasmic reticulum (KDEL), Golgi-apparatus (GM130), early endosomes 
(EEA1), late endosomes (LBPA) and late endosomes (LAMP2, Cathepsin D and CD63). Scale bar, 10 µm. 
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The low nuclease activity detected in PLD3 KO HeLa cells, where faint signals of smaller 
DNA fragments are observed, could be due to PLD4 activity or other non-described 
nuclease(s). Next, PLD3 nuclease activity was evaluated under overexpressing 
conditions. Experiments with overexpressed constructs were always performed in PLD3 
KO HeLa cells in order to avoid any endogenous (background) nuclease activity. As 
observed in Figure 53B, overexpression of hPLD3 led to an increase of enzymatic activity, 
where substrate detection was very low after incubation at the indicated time points. This 
might be explained due to the high amount of PLD3 enzyme expressed. In summary, these 
experiments indicate that HeLa cells have endogenous PLD3 5’ exonuclease activity and 
its overexpression leads to higher substrate degradation under the conditions used, 
making this a suitable assay to test the effect of different PLD3 variants on nuclease 
activity and further study PLD3 enzymological properties.  
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Figure	53	|	WT	HeLa	cells	have	endogenous	PLD3	5’‐nuclease	activity. Wild-type (WT) or PLD3 KO 
HeLa cell lysates (A) or PLD3-transfected cell lysates (B) were incubated with 4 µM 55 nt-long ssDNA in 
reaction buffer (MES pH 4.5, 100 mM NaCl) at 37°C for the indicated time points. For the experiment shown 
in (A), incubation was performed for 2 h. A DNA polyacrylamide gel electrophoresis was run with reaction 
products in Tris-Borate-EDTA (TBE) buffer. Gels were incubated for 5 min in SYBR Gold Nucleic Acid Gel 
Stain and visualized at a 600 nm wavelength. For experiment B, only PLD3 KO HeLa cells were used.  
 
 
As mentioned previously, PLD3 contains two HKD motifs, a key structural feature for 
phospholipase D family members. However, the second (in direction to the C-terminus) 
motif of PLD3 is not fully conserved, where the aspartic acid (D) is substituted by a 
glutamic acid (E). Therefore, we investigated if this amino acid might be important and 
dispensable for PLD3 nuclease activity, by its substitution with alanine (PLD3 E423A, 
Figure 54A). Besides, another HKD mutant (PLD3 K418R), located in the first motif, has 
been formerly reported to eliminate enzymatic activity for different PLD isoforms tested 
(Sung et al., 1997). Thus, both mutants were overexpressed in PLD3 KO HeLa cells and a 
nuclease assay was performed as discussed above. DNA-PAGE analysis revealed a 
complete abolishment of exonuclease activity for both mutants, where no substrate 
degradation was observed (Figure 54B). Mutants were also analyzed by 
immunocytochemistry by co-staining with the N-terminal and luminal specific anti-PLD3 
antibodies and antibodies against the intracellular proteins KDEL (ER marker) and 
LAMP2 (lysosomal marker). PLD3 K418R, comparable to the WT, was localized to 
lysosomes, while PLD3 E423A expression led to its retention in the ER, where a high 
degree of co-localization with KDEL was observed (Figure 54C). This indicates that both 
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motifs are important for proper PLD3 exonuclease activity and that the glutamic acid 
position of the second motif might also be a key residue for proper PLD3 folding and, in 
consequence, for appropriate delivery to lysosomes.  
 
 
 
 
 
Figure	54	|	PLD3‐HKD	motif	mutants	have	altered	nuclease	activity. A, Schematic representation of 
PLD3 protein structure with both HKD/HKE motifs. The two PLD3-HKD mutants generated are encircled 
in red boxes. B, nuclease activity assay of PLD3 WT and both HKD/E mutants. Cell lysates (50 µg) were 
incubated with 4 µM 55 nt-long ssDNA in reaction buffer (MES pH 4.5, 100 mM NaCl) at 37°C for 30 min. 
Products were further analyzed by DNA PAGE, stained with SYBR Gold Nucleic Acid Gel Stain and visualized 
at a 600 nm wavelength. C, immunofluorescence images of HeLa cells transfected with both mutants and 
further co-stained with the N-terminal and luminal PLD3-specific antibodies (green) together with anti-
KDEL (ER marker) and anti-LAMP2 (lysosomal marker) antibodies depicted in red. Scale bar, 10 µm. 
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We have previously described that PLD3 proteolytic processing is pH-dependent and that 
its cleavage is abolished by inhibitors of lysosomal acidification (Figure 19B). To analyze 
if PLD3 nuclease activity is dependent on proteolytic processing, PLD3-transfected cells 
were incubated in	vivo with the inhibitors Bafilomycin A, Chloroquine and ammonium 
chloride (NH4Cl). After incubation of the corresponding inhibitor treated-cell lysates with 
the ssDNA substrate and further separation of the products by DNA-PAGE, it was 
observed that interference with PLD3 cleavage did not inhibit its activity as a nuclease 
(Figure 55A). A slightly stronger DNA product signal was detected in the treated samples 
compared to untreated (DMSO) cells, suggesting a delay but not total inhibition of PLD3 
nuclease activity. As a confirmation that all inhibitors used had an effect on PLD3 
cleavage, a Western blot analysis with the same lysates was performed by 
immunoblotting with the antibody against the luminal domain of PLD3 (Figure 55B). In 
order to further investigate the enzymatic properties of PLD3, we analyzed the effect of 
different compounds on the modulation of PLD3 exonuclease activity (Figure 56 and 
Figure 57).  
 
 
 
 
Figure	55	|	PLD3	nuclease	activity	is	not	cleavage‐dependent. A,	PLD3‐transfected cells were incubated 
in	 vivo with different inhibitors of lysosomal acidification described before to avoid PLD3 cleavage 
(Bafilomycin A, chloroquine and ammonium chloride). DMSO was used as a negative control of treatment. 
Cell lysates (50 µg) of treated and non-treated cells were incubated with 4 µM 55 nt-long ssDNA in reaction 
buffer (MES pH 4.5, 100 mM NaCl) at 37°C for 2 h. Products were further analyzed by DNA PAGE, stained 
with SYBR Gold Nucleic Acid Gel Stain and visualized at a 600 nm wavelength. B, Cells treated with the 
indicated inhibitors were analyzed by Western blot and further immunodetection with the PLD3-specific 
luminal antibody (PLD3-specific signal is shown with black arrowheads). GAPDH is depicted as a loading 
control.  
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Regulation of enzymes though metal ion complexation, accounting for 63 % of all 
cofactors, is widespread in biology underscoring a physiological need for enzyme 
stability and catalytic activity (Gohara and Cera, 2016). Moreover, it has been reported 
that the mouse Zuc (mZuc, also known as PLD6), another member of the phospholipase 
D family, also possesses single-strand-specific nuclease activity (Ipsaro et al., 2012; 
Nishimasu et al., 2012). This enzyme contains a Zn-binding domain known to be 
important for its catalytic activity. In order to test if PLD3 nuclease activity is dependent 
on metal cofactors, PLD3-transfected cell lysates were incubated in	vitro with different 
divalent cations in the form of chloride salts or with described chelating agents, including 
ethylenediaminetetraacetic acid (EDTA) and 1,10-phenanthroline. A nuclease activity 
assay was applied by incubation of the treated lysates with a ssDNA substrate. In 
comparison to untreated lysates, DNA-PAGE analysis showed a complete absence of DNA 
products after incubation with EDTA, but not with phenanthroline (Figure 56). A similar 
result was observed after the addition of CaCl2, suggesting that PLD3 activity might be 
induced by calcium as a divalent cation. In contrast, no apparent differences in substrate 
degradation was observed for the lysates incubated with either Zn2+, Mg2+ or Cu2+, 
indicating that PLD3 exonuclease activity is not influenced by the presence of these 
divalent cations. Further analyses are required to address the activating effect of calcium 
ions in PLD3 enzymatic activity.  
 
Figure	56	|	PLD3	nuclease	activity	is	enhanced	by	EDTA	and	Ca2+. PLD3	transfected cell lysates (50 µg) 
were pre-incubated in	 vitro with chelating agents (10 mM EDTA or 10 mM phenanthroline) or with 
different divalent cations (3 mM ZnCl2, 3 mM MgCl2, 3 mM CaCl2 and 1 µM CuCl2) for 30 min at 37 °C in 
reaction buffer (MES pH 4.5, 100 mM NaCl). Then, 4 µM 55 nt-long ssDNA was added and further incubated 
for 1 h at 37 °C. Products were analyzed by DNA PAGE, stained with SYBR Gold Nucleic Acid Gel Stain and 
visualized at a 600 nm wavelength.  
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As a result of PLD3 exonuclease activity, PLD3 can be grouped in the family of 
phosphodiesterases by cleavage of phosphodiester bonds from single-stranded DNA in a 
5´  3’ direction. Phosphate (PO43-), sulfate (SO43-) and vanadate (VO43-) ions are 
polyatomic anions with a central atom (phosphorus, sulfur and vanadium, respectively) 
surrounded by four oxygen atoms in a tetrahedral arrangement. Due to this structural 
similarity, the effect of these anions (as competitive analogs) on PLD3 exonuclease 
activity was evaluated. Additionally, it is known that β-glycerophosphate, sodium 
pyrophosphate and sodium fluoride are phosphate inhibitors (Chung et al., 1992; Orriss 
et al., 2016). DNA-PAGE analysis of the products derived from the in	vitro incubation of 
all these compounds with a ssDNA substrate revealed that vanadate (VO43-) completely 
inhibited the nuclease activity of PLD3 (Figure 57). β-glycerophosphate and 
pyrophosphate increased PLD3 exonuclease activity, where the substrate was almost 
completely degraded. In comparison to untreated lysates, sulfate, phosphate and fluoride 
did not show any effect on PLD3 activity (Figure 57). Taken together from our 
experiments we can conclude that PLD3 is a 5’ specific single-stranded exonuclease 
endogenously expressed in HeLa cells. Both PLD3 HKD/E motifs are important for its 
catalytic activity and vanadate inhibits the PLD3 exonuclease activity. 
 
	
Figure	57	|	PLD3	nuclease	activity	is	inhibited	by	vanadate	(Na3VO4). PLD3	transfected cell lysates (50 
µg) were pre-incubated in	vitro with different anions (10 mM Na3SO4, 10 mM NaH2PO4, 5 mM Na3VO4), β-
glycerophosphate, 10 mM pyrophosphate (PPi) or 2 mM NaF for 30 min at 37 °C in reaction buffer (MES 
pH 4.5, 100 mM NaCl). Then, 4 µM 55 nt-long ssDNA was added and further incubated for 1 h at 37 °C. 
Products were analyzed by DNA PAGE, stained with SYBR Gold Nucleic Acid Gel Stain and visualized at a 
600 nm wavelength.  
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 PLD3	is	the	main	5´‐exonuclease	in	the	brain	
As a result of the distinctive expression levels of PLD3 observed in the different mouse 
organs, we wanted to further investigate PLD3 exonuclease activity in	 vivo	 in mouse 
tissue. Hence, a nuclease assay was performed with brain, spleen and bone marrow 
lysates by incubation with the same substrate used for the cell-based analysis. As a 
control, wild-type (WT) mouse tissue lysates were compared with Pld3 knockout (KO) 
lysates at 0 h and after 4 h of incubation. DNA-PAGE analyses of the incubation products 
showed a complete substrate degradation in WT brain lysates, while in the Pld3 KO 
lysates no nuclease activity was observed (Figure 58, upper panel). Similar results were 
obtained for the spleen and the bone marrow. However, in the Pld3 KO lysates of these 
tissues approximately half of the substrate was degraded, shown by densitometric 
quantification of the ssDNA degradation signal (Figure 58, lower panel).  
 
	
Figure	58	|	Pld3	is	the	main	5´‐nuclease	in	the	brain. A, nuclease activity assay of brain, spleen and bone 
marrow lysates of WT (Pld3+/+) and KO (Pld3-/-) mice. Lysates (50 µg) were incubated with 4 µM 55 nt-
long ssDNA in reaction buffer (MES pH 4.5, 100 mM NaCl) at 37°C for the indicated time points. Products 
were further analyzed by DNA PAGE, stained with Ethidium Bromide and visualized under UV light. The 
respective quantification of ssDNA degradation is shown. Error bars represent SEM. ***p < 0.001; **p < 
0.01; *p < 0.1; unpaired Student´s t test (n = 3). ns, not significant. 
3. Results 110 
 
 
To confirm the observed Pld3-specific nuclease activity in the brain, increasing amounts 
(between 1 and 100 µg) of WT or Pld3 KO brain lysates were incubated with a ssDNA 
substrate and further analyzed by DNA-PAGE (Figure 59). Increasing concentrations of 
Pld3 enzyme led to progressive degradation of the ssDNA substrate until its 
disappearance with 100 µg of lysate (Figure 59, left). Conversely, increasing amount of 
Pld3 KO brain lysate led only to a minor substrate degradation at very high 
concentrations. Altogether, these data indicate that Pld3 is the main 5’exonuclease in the 
brain and its absence in other organs is most likely compensated by Pld4 activity or other 
non-described 5’ exonucleases.  
 
 
Figure	59	|	5´‐nuclease	activity	is	abolished	in	the	Pld3	KO	mouse	brain. Increasing concentrations of 
WT and Pld3 KO mice brain lysates were analyzed for nuclease activity by incubation with 4 µM 55 nt-long 
ssDNA in reaction buffer (MES pH 4.5, 100 mM NaCl) at 37°C for the indicated time points. Products were 
further analyzed by DNA PAGE, stained with Ethidium Bromide and visualized under UV light. 
 
 
3.4 Role	 of	 PLD3	 variants	 as	 a	 genetic	 risk	 factor	 of	 Alzheimer´s	
disease	development	
In 2014, Cruchaga et al. described a series of variants in	 PLD3	 that were either 
significantly associated with Alzheimer’s disease (AD) risk (e.g. PLD3 V232M variant) or 
variants that were only found in AD cases but not in healthy controls. Consequently, PLD3	
became of high interest to the scientific community. In follow-up genetic studies only one 
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group was able to reproduce the significant association of PLD3 V232M and AD (van der 
Lee et al., 2015). However, other independent reports failed to reveal a risk effect of PLD3 
in AD (Heilmann et al., 2015; Hooli et al., 2015; Lambert et al., 2015). Despite the efforts, 
to date it is still in debate if there is a real genetic association of PLD3	with Alzheimer´s 
disease.  
 
 Described	 Pld3	 variants	 in	 AD	 patients	 exhibit	 different	 proteolytic	
processing	and	nuclease	activity	
We wanted to investigate the effect of different reported Alzheimer´s disease-related	
variants on PLD3 proteolytic processing and nuclease activity. A set of these variants 
were generated by site directed mutagenesis (Figure 60), including the variant reported 
to significantly confer risk for AD (PLD3 V232M), a conserved mutant located in the N-
terminal PLD3 sequence (PLD3 M6R), mutations close to the possible PLD3 cleavage site 
(PLD3 G63S and PLD3 P76A), a mutation found in AD cases of European-descent and 
African-American cases (PLD3 K228R), glycosylation mutants (PLD3 N236S and PLD3 
N284S) and a variant very close to the second HKE motif (PLD3 T426A).  
 
 
 
Figure	60	 |	Schematic	 representation	of	different	PLD3	 coding	variants. Scheme of PLD3 variants 
generated for further analysis. *Variants signiϐicantly associated with Alzheimer’s disease risk. †Variants 
found only in Alzheimer’s disease cases. ‡Variants that are more frequent in Alzheimer’s disease cases than 
in controls. Data from Cruchaga et al. 
 
 
After cDNA expression in HeLa cells, all PLD3 variants were analyzed using Western blot 
(Figure 61) and immunodetection with antibodies against the N-terminal and luminal 
region of PLD3. In addition, for immunofluorescence analyses (Figure 62), PLD3 was co-
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stained with antibodies against protein expressed in the lysosomes (anti-LAMP2) and the 
ER (anti-KDEL). In spite of the different expression levels, PLD3 V232M, G63S, P76A, 
N284S and T426A had normal processing (Figure 61) and delivery to lysosomes (Figure 
62). The weak signal observed for the full-length and N-terminal fragment of the PLD3 
M6R expressed variant might be due to the amino acid change in the epitope and 
therefore a lower recognition with the N-terminal specific antibody. On the other hand, 
an altered proteolytic processing was observed after ectopic expression of the PLD3 
variants K228R and N236S. Both PLD3 mutants were retained in the ER, shown by the 
high degree of co-localization with the KDEL marker (Figure 62). Interestingly, the PLD3 
N236S mutant led to a shift to a lower molecular weight of full-length PLD3. This result 
that was also observed when glycosylation mutants were analyzed (Figure 14). These 
indicates that these two amino acids (K228 and N236) are key residues for proper PLD3 
folding and correct transport to lysosomes.  
 
 
Figure	 61	 |	 AD‐related	 mutants	 exhibit	 differential	 PLD3	 proteolytic	 processing. Different 
Alzheimer´s disease-related mutants were analyzed by Western blot by immunoblotting with both N-
terminal and luminal PLD3-specific antibodies. The different and specific cleavage products are indicated 
with black arrowheads. GAPDH is presented as a loading control.  
 
 
Next, we wanted to analyze the effect of the described PLD3 variants on the nuclease 
activity. To this end, all mutants were overexpressed in PLD3 KO HeLa cells and cell 
lysates were incubated with the ssDNA substrate. DNA-PAGE analysis revealed that the 
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expression of PLD3 K228R and PLD3 N236S led to decreased nuclease activity, especially 
for the first mutant (K228R) where most of the ssDNA substrate was not degraded 
(Figure 63). This result validates the assumption that proper folding and lysosomal 
delivery is necessary for suitable PLD3 5’ exonuclease activity. For the other variants, a 
similar degradation pattern was observed when compared to PLD3 WT, arguing that 
these mutants do not have a high impact on PLD3 nuclease activity.  
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▲Figure	62	 |	AD‐related	mutants	PLD3	K228R	 and	N236S	have	 abrogated	delivery	 of	PLD3	 to	
lysosomes. Alzheimer´s disease-related PLD3 mutants were analyzed by immunocytochemistry, where 
transfected HeLa cells were further co-labeled with the luminal PLD3-specific antibody (green) and 
antibodies against the intracellular protein markers KDEL and LAMP2 (red). Insets show enlarged regions 
of the cell. Scale bar, 10 µm. 
 
 
 
Figure	63	|	AD‐related	mutants	PLD3	K228R	and	N236S	have	decreased	5´‐exonuclease	activity. Cell 
lysates (50 µg) of the different AD-related PLD3 mutants were incubated with 4 µM 55 nt-long ssDNA in 
reaction buffer (MES pH 4.5, 100 mM NaCl) at 37°C for 30 min. Products were further analyzed by DNA 
PAGE, stained with SYBR Gold Nucleic Acid Gel Stain and visualized at a 600 nm wavelength. 
 
 
 Characterization	of	Pld3	deficiency	in	the	5XFAD	Alzheimer’s	mouse	model		
As previously mentioned, PLD3	has been described as a genetic risk factor for Alzheimer’s 
disease (AD). Pld3 deficiency led to increased CD68 immunoreactivity within brain 
regions where adult neurogenesis occurs (e.g. the dentate gyrus of the hippocampus, 
section 3.2.5) together with a depression like behavior (section 3.2.6). Interestingly, AD 
pathogenesis is characterized by the deposition of amyloid beta (Aβ) plaques, especially 
in the hippocampus (Kayed et al., 2003), as well as neuroinflammation (activated 
microglia and reactive astrocytes)(Wyss-Coray and Mucke, 2002). Therefore, we wanted 
to investigate how Pld3 deficiency possibly contributes to the development of AD, 
especially in regard to APP biology.   
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3.4.2.1 Protein	levels	of	APP	and	its	fragments	are	not	altered	in	the	Pld3‐/‐	5XFAD	mice	
The precise physiological function of the amyloid precursor protein (APP) remains 
unknown. However, it is well described that aberrant proteolytic processing of APP 
(increased amylodogenic pathway) promotes the generation and oligomerization of the 
amyloid beta (Aβ) peptide, leading to different mechanisms of neurotoxicity (Glenner, 
1983; Glenner and Wong, 1984; Masters et al., 1985). Moreover, Cruchaga et al. reported 
that overexpression of PLD3 decreased the extracellular levels of Aβ40 and Aβ42, while 
its knockdown had opposite effects.  
Therefore, we first investigated whether PLD3 deficiency affects APP processing. Whole 
brain lysates of Pld3 WT (+/+) and Pld3 KO (-/-) mice were analyzed by Western blot and 
further immunodetected with different antibodies against full-length (FL) APP, APP 
proteolytic products (e.g. C-terminal fragments [CTFs] and soluble APP alpha [sAPPα]) 
and key proteins involved in APP processing (e.g. Bace1 and presenilin). As observed in 
Figure 64, Pld3 deficiency did not alter the overall processing of APP, where the levels of 
full-length (FL APP), the C-terminal fragments (CTFs) and soluble APP (sAPPα) were 
unchanged. No changes in the protein levels of the proteases involved in APP 
amyloidogenic pathways (Bace1 and presenilin) were either observed.  
The unaltered protein levels observed for APP and its cleavage products led us to 
hypothesize that breeding the Pld3 knockout mice with the well-established AD-related 
mouse model (5xFAD) (Oakley et al., 2006), would help us to better decipher the role of 
Pld3 on the turnover and processing of APP and Aβ. Thus, 5xFAD Pld3-/- mice were 
generated (section 2.6.2). Western blot analysis of 6 months old 5xFAD and 5xFAD Pld3-
/- mouse brain lysates were performed. Immunodetection against antibodies of full-
length APP and its C-terminal fragments did not reveal any changes at the protein level 
between 5xFAD and 5xFAD Pld3-/- (Figure 65). As a control, an antibody against a 
lysosomal hydrolase (Cathepsin D) was used. Cathepsin D is known to be present in 
neuritic plaques (Cataldo et al., 1995; Ginsberg et al., 2000). Contradictory to what 
Cruchaga et al. reported in 2014, these results suggest that Pld3 deficiency do not lead to 
any alterations on APP proteolytic processing in	vivo.  
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Figure	64	|	APP	processing	is	not	affected	in	Pld3	deficient	mice. Brain lysates of 6 months old Pld3 
WT (+/+) and Pld3 KO (-/-) mice were analyzed by Western blot and further immunodetection with 
antibodies against full-length (FL) APP (anti-APP, clone 22C11), C-terminal fragments (CTFs, anti-APP, 
clone A8717), soluble APP alpha (sAPPα) and the proteases Bace1 and preselinin. GAPDH is presented as 
a loading control. Densitometry quantification of FL APP and CTFs are presented in the graphs. Error bars 
represent SEM, unpaired Student´s t test (n = 4). ns, not significant, m, mature; i, immature. 
 
 
 
 
	
Figure	65	|	APP	processing	is	not	affected	in	5xFAD	Pld3‐/‐	mice.	Western blot analyses of 6 months 
old 5xFAD and 5xFAD Pld3-/- mouse brain lysates. Membrane were immunodetected with antibodies 
against full-length (FL) APP (anti-APP, clone 22C11) and the cathepsin D (CtsD). Densitometry 
quantification of FL APP and CTFs are presented in the graphs. Error bars represent SEM, unpaired 
Student´s t test (n = 4-5). ns, not significant, m, mature; i, immature, int, intermediate.  
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3.4.2.2 Pld3	is	localized	to	Amyloid	beta	(Aβ)	plaques		
It has been shown that lysosomes which are rich in membrane proteins but with low 
levels of soluble hydrolases, accumulate in dystrophic neurites around amyloid plaques 
(Gowrishankar et al., 2015). To investigate the Pld3 localization, 5xFAD brain sections 
were fluorescence labeled with an anti-PLD3 luminal specific antibody and an anti-Aβ 
(clone 6E10) antibody. Fluorescence microscopy revealed that Pld3 is found within the 
same brain regions where Aβ plaques are concentrated, especially in the murine cortex 
and the hippocampus (Figure 66). With higher magnification, Pld3 staining is observed 
around extracellular Aβ deposits, an observation that was consistent within the different 
brain regions, including the CA2 region and subiculum of the hippocampus (Figure 66B 
and Figure 67E) and the cortex (Figure 67C). In the dentate gyrus, compared to other 
regions, several Aβ positive plaques were not stained with Pld3 (shown with white 
arrowheads, Figure 66A). Surprisingly, high levels of Pld3 surrounding Aβ deposits were 
observed in the thalamus (Figure 67D), a region where very low detection of Pld3 was 
found in wild-type mice (Figure 38A and Figure 39). Lower Pld3 labeling around plaques 
was observed in the brainstem (Figure 66). These data suggest that Pld3 accumulates 
around Aβ plaques, similar to what was reported for LAMP1, which resides in swollen 
axons that contact the amyloid deposits (Gowrishankar et al., 2015). 
 
3.5 PLD3	and	spinocerebellar	ataxia	
 	A	 Pld3	 variant	 linked	 to	 spinocerebellar	 ataxia	 shows	 altered	 proteolytic	
processing,	intracellular	localization	and	nuclease	activity		
During the course of my PhD studies, PLD3 was described as a novel gene for autosomal 
dominant spinocerebellar ataxia (SCA) via a combination of whole exome sequencing 
(WES) and gene network analysis (Nibbeling et al., 2017). More exactly, a PLD3 variation 
(c.923T>C; p.Leu308Pro) resulting in reduced phospholipase D activity was identified in 
undiagnosed families. The same group showed that overexpression of turboGFP-PLD3-
WT in Cos7 cells, led to an ER localization of PLD3. As described in this thesis, PLD3 is a 
lysosomal protein (section 3.1) and no significant changes or accumulation of lipid 
species as products of phospholipase D activity were observed in brain lysates Pld3 KO 
mice (section 3.3.1).  
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▲Figure	 66	 |	 Pld3	 accumulates	within	 the	 same	 brain	 regions	 as	 amyloid	 beta	 (Aβ)	 plaques.		
Immunofluorescence staining of a 6 months old 5xFAD brain section. Pld3 was labeled with an antibody 
against its luminal domain (green) and an anti-Aβ (clone 6E10) antibody (red). Fluorescence image was 
generated by acquisition of more than 300 single images and further stitching overlapping. Boxes (A-E) 
correspond to brain regions with higher magnification (see also Figure 67) . A’, B’ and B’’ represent images 
of the same region from the dentate gyrus and CA2 region, respectively, taken at a higher magnification.  
 
 
 
 
Figure	67	|	Pld3	accumulates	around	amyloid	beta	(Aβ)	plaques	in	the	cortex,	the	thalamus	and	the	
subiculum	in	5x	FAD	mice. Enlarged fluorescence images of the cerebral cortex (C), the thalamus (D) and 
the subiculum (E) from the stitching fluorescence picture shown in Figure 66. A 6 months old 5xFAD brain 
section was co-labeled with an antibody against the luminal domain of PLD3 (green) and with an anti-Aβ 
(clone 6E10) antibody (red). E’ represents an image of the same region taken at a higher magnification.  
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Therefore, the effect of this PLD3 variant on intracellular localization, proteolytic 
processing and nuclease activity was analyzed in more detail. Immunofluorescence 
images of HeLa cells transfected with either hPLD3	WT	 or hPLD3	 L308P and further 
staining using both N-terminal and luminal PLD3-specific antibodies, showed that this 
PLD3 variant is mostly localized in the endoplasmic reticulum (ER) (Figure 68). In 
contrast, as already described in the first section of my results, PLD3 WT is confined to 
lysosomes.  
In order to analyze any changes on the proteolytic processing of PLD3 L308P, Western 
blot analyses were performed in technical triplicates and immunodetected with both 
described PLD3-specific antibodies. When the membrane was detected with the antibody 
against the luminal domain of PLD3, a significant reduction of the PLD3 processed form 
(~50kDa) was observed, also confirmed by densitometric quantification of the luminal / 
full length (FL) PLD3 signal (Figure 69). Intriguing, no apparent reduction of the PLD3 N-
terminal fragment (~12 kDa) was observed in cells transfected with the L308P variant, 
suggesting a partial abolishment of PLD3 cleavage.  
Our functional analyses together with the data reported by Gavin et al. revealed that PLD3 
is a 5’-exonuclease. Thus, lysates of HeLa cells transfected with the hPLD3	L308P variant 
were incubated with a ssDNA substrate and a nuclease assay was performed. DNA-PAGE 
analysis of the incubation products showed a basal nuclease activity for the PLD3 L308P, 
comparable to the activity observed for untransfected (UT) cells, arguing for a loss of 
function (Figure 70). In contrast, in PLD3	WT transfected cells, all the substrate was 
degraded after 2 h of incubation. These results were also validated by desintometric 
quantification of the signal between transfected (+PLD3) and untransfected (UT) cells. 
Together, these results indicate that the PLD3 L308P variant leads to a loss of function, 
probably due to improper folding and in consequence defective sorting to lysosomes.  
 
 
 
▼Figure	68	|	The	spinocerebellar	ataxia	variant	PLD3	L308P	is	localized	in	the	ER. HeLa cells were 
transfected either with hPLD3	WT	or the SCA variant hPLD3	L308P and further co-stained with antibodies 
against PLD3 N-terminal and luminal domains (green) and antibodies against the intracellular markers 
LAMP2 (lysosomal marker) or KDEL (ER marker) depicted in red. The corresponding Pearson correlation 
coefficient (PCC) values between PLD3 and each marker are shown. Error bars represent SEM. ***p < 0.001; 
unpaired Student´s t test (n = 12). Scale bar, 10 µm. ns, not significant. 
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Figure	69	|	The	PLD3	L308P	variant	shows	altered	proteolytic	processing. Western blot analyses of 
cell lysates transfected in technical replicates with either hPLD3	WT	or PLD3	L308P	and immunoblotted 
with both PLD3-specific antibodies. GAPDH is presented as a loading control. The respective densitometric 
quantification of luminal / full length (FL) PLD3 signal is shown. Error bars represent SEM. ***p < 0.001; 
unpaired Student´s t test (n = 3). 
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Figure	70	|	Nuclease	activity	of	the	PLD3	L308P	variant	is	impaired. Indicated transfected cell lysates 
(50 µg) were incubated with ssDNA substrate (2 µM) in reaction buffer (50 mM MES buffer, pH 4.5 and 100 
mM NaCl) for 2 h at 37 °C and further analyzed by DNA-PAGE. Polyacrylamide gels were stained with 
Ethidium Bromide. The corresponding quantification of PLD3 / UT ratio is shown. Error bars represent 
SEM. ***p < 0.001; unpaired Student´s t test (n = 3). ns, not significant. 
 
 Pld3‐deficient	 mice	 show	 unaltered	 cerebellar	 morphology	 or	 cerebellar	
dysfunction	
When Pld3 expression levels were analyzed in different brain regions, very low or no 
protein expression was observed in the cerebellum (Figure 38 and Figure 39). 
Additionally, X-gal staining of mouse brain sections also showed very low β-galactosidase 
activity (Figure 38B). Accordingly, we were surprised that PLD3 was described as a 
causative gene of spinocerebellar ataxia (SCA, Nibbeling et al., 2017). To have a closer 
look, we analyzed any changes on the cerebellar function or morphology. Fist, no evident 
changes in the size or whole brain structure of 20 months old WT and Pld3 knockout (KO) 
mice were observed (Figure 71A). 
 
 
▼Figure	71	|	Pld3	deficient	mice	do	not	show	cerebellar	alterations. A, photograph of the brain of a 
20 months old Pld3 wild-type (Pld3 +/+) and a Pld3 deficient (Pld3 -/-) mouse. B,	 calbindin 
immunofluorescence staining of 20 months old Pld3 wild-type and Pld3 deficient mice. C, brain sections of 
the molecular layer in lobule IV of 20 months old Pld3 wild-type and Pld3 deficientmice were fluorescence 
labeled with antibodies against calbindin (red) and GFAP (green). Nuclei are stained with DAPI (blue). Scale 
bar, 50 µm. 
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Additionally, immunofluorescence labeling of 20 months old brain sections with 
calbindin did not reveal loss of Purkinje cells in the cerebellum (Figure 71B) or sign of 
Bergmann astrogliosis or demyelination (Figure 71C). Rotarod is a widely used test to 
evaluate the motor coordination of rodents and is especially sensitive in detecting 
cerebellar dysfunction (Caston et al., 1995; Lalonde et al., 1995). Consequently, 
behavioral studies via rotarod test of two cohort of adult mice (5months and 9 months), 
did not show any sign of cerebellar dysfunction (Figure 72). Altogether, these data did 
not revealed hints of cerebellar dysfunction in the PLD3 deficient mice, suggesting that 
PLD3 is not the described causative gene of spinocerebellar ataxia by Nibbeling et al.  
 
 
Figure	72	|	Behavior	analyses	of	Pld3	deficient	mice	do	not	show	any	sign	of	cerebellar	dysfunction. 
Rotarod performance test of 5 months and 9 month Pld3 wild-type and deficient animals in four 
independent trials. The corresponding average latency (s) is shown for both set of mice (n = 9 – 11). ns, not 
significant. Rotarod test was performed in collaboration with Dr. Stijn Stroobants at the Laboratory of 
Biological Phycology in Leuven (Belgium). 
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4 DISCUSSION	
 
4.1 Biochemical	characterization	of	PLD3	
PLD3 is a member of the PLD protein superfamily. Due to the presence of two motifs 
characteristic of this family, it has been suggested that PLD3 exerts a role in lipid 
metabolism, as described for other family members like PLD1 and PLD2 (Cao et al., 1997). 
However, PLD3 is still a poorly characterized member of the PLD superfamily and no 
canonical phospholipase activity has yet been described. Although PLD3 was proposed 
to be associated to the endoplasmic reticulum (Munck et al., 2005), opposite findings 
provided evidence that PLD3 is a bona fide lysosomal protein (Palmieri et al., 2011; Sleat 
et al., 2013). In order to gain better insight in the biology of PLD3, a detailed biochemical 
characterization was performed. This analysis was fundamental for the follow-up study 
of PLD3’s physiological function and its possible involvement in the development of 
Alzheimer’s disease and other neurodegenerative disorders.  
 
 PLD3	is	a	lysosomal	protein	
Despite the few reports on PLD3, initial studies support a localization of PLD3 in the 
endoplasmic reticulum (ER) (Munck et al., 2005; Nibbeling et al., 2017; Osisami et al., 
2012). Other groups revealed that PLD3 is localized to lysosomes (Fazzari et al., 2017; 
Palmieri et al., 2011; Sleat et al., 2013). Our own data show that PLD3 is a lysosomal 
protein, as revealed by its co-localization with an anti-LAMP2 antibody as a marker for 
this compartment. These observations were validated under PLD3 overexpression and 
endogenous conditions in SH-SY5Y cells and human brain sections, respectively.  
In addition, treatment with different glycosidases demonstrated that PLD3 is mainly 
decorated with complex-type glycans, modifications that occur in post-ER compartments. 
Lysosomal localization is also supported by the work of Palmieri et al. in 2011, where 
PLD3 was reported as a member of the CLEAR (Coordinated Lysosomal Expression and 
Regulation) gene network. PLD3 is transcriptionally regulated by the transcription factor 
EB (TFEB), the master regulator of lysosomal biogenesis. TFEB directly binds to specific 
E-box sites at the promoter of PLD3 (Palmieri et al., 2011). In addition, a database search 
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reported a set of genes that are co-expressed with PLD3. This molecular network 
corresponds to lysosomal proteins including cathepsin A, cathepsin D and progranulin 
(Satoh et al., 2014).  
 
 PLD3	is	proteolytically	processed	into	a	stable	soluble	form	
4.1.2.1 PLD3	is	proteolytically	processed	by	acidic	cysteine	proteases	
Using antibodies against the N-terminus and C-terminus of PLD3, Western blot analysis 
revealed several PLD3-specific polypeptides with different molecular mass, arguing for 
post-translational modifications. The results obtained during this work indicate that full-
length PLD3 is not only modified with complex- and high-mannose-type glycans, but it is 
further cleaved at an amino acid position C-terminal of the transmembrane domain 
yielding a soluble lysosomal peptide and a short membrane-bound N-terminal peptide.  
Notably, PLD3 proteolytic processing occurs under acidic conditions, where PLD3 
cleavage is abrogated after adding inhibitors of lysosomal acidification. This result 
provides additional evidence that PLD3 leaves the ER to be transported to endocytic 
compartments where cleavage takes place.  
The primary intracellular proteases that exhibit proteolytic activity in acidified vesicles 
are “cathepsins”, classified in different groups based on their structure and catalytic site 
(Müller et al., 2012). Incubation of PLD3‐transfected HeLa cells with inhibitors of 
different classes of proteases suggests that PLD3 cleavage is mediated by one or several 
cysteine protease(s). This group constitutes the largest among the cathepsin family 
(Rawlings et al., 2010). However, brain lysates of mice deficient for the most abundant 
cysteine proteases, including cathepsin B, L and legumain (another member of the 
cysteine protease superfamily) revealed normal PLD3 proteolytic processing, suggesting 
that other protease(s) of this class are involved in the initial PLD3 cleavage event. 
However, this can be also explained by the redundancy reported for cysteine proteases, 
most of them having a broad substrate specificity (Turk et al., 2012). For instance, mutual 
compensation between cathepsin B and L in	 vivo has been suggested, where double 
knockout mice exhibited an early-onset neurodegeneration. These mice were lethal 
during the second to fourth week in life  (Felbor et al., 2002; Stahl et al., 2007).  
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4.1.2.2 PLD3	is	N‐glycosylated	
It is known that the vast majority of lysosomal proteins are heavily glycosylated 
(Tokhtaeva et al., 2017). This modification plays an important role in protein sorting and 
trafficking towards different intracellular compartments, and it influences the catalytic 
properties of lysosomal enzymes (Wang et al., 2005; Wei et al., 2005). Treatment with 
glycosidases under endogenous and overexpression conditions showed that PLD3 is 
mainly decorated with complex-type glycans. More specifically, analysis of predicted N‐
glycosylation sites in the luminal PLD3 domain, where single mutants were generated by 
substitution of the asparagine amino acids to alanine, revealed that the positions N97, 
N132, N236, N387 and N432 are glycosylated (Figure 73). Although Munck et al. reported 
that PLD3 is N-glycosylated, so far no experimental data have revealed which asparagine 
positions of PLD3 are modified. Noteworthy, Western blot and immunocytochemistry 
analyses showed that glycosylation of position N236 is indispensable for proper PLD3 
folding and lysosomal sorting.  
Western blot analysis of the described N-glycosylation mutants also revealed that the 
PLD3 N-terminal peptide of all the evaluated mutants was not shifted towards a lower 
molecular weight after deglycosylation, indicating that this short peptide is not N‐
glycosylated. This observation led to the assumption that PLD3 proteolytic processing 
occurs N-terminal to amino acid position N97. N97 is the most N-terminal asparagine 
position of the PLD3 sequence that was experimentally proven to be N-glycosylated. 
Molecular mass prediction of the first 97 amino acids of the PLD3 sequence computed a 
theoretical value of ~11 kDa, which matches with the observed size of the N-terminal 
PLD3 peptide. Therefore, it can be assumed that cleavage must take place after the 
transmembrane domain (TMD) and before position N97 (Figure 73). Several single 
alanine mutants replacing the amino acids located after the TMD (E61) and position N97 
did not reveal alterations in PLD3 proteolytic processing when analyzed by Western blot 
(data not shown). Edman sequencing and LC-MS/MS analysis of PLD3 transfected cells 
followed by immunoprecipitation with an antibody against the luminal domain of PLD3, 
also failed to decipher the cleaved neo-N-terminal peptide, possibly due to potential post-
translational modifications after the cleavage process that hamper the peptide 
identification (data not shown). It should be noted that all these approaches were 
performed under overexpression conditions of PLD3-transfected HeLa cells.  
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In order to investigate PLD3 cleavage site under endogenous conditions, we established 
a collaboration with Dr. Ole Greiner-Tollersrud from the Department of Medical Biology 
at the Arctic University of Norway – University of Tromsø. The analysis was performed 
with a pool of porcine brain where high concentrations of PLD3 could be obtained after 
several purification steps, including heat treatment, concanavalin A, hydroxyapatite and 
diethylaminoethanol (DEAE)-Sepharose ion exchange chromatography. This procedure 
was followed by MS/MS analysis, where intramolecular cleavage of endogenous PLD3 
was assigned to amino acid position Q72 (Greiner-Tollersrud, personal communication) 
(Figure 73). Generation of PLD3 mutants, where three blocks of ~10 amino acids between 
positions E61 and I89 were deleted, suggests that the initial cleavage takes place between 
amino acids 61 and 65 (Cedric Cappel, personal communication). Thus, additional 
trimming from the N-terminus of the PLD3 luminal domain until position Q72 cannot be 
excluded (Figure 73). Further analyses are required to validate these results, especially 
to learn if this cleavage site is conserved among other mammals, e.g. in the human and 
mouse PLD3 protein.  
 
 
 
 
Figure	 73	 |	 Schematic	 representation	 of	 PLD3	 proteolytic	 processing.	 Full length (FL) PLD3 is 
proteolytically processed by an unidentified protease at an amino acid closer to the transmembrane 
domain (TMD) (A), yielding a luminal domain (~50 kDa) and a short (~12 kDa) N-terminal peptide (B). 
This membrane-bound peptide is further degraded by cathepsin B and L. Initial cleavage site at position 
Q72 or possible C-terminal (CT) trimming remain to be validated. Described N-glycosylation sites at amino 
acid position N97, N132, N236, N387 and N432 are also depicted.  
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4.1.2.3 The	PLD3	N‐terminal	peptide	is	degraded	by	cathepsin	B	and	L	
Western blot analysis revealed strikingly increased levels of the ~11 kDa N-terminal 
peptide when lysates of CtsB/L double knockout (dKO) were analyzed. A similar result 
was observed when PLD3-transfected cells were treated with the cysteine protease 
inhibitor E64D. These observations suggest that the cysteine proteases CtsB and CtsL are 
responsible for the degradation of the short membrane-bound N-terminal peptide but 
are not involved in the initial PLD3 cleavage that generates the soluble peptide. Of note, 
subcellular fractionation and LC-MS/MS analysis of brain lysosomes, revealed several 
PLD3 peptides that were four-fold increased in CtsB/L dKO samples (Stahl et al., 2007). 
However, the identified PLD3 peptides were not reported.  
	
	
4.1.2.4 PLD3	is	transported	via	the	plasma	membrane	
According to our data, PLD3 follows a similar pathway and processing as the lysosomal 
acid phosphatase (LAP) protein. Although LAP has a type-I topology, it contains, 
comparable to PLD3, seven or eight N-linked oligossacharides, a single transmembrane 
domain and a short cytosolic tail of 18 amino acids (Pohlmann et al., 1988; Waheed et al., 
1988). LAP is transported to the cell surface where it is rapidly endocytosed via a 
tyrosine-based sorting motif in the short cytosolic tail. From early endosomes, LAP 
follows several cycles of rapid recycling (Braun et al., 1989; Peters et al., 1990). Once LAP 
reaches lysosomes, two sequential cleavage steps occur: (1) a thiol protease cleaves at 
the outside of the lysosomal membrane releasing the cytosolic LAP tail, and (2) an 
aspartyl protease cleaves within the luminal domain close to the transmembrane domain, 
which generates the soluble mature form of LAP (Gottschalk et al., 1989).  
Our data indicate that PLD3 is transported through the plasma membrane. However, 
mutation of the tyrosine at position 7 in the cytosolic region of PLD3, which we identified 
as a conserved tyrosine-based motif with the sequence YQEL, did not abolish transport 
of PLD3 to lysosomes. However, PLD3 localization was increased at the plasma 
membrane. This suggests that PLD3 may partially follow either the “indirect” or the 
“direct” transport pathway described for lysosomal membrane proteins (Figure 1). 
Additional evidence for a transport via the plasma membrane comes from a study of Kuhn 
et al., in 2016, where Pld3 levels were increased in the cellular membrane glycoproteome 
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of ADAM10-deficient neurons. Two years later, the same group identified following cell 
surface membrane glycoprotein biotinylation, that surface expression of Pld3 was 
significantly changed after BACE-1 inhibiton (Herber et al., 2018). Despite these findings, 
own studies of PLD3-transfected HeLa cells treated with ADAM10 and BACE-1 inhibitors 
or analysis of mouse embryonic fibroblasts (MEFs) and brain lysates deficient from 
ADAM10 or BACE1, did not reveal alterations in the PLD3 proteolytic cleavage pattern 
(data not shown).  
Interestingly, PLD3 levels were decreased in the cerebrospinal fluid (CSF) from primary 
central nervous system lymphoma (PCNSL) patients (Waldera-Lupa et al., 2017). These 
data indicate that PLD3 is mainly sorted to lysosomes, most likely via the “direct” 
pathway, to exert the main function in this compartment. Yet, a smaller fraction of PLD3 
could be alternatively transported to the cell surface where further processing takes 
place to release the luminal domain in the extracellular matrix.  
PLD3 proteolytic processing is complex and most likely tightly regulated in order to reach 
late endosomal-/lysosomal- compartments. N-glycosylation plays a pivotal role in PLD3 
stability and may function as a protective mechanism to avoid degradation by acidic 
proteases.  
 
 ESCRT‐dependent	delivery	of	PLD3	to	lysosomes	
4.1.3.1 PLD3	is	localized	to	intraluminal	vesicles	within	multivesicular	bodies	
It appears that PLD3 behaves as a hybrid between a membrane and a soluble protein. 
First, PLD3 is transported through the secretory and early endocytic pathway as a full-
length membrane-bound protein. After cleavage in acidic compartments, a stable PLD3 
soluble protein is released in the lysosomal lumen. PLD3 was initially identified as a novel 
lysosomal protein by mass spectrometry analysis, suggesting to be modified with 
mannose 6-phosphate residues (Sleat et al., 2008; Sleat et al., 2013). This study proposes 
that PLD3 is transported to lysosomes via the M6P pathway. Immunofluorescence 
staining of MEF cells deficient for the cation independent M6P receptor (CI-M6PR 
/MPR300) or the GlnNac-1-phosphotransferase, did not reveal alterations on the 
localization of endogenous Pld3 in lysosomes (data not shown). Moreover, affinity 
purification of immobilized bovine soluble CI-MPR was not able to immunoprecipitate 
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the possible M6P-modified PLD3 protein (data not shown). This data indicate that PLD3 
is not transported via the M6P pathway. However, it cannot be excluded that PLD3 may 
interact with M6P-modified proteins in the Golgi apparatus as an indirect mechanism of 
transport to early endosomes.  
Co-transfection of PLD3 with a dominant active form of Rab5 (Rab5-Q79L) revealed a 
distinct staining with both PLD3-specific antibodies. Particularly, a punctate-like PLD3 
staining within enlarged endosomes was observed with the N-terminal PLD3-specific 
antibody. This pattern resembles the formation of intraluminal vesicles (ILVs) of 
multivesicular bodies (MVBs). PLD3 labeling co-localized with the staining of an anti-
CD63 antibody, a marker of ILVs.  
To date, the best characterized pathway for delivery of proteins into ILVs is through the 
ESCRT (endosomal sorting complexes required for transport) machinery (see section 
1.2). However, eukaryotes have developed alternative, ESCRT-independent, routes for 
sorting of protein into ILVs. CD63 itself directly participates in the ESCRT-independent 
sorting of the premelanosome protein (PMEL), a component of melanocyte lysosome-
related organelles (LROs), to ILVs. Similar to PLD3, PMEL undergoes proteolytic 
processing yielding a stable luminal polypeptide (van Niel et al., 2011). However, 
immunocytochemistry analysis of CD63-deficient MEFs cells did not reveal alterations in 
PLD3 sorting to lysosomes. In other cell systems, ESCRT-independent formation of ILVs 
requires ceramide. The only reported cargo sorted via this pathway is the proteolipid 
protein (PLP), where ILV formation depends on the sphingolipid ceramide, localized to 
raft-based microdomains important for the lateral segregation of the cargo within the 
endosomal membrane (Trajkovic et al., 2007). Treatment of PLD3-transfected HeLa cells 
with the neutral sphingomyelinase inhibitor GW4869, neither altered PLD3 processing 
and lysosomal localization. These results indicate that PLD3 is not sorted to ILVs via its 
interaction with CD63 or ceramide.  
 
4.1.3.2 PLD3	is	transported	to	lysosomes	via	the	ESCRT	pathway	in	a	PtdIns3P‐dependent	
manner	
The data characterized so far from PLD3 proteolytic processing and transport to 
lysosomes resembles in several aspects the pathway described for carboxypeptidase S 
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(CPS) in yeast. CPS is synthesized as a type II transmembrane precursor protein (pCPS) 
which transits the secretory pathway to the endosomal system and requires a functional 
multivesicular body (MVB) sorting pathway. Delivery to the lumen of the vacuoles results 
in hydrolytic clipping of pCPS to its mature soluble form (mCPS) (Odorizzi et al., 1998; 
Spormann et al., 1992). This pathway is not only dependent on the synthesis of 
PtdIns(3,5)P2 (Odorizzi et al., 1998), but also depends on the ubiquitination of the 
endosomal cargo, here CPS, which serves as a signal for the sorting into the vesicles that 
invaginate into the MVB (Katzmann et al., 2001).  
Although the ESCRT pathway has been mainly described for rapid cargo downregulation 
and degradation by fusion of MVBs with lysosomes (Felder et al., 1990; Gruenberg and 
Maxfield, 1995), we investigated the possibility that PLD3 is transported to lysosomes in 
an ESCRT-dependent manner as a biosynthetic pathway.  
Experiments where key components of the ESCRT machinery were either overexpressed 
or downregulated, like Hrs (member of the ESCRT-0 complex) and Vps4a (responsible 
for the final step of ILV formation), revealed that PLD3 processing and PLD3 lysosomal 
sorting was abrogated. Notably, overexpression and knockdown of Hrs prevented the 
localization of PLD3 to ILVs. The PLD3 signal was mainly restricted to the limiting 
endosomal membrane, comparable to CD63. A similar effect was observed when PLD3-
transfected HeLa cells were treated with the fungal metabolite Wortmannin, an inhibitor 
of the Vps34 kinase (phosphatidylinositol 3-kinase, PtdIns 3-kinase) responsible for the 
conversion of PtdIns into PtdIns3P and its derivative PtdIns(3,5)P2 (Powis et al., 1994). 
In Wortmannin-treated cells, PLD3 was also exclusively detected in the limiting 
membrane of endosomes. PtdIns 3-kinases are key regulators of protein sorting to the 
lysosome/vacuole in both yeast and mammalian cells. Moreover, PtdIns3P binding is 
essential for the recruitment/activation of components in the PtdIns 3-kinase signaling 
cascade at unique membrane sites (Burd and Emr, 1998; Herman et al., 1991; Patki et al., 
1998).  These data indicate that PLD3, comparable to CPS, is transported via the ESCRT 
machinery in a PtdIns3P- or PtdIns(3,5)P2-dependent manner, required for the 
invagination of the endosomal membrane (ILV formation) and subsequent formation of 
MVBs.  
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4.1.3.3 PLD3	is	ubiquitinated	
A prerequisite for endosomal sorting in the MVB pathway is cargo ubiquitination, as 
extensively described for several membrane proteins, e.g. for the downregulation of 
activated epidermal growth factor receptor (EGFR) (Huang et al., 2006; Pennock and 
Wang, 2008; Raiborg and Stenmark, 2009). Our data indicate that PLD3 is ubiquitinated 
at different lysine residues at the N-terminus, suggesting that ubiquitin-binding is the 
major signal for PLD3 ESCRT-recognition. However, it cannot be excluded that other 
sorting mechanisms are responsible for PLD3 transport to ILVs of MVBs. For example, 
protein-protein interaction with ESCRT proteins (Mageswaran et al., 2014) or non-
canonical ubiquitination, where ubiquitin is covalently added to the N-terminal amide 
group of the protein, the hydroxyl group of serine and threonine residues or to the thiol 
groups of cysteine residues, regulate the activity and fate of several proteins (McDowell 
and Philpott, 2013). This might explain why mutating all lysine residues did not 
completely abrogate PLD3 ubiquitination. PLD3 was still sorted to ILVs after 
overexpression of this mutant.  
Noteworthy, PLD3 was identified in multiple screens for proteins that are ubiquitinated 
(Lee et al., 2011; Liu et al., 2012; Pridgeon et al., 2009; Shi et al., 2011). One site of PLD3 
ubiquitination was found at position K11 of the short cytoplasmic N-terminal domain 
(Lee et al., 2011). Interestingly, a TUBE-based assay for evaluation of PLD3 
ubiquitination, revealed that the PLD3 mutant K11R showed a slight decrease 
ubiquitination compared to the other mutants. This suggests that this lysine position is 
important for PLD3 ubiquitination. Since PLD3 was identified as a ubiquitinated 
substrate of HRD1, an E3 ubiquitin ligase (Lee et al., 2011), it would be interesting to 
know if abrogation of this enzyme influences the delivery of PLD3 to ILVs.  
A new alternative pathway in mammalian cells for the sorting of a lysosomal protein is 
proposed (Figure 74). PLD3 is synthesized as a type II transmembrane protein in the ER 
(1) and transported to endocytic compartments via an “indirect” pathway through the 
plasma membrane (2) and further endocytosis (3), or via a “direct” pathway from the 
Golgi apparatus (4). PLD3 ubiquitination (5) acts then as a signal for ESCRT-dependent 
invagination of endosomes leading to the formation of ILVs within MVBs (6). Fusion of 
MVBs with lysosomes (7) leads to cysteine protease-dependent PLD3 proteolytic 
processing in a position close to the transmembrane domain, releasing a mature and 
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stable soluble peptide in the lumen of lysosomes, where PLD3 might exert its main 
function (Figure 74). This work opens up the concept that the ESCRT pathway is not 
purely involved in cargo degradation, but also in protein sorting. If other hitherto 
undescribed mammalian proteins follow the same pathway for lysosomal delivery 
remains to be elucidated.  
 
 
Figure	74	 |	Schematic	representation	of	PLD3	 transport	and	 its	route	 to	 lysosomes. After proper 
folding and subsequent processing of carbohydrates in the endoplasmic reticulum (ER) and Golgi 
apparatus (1), PLD3 is either partially transported to the plasma membrane (2 and 3) or directly 
transported to endosomes (4) (data not analyzed). Ubiquitination of PLD3 (5) acts as a signal for transport 
to intraluminal vesicles (ILVs) within multivesicular bodies (MVBs) (6) dependent on the ESCRT 
machinery. After fusion of MVBs with acidic lysosomal structures (7), PLD3 will be processed to generate 
a stable PLD3 luminal domain. The membrane-bound N-terminal peptide is degraded by cathepsin B and 
L. TGN, trans-Golgi network; NT, N-terminal; TMD, transmembrane domain; CT, C-terminal. 
	
4.2 In	vivo	characterization	of	PLD3	function	
PLD3 expression analysis by in	situ hybridization	revealed a pronounced localization in 
mature neurons of the forebrain (Pedersen et al., 1998). Later, PLD3 expression was 
found upregulated during skeletal muscle differentiation (myogenesis) (Lee et al., 2011; 
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Tomczak et al., 2004). PLD3 was also expressed in an enriched insulin granule fraction 
from the rat insulin-secreting cell line INS-1E (Brunner et al., 2007). Munck et al. showed 
ubiquitous PLD3 mRNA levels in a range of tissues, with highest levels in the brain 
(Munck et al., 2005). Our characterization of PLD3 as a lysosomal protein prompted a 
further study of its expression pattern and tissue distribution in mice.  
 
 Pld3	is	a	neuronal	protein	
Compared to other mouse tissues, the highest Pld3 expression was observed in the brain. 
Further characterization of Pld3 expression in the brain revealed that the cerebral cortex 
and the hippocampus are the major regions where Pld3 is expressed. In agreement with 
this results, PLD3 gene expression analysis of mouse and human brain tissue revealed 
high PLD3	levels in the frontal, temporal and occipital cortices and in the hippocampus 
(Cruchaga et al., 2014; Hawrylycz et al., 2012; Lein et al., 2007). Nibbeling et al., proposed 
a role of PLD3	in the etiology of spinocerebellar ataxia. However, Western blot analysis 
and X-gal staining of mouse brains sections revealed only low expression levels of Pld3 
in the cerebellum.  
Primary mixed co-cultures of neurons, astrocytes and microglia cells prepared from 
newborn WT mice embryos showed that Pld3 is exclusively found in neuronal cells. Pld3 
immunostaining of mouse brain sections showed high levels of co-localization with the 
anti-NeuN neuronal marker, both in the hippocampus and the cerebral cortex. Similar 
results were reported by Pedersen et al., with pronounced Pld3 expression in the 
forebrain of mature neurons. Interestingly, low levels of Pld3 mRNA were reported in the 
neurons of early mouse embryos (between P7 and P10). Instead, a progressive 
upregulation of PLD3	expression until mouse adulthood was observed (Pedersen et al., 
1998). Immunohistochemistry analyses also indicate that Pld3 expression is restricted to 
distinct neuronal sub-types.  
RNA transcriptome analyses have shown that Pld3 is also expressed in microglia cells 
(Schaum et al., 2018; Zhang et al., 2014). Immunocytochemistry analysis of murine BV-2 
microglia cells did not show any staining for Pld3 (data not shown). Of note, in human 
brain sections, reactive astrocytes and activated microglia accumulating around senile 
plaques, did not express PLD3 (Satoh et al., 2014). However, Western blot analysis of the 
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BV-2 cells revealed a faint band of the luminal domain of Pld3. Thus, it cannot be excluded 
that minor levels of Pld3 are expressed in microglia cells. In summary, Pld3 is mainly a 
neuronal protein most likely expressed in selective sub-types of cells. Additional studies 
are necessary to validate Pld3 expression in other cells types, e.g. microglia.  
 
 Pld3‐deficient	mice	show	a	subtle	phenotype		
Lysosomes are the key cellular hub for macromolecule catabolism, recycling and 
signaling. Mutations in genes encoding lysosomal proteins, such as lysosomal 
glycosidases, proteases or integral membrane proteins, cause the accumulation of 
undigested or partially digested macromolecules in lysosomes (‘storage’), leading to the 
development of lysosomal storage disorders (LSDs) (Platt et al., 2018). If PLD3 is 
responsible for the bulk hydrolysis of a certain substrate, an enlargement of lysosomes 
should be expected. This is a common cellular phenotype observed in many LSDs. 
However, staining of PLD3 KO HeLa cells with an anti-LAMP2 antibody and electron 
microscopy analysis of neuronal lysosomes of Pld3 KO mice (data not shown), did not 
show obvious alterations on the size of lysosomes. 
Analysis of three different lysosomal enzymes (β-hexosaminidase, β-glucuronidase and 
β-glucocerebrosidase) revealed a decrease in their activity in Pld3 KO brain lysates, 
compared to WT mice. Although no substrate accumulation was evident, Pld3 deficiency 
may induce secondary effects leading to a mild lysosomal dysfunction, disturbing the 
activity of some lysosomal enzymes. Noteworthy, Fazzari et al. reported an increased 
lysosomal density, size and total area occupied by electron microscopy of Pld3-deficient 
CA1 neurons. Several of these lysosomes showed electron-transparent inclusions 
compatible with lipid droplets (Fazzari et al., 2017). It is tempting to speculate that such 
lysosomal inclusions could correspond to undigested DNA, as it will be later discussed in 
regard to PLD3 enzymatic activity. 
Behavioral studies of Pld3 KO mice suggest that these mice develop a depression-like 
behavior. Additionally, immunohistochemistry of Pld3 KO brain revealed an increased 
immunoreactivity of the microglia marker CD68, especially pronounced in the dentate 
gyrus of the hippocampus and the subventricular zone, known to be the largest regions 
were adult neurogenesis takes place (Doetsch and Alvarez-Buylla, 1996). Decreased 
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neurogenesis has been implicated in the pathogenesis of anxiety and depression, but 
direct evidence for this role is lacking (Drew and Hen, 2007; Sapolsky, 2004). Moreover, 
microglia cells are involved in shaping neuronal circuits in perinatal and postnatal stages, 
regulating adult hippocampal neurogenesis (Cunningham et al., 2013; Reemst et al., 
2016; Sierra et al., 2010; Ueno et al., 2013).  
Using antibodies against a neuronal mitotic marker (anti-Ki67) and a marker of immature 
neurons (anti-DCX, doublecortin), the possibility that Pld3-deficient mice may alter the 
process of neurogenesis was analyzed. However, no clear differences were observed in 
the staining of Ki67- or DCX-positive cells in brain sections between WT and Pld3 KO 
mice. An alternative approach would be BrdU (Bromodeoxyuridine / 5-bromo-2’-
deoxyuridine) labeling, which is an analogue of the nucleoside thymidine used to identify 
proliferating cells in	vivo (Kee et al., 2002).  
It is known that the majority of newborn cells during neurogenesis undergo death by 
apoptosis, which are rapidly cleared though phagocytosis of microglia (Sierra et al., 
2010). Thus, analysis of the interplay between neurogenesis and neuronal death should 
be considered. Due to the Pld3 expression pattern observed in the dentate gyrus of the 
mouse brain at different postnatal stages, Pedersen et al. suggests that Pld3 is involved in 
processes associated with target cell innervation, neurotransmission and neuronal 
survival, but less involved in early developmental processes, such as axonal growth, 
neurogenesis and neuronal migration (Pedersen et al., 1998). Further studies are 
necessary to unravel if the microglia activation and the behavioral despair are explained 
by a role of Pld3 in neuronal homeostasis or is merely a secondary response of Pld3 
deficiency.  
 
 Pld3	is	a	5’exonuclease		
The phospholipase D (PLD) members, PLD1 and PLD2, catalyze the conversion of 
phosphatidylcholine (PC) to choline and phosphatidic acid (PA), inducing a variety of 
intracellular signal transduction events, which are involved in the regulation of 
membrane and vesicle trafficking, cell proliferation, migration and actin cytoskeleton 
dynamics (Cockcroft, 2001; Riebeling et al., 2009; Roth, 2008; Rudge and Wakelam, 
2009). The non-classical PLD members PLD3 and PLD4, do not exhibit typical PLD 
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enzymatic activity for conversion of PC to choline and PA (Munck et al., 2005; Pedersen 
et al., 1998). PLD3 and PLD4, both share structural similarities composed of a short N-
terminal cytoplasmic tail, a transmembrane domain, and a long C-terminal region (Munck 
et al., 2005; Yoshikawa et al., 2010).  
Considering the high Pld3 expression levels in the murine brain, a lipidomic analysis of 
brain lysates between WT and Pld3 KO mice was performed in order to investigate a 
possible accumulation of putative substrate lipid species. However, from the 220 lipid 
species analyzed, no significant changes were detected in the levels of phosphatidic acid 
species, where a decrease was expected if PLD3 would be a classical PLD enzyme. A 
decrease in some ceramide species was observed, though the changes were subtle, 
making it difficult to draw any clear conclusions. It is worth mentioning that if PLD3 
and/or PLD4 may function as possible phospholipases, other substrates should be 
considered. In comparison to PLD1 and PLD2 which are facing the cytosol, the catalytic 
domains of PLD3 and PLD4 are facing the lumen of endo-lysosomes.  Thus, only lipids 
present in the inner leaflet of the lysosomal membrane are putative substrates. These 
data strengthen the hypothesis that PLD3 does not exert a classical PLD enzymatic 
phospholipase D activity as previously reported.  
In the course of this doctoral project, PLD3 and PLD4 were identified as lysosomal single-
stranded exonucleases (Gavin et al., 2018). In	vitro	incubation of the recombinant luminal 
domain of mouse PLD3 and PLD4 with different DNA substrates only led to a degradation 
of single-stranded DNA (ssDNA) in the 5’ to 3’ direction, showing high substrate 
specificity. As a consequence of these findings, PLD3 nuclease activity was further 
evaluated. To this end, a nuclease cell-based assay was stablished and standardized by 
incubation in an acidic buffer of the same ssDNA substrate reported by Gavin et al. (a 55 
nucleotide (nt) ssDNA) with lysates of untransfected or PLD3‐transfected HeLa cells. The 
degradation products of this incubation were further analyzed by DNA-PAGE. Nuclease 
activity analysis of WT and PLD3 KO HeLa cells revealed endogenous enzymatic activity 
in WT, but not in PLD3 KO HeLa cells, suggesting that PLD3 is the major 5’-exonuclease 
in this cell line. It would be interesting to investigate if PLD3 represents the main 5’-
exonuclease in other cell lines, e.g. SH-SY5Y cells.  
Comparison of untransfected HeLa cells and PLD3-transfected cells revealed a high PLD3-
dependent nuclease activity, where most of the substrate was degraded after 30 min of 
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incubation. This assay via ectopic expression was therefore a suitable approach to further 
analyze the effect of different described PLD3 variants on their catalytic activity.  
PLD1 and PLD2 mediate their catalytic activity via a pair of HKD motifs, described to form 
the catalytic center (Jenkins and Frohman, 2005). PLD3 also contains two of these motifs. 
However, the most C-terminal motif is not conserved, where an aspartic acid (D) is 
substituted by a glutamic acid (E) at positon 423. Analysis of the PLD3 variant E423A 
revealed that this amino acid is indispensable not only for the 5´-exonunclease activity 
but also for proper folding and appropriate delivery to lysosomes. Another HKD mutant 
(PLD3 K418) previously shown to eliminate the enzymatic activity of all PLD isoforms 
(Sung et al., 1997), also showed impaired nuclease activity. These results indicate that the 
HKD motifs are not only important for the catalytic activity of the classical 
phospholipases, but also, as report here, essential for nucleases.  
Conservation of the HKD motifs is the most important feature for the inclusion of a 
protein in the PLD superfamily because these enzymes share a two-step (SN2) ping-pong 
mechanism that proceeds through a covalent phospho-protein intermediate in 
phosphodiester hydrolysis (Stanacev and Stuhne-Sekalec, 1970; Yang et al., 1967). 
Several studies propose a reaction mechanism where the N-terminal histidine residue 
within the HKD motif, nucleophilically attacks the phosphate group of the substrate (step 
1), and forms a covalent phospho-histidine intermediate. The histidine residue of the C-
terminal HKD/E motif serves as a general acid and donates a proton to the leaving group 
(step 2) (Gottlin et al., 1998; Rudolph et al., 1999). Structural data support the proposed 
SN2 mechanism, as the catalytic cores of PLD superfamily enzymes are predicted to share 
a bilobal structure similar to that of the conserved HKD residues oriented adjacent to one 
another in the active site. Thus, this reaction mechanism is thought to extend to all PLD 
superfamily enzymes (Selvy et al., 2011). PLD3 shares high homology (48 %) with the 
Vaccinia	 virus protein K4L, reported to exhibit nuclease and viral DNA condensation 
function (Eckert et al., 2005). This suggests that the viral protein has evolved from one or 
more eukaryotic genes to finally incorporate the conserved HKD motifs and perform 
similar cellular processes (Cao et al., 1997). If K4L also have similar substrate specificity 
like PLD3 remains unclear.  
Several of the here analyzed enzymatic properties of PLD3 are reminiscent of the activity 
previously described as ‘spleen acid exonuclease’ or ‘spleen phosphodiesterase’. This 
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enzyme, purified from hog spleen, has 5’ single-strand specificity in an acidic milieu 
(Bernardi and Bernardi, 1968; Hilmoe, 1960; Razzell, 1961). As observed for PLD3, 
ethylenediaminetetraacetic acid (EDTA) was described as an activator for the spleen acid 
exonuclease (Hilmoe, 1960). Addition of the divalent cations Mg2+, Zn2+ and Cu2+ did not 
either affect PLD3 activity. This result indicates that PLD3 is a metal-independent 
nuclease. Substrate specificity studies of the spleen exonuclease showed that this enzyme 
degrades in the preferred nucleotide order guanine (G) > adenine (A) > uracil (U) > 
cytosine (C) (Bernardi and Bernardi, 1968; Holý, 1974). Preliminary data where the 5’ 
nucleotide of the substrate was replaced with A, C, T, U or G, revealed that 5’-G-ssDNA 
was preferentially degraded by PLD3, followed by 5’-T, 5’-A and 5’-U which were 
catalyzed with slower but comparable kinetics (data not shown). 5’-C-ssDNA was a poor 
substrate, as described for the spleen exonuclease. 
Regarding the intracellular localization, using synthetic substrates, spleen exonuclease 
was found in the mitochondrial-lysosomal fraction (Razzell, 1961). Subsequent work 
confirmed the hypothesis that acid exonuclease is a lysosomal enzyme like other acid 
hydrolases that degrade nucleic acids (Erecińska et al., 1969; Van Dyck and Wattiaux, 
1968). Mass spectrometry analysis of the commercially available phosphodiesterase II 
from bovine spleen identified six PLD3 peptides (Gavin et al., 2018). However, the gene 
encoding spleen exonuclease has never been cloned. These data support the idea that 
PLD3 and/or PLD4 represent the long sought ‘spleen exonuclease’. Since the spleen 
exonuclease was also identified to degrade RNA, additional experimental data is required 
to decipher if ribonucleic acids would be also cleaved by PLD3 with such a high specificity.  
Protein structure prediction tools suggest that PLD3 does not form a dimer to exert its 
catalytic activity, as described e.g. for PLD6, an endonuclease member of the PLD family 
(Ipsaro et al., 2012; Nishimasu et al., 2012). Instead, the large C-terminal region of PLD3 
would fold itself into two globular domains, each containing one HKD/E motif. PLD3 
crystallization could provide more information in regard to protein structure and the 
mechanism behind substrate binding. As shown for several PLD members, other 
cofactors that could regulate PLD3 activity should be considered, e.g. regulatory proteins 
or alternative post-translational modifications. Of note, treatment of PLD3-transfected 
cells with different inhibitors of lysosomal acidification did not alter PLD3 exonuclease 
activity. Additionally, membrane separation by ultracentrifugation followed by nuclease 
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activity analysis, revealed a comparable nuclease activity between the soluble PLD3 
fraction and the membrane-bound full-length PLD3 fraction (data not shown). These 
results indicate that in acidic milieu proteolytic processing is dispensable for its 
enzymatic activity. This raises the question, why such a regulated mechanism of PLD3 
trafficking and proteolytic cleavage to produce a soluble stable form in lysosomes does 
not influence PLD3 nuclease activity. A better accessibility of the soluble PLD3 enzyme to 
the substrate in comparison to the membrane-bond form of PLD3 could be envisaged. 
Further analyses are required to elucidate this assumption.   
 
 Pld3	is	the	main	5´	exonuclease	in	the	brain	
In the light of the findings that Pld3 is mainly expressed in the brain, an analysis of Pld3 
exonuclease activity was performed using tissue lysates of WT and Pld3-deficient mice. 
Noteworthy, besides the highest Pld3 expression observed in the mouse brain, a 
substantial protein expression level was also detected in the spleen and the bone marrow, 
both primary immune competent tissues. Nuclease analysis revealed a high 5’ 
exonuclease activity of all WT tissues (brain, spleen and bone marrow), where the 
substrate was completely degraded after 4 h of incubation. Strikingly, no nuclease activity 
was detected in the brain lysates of Pld3 KO mice. In contrast, ~40 % of substrate 
degradation was depicted in the spleen and bone marrow of Pld3 KO mice. Increasing 
amounts of PLD3 KO brain lysates only revealed minor nuclease activity at very high 
concentrations. These results indicate that Pld3 is the major 5’ exonuclease in the brain. 
It can be speculated that the remaining nuclease activity observed in the spleen and the 
bone marrow and the minor activity observed with very high concentrations of Pld3 KO 
brain lysates, is due to Pld4 activity.  
Both enzymes were identified as ssDNA exonucleases with overlapping functions (Gavin 
et al., 2018). The expression of Pld3 and Pld4 is likely tissue-specific. A previous study 
using Pld4 KO mice showed that Pld4 was mainly expressed in the marginal zone of the 
spleen and white matter tracks in the brain, including the corpus callosum and cerebellar 
white matter (Yoshikawa et al., 2010). The same group later described that Pld4 is 
implicated in the proliferation and phagocytosis function of microglia in the central 
nervous system (Otani et al., 2011). Proteomics data suggest high expression of PLD4 in 
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dendritic cells (DCs) and other myeloid cells and low expression in B cells. Moreover, 
studies have linked PLD4 gene polymorphisms to systemic sclerosis, rheumatoid arthritis 
(Chen et al., 2017; Terao et al., 2013) and more recently, to systemic lupus erythematosus 
(Akizuki et al., 2019). These finding suggest a functional involvement of PLD4 in the 
development of autoimmunity through controlling functions of immune cells.  
It can be hypothesized that in the brain, the major 5’ exonuclease activity comes from 
PLD3 expression in neuronal cells, whereas a minor activity can be expected from PLD4 
expression in microglia or other immune-related cells. Moreover, it can be speculated 
that in lymphatic organs, including the spleen and the bone marrow, PLD3 and PLD4 play 
a coordinated role in the specific degradation of ssDNA. Gavin et al. reported that wild-
type macrophages had a high expression of Pld3 and low expression of Pld4, whereas 
wild-type dendritic cells showed the opposite pattern of expression. Analysis of Pld3-
deficient macrophages and Pld4-deficient dendritic cells revealed a large inflammatory 
response, marked by elevated levels of interferon- γ (IFN-γ) and interleukin-6 (IL-6). 
These abnormalities were dependent on toll-like receptor 9 (TLR9) (Gavin et al., 2018). 
Toll-like receptors (TLRs) are type-I transmembrane proteins that mediate innate 
immunity by the recognition of pathogen- or damage-associated patterns (P/DAMPs) 
(Gordon, 2002). TLR9 resides in endo-/lysosomes and senses single-stranded DNA 
(ssDNA) containing unmethylated CpG dinucleotides (Krieg, 2002). Several classes of 
synthetic ligands, assigned as oligodeoxynucleotides (ODNs), which mimic the 
immunostimulatory activity of bacterial DNA, have been described and activate 
downstream signaling of TLR9 (Guiducci et al., 2006; Vollmer et al., 2004). Gavin et al. 
propose that PLD3 and PLD4 trim the 5’ end of single-stranded ODNs, degrading them 
and limit their ability to stimulate TLR9. Thus, we hypothesize that the increased CD68 
immunoreactivity at sites of neurogenesis observed in Pld3-deficient mice could 
correspond to an inflammatory response due to TLR9 overstimulation. TLR9 regulates 
aberrant adult neurogenesis upon injury (Matsuda et al., 2015). However, it should be 
noted that an analysis of Pld3-/- Tlr9-/- mice did not reveal a rescue of the phenotype of 
the Pld3 KO mice (data not shown). This indicates that the increased CD68 
immunoreactivity was not necessarily dependent on TLR9. Since TLR9 stimulation 
activates a downstream signaling cascade, measurement of activated transcription 
factors or proinflammatory cytokines should be considered.  
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The assay of the PLD3 exonuclease activity described here and the proposed function of 
PLD3 as a nucleic acid degrading enzyme of TLR9 ligands were all performed with 
synthetic or artificial ssDNA substrates. However, the physiological substrate of PLD3 is 
still unknown. Danger signals can arise not only from pathogens, but also from 
endogenous damage-associated molecular patterns (DAMPs), which can either be 
secreted from cells or be released following cell injury and death (Kono and Rock, 2008; 
Krysko et al., 2011). These endogenous molecules can include extracellular matrix, 
cytosolic compounds and fragments of damaged organelles (McCarthy et al., 2014).  
An example of such DAMPs is mitochondrial DNA (mtDNA). mtDNA contains 
unmethylated CpG dinucleotides, known to stimulate TLR9 (Krysko et al., 2011; Oka et 
al., 2012; Zhang et al., 2010). Thus, a natural substrate of PLD3 could be mtDNA. After 
translocation to the lysosomal lumen, autophagic substrates undergo degradation by 
catabolic enzymes. RNase T2 and DNaseII are a well-characterized lysosomal RNases and 
DNases, respectively. DNaseII is an endonuclease that cleaves double-stranded DNA with 
low sequence specificity (Evans and Aguilera, 2003). The contribution of DNaseII to 
autophagic degradation of mtDNA, which prevents inflammation, has also been reported 
(Oka et al., 2012).  
Interestingly, the successful purification of the initially described ‘spleen exonuclease’ 
was largely dependent on the choice of the oligonucleotides obtained by digestion of DNA 
by DNaseII (Bernardi and Bernardi, 1968). Moreover, it has been shown that DNaseII-
dependent digestion is required for DNA sensing by TLR9 (Chan et al., 2015). Thus, it can 
be speculated that, upon autophagy-mediated mitochondrial degradation (‘mitophagy’) 
(Rodriguez-Enriquez et al., 2006), mtDNA is accessible for its degradation by DNaseII to 
produce ssDNA fragments of approximately 10 nucleotides. This natural ‘ODNs’ would 
then stimulate TLR9.  
Downregulation of this response is then regulated by the degradation of these shorter 
oligonucleotides by means of the 5’ exonuclease activity of PLD3 and/or PLD4. If this 
hypothesis holds true, a bulk DNA degradation is not expected. Considering the 
similarities in the enzymatic activities of PLD3 and PLD4, it can be suggested that these 
nucleases have redundant functions in key cell types. In fact, mice deficient in both genes 
did not survive to the age of weaning. However, only a single allele of either Pld3	or Pld4 
was required to allow survival (Gavin et al., 2018).  
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4.3 PLD3	and	its	role	in	neurodegenerative	disorders	
 PLD3	and	Alzheimer’s	disease	
An increasing interest for PLD3 has evolved in the past years, especially after a 
polymorphism in the PLD3	gene (PLD3	V232M variant), was associated with a higher 
probability to develop late-onset Alzheimer´s disease (LOAD) (Cruchaga et al., 2014). 
Later studies attempted to reproduce this genetic association (Heilmann et al., 2015; 
Hooli et al., 2015; Lambert et al., 2015). However, only one group reported that the 
frequency of the PLD3 V232M variant was higher in AD cases compared to controls (van 
der Lee et al., 2015).  
The functional consequences of the PLD3	variants on the nuclease activity, however, has 
not yet been investigated. Besides PLD3	V232M, other variants were also associated with 
AD risk or were more frequent in AD cases than in controls (Cruchaga et al., 2014). From 
some of the PLD3 variants reported by Cruchaga et al., PLD3	K228R and N236S showed 
alterations in PLD3 proteolytic processing. This can be explained by an ER retention. As 
expected, PLD3 K228R and N236S also revealed lower exonuclease activity, indicating 
that these amino acid positions are conserved and important for proper PLD3 folding, 
transport and nuclease activity. It would be interesting to evaluate the PLD3 exonuclease 
activity using brain lysates of post-mortem AD cases. However, sequencing of	 PLD3 
alleles of each individual case should be performed in order to directly compare PLD3 
variants and PLD3 activity.  
Cruchaga et al. and Satoh et al. reported that PLD3 mRNA and protein levels are lower in 
neurons from AD brains compared to control brains. Moreover, overexpression of PLD3 
led to a significant decrease of the intracellular amyloid precursor protein (APP) 
(Cruchaga et al., 2014). Western blot analysis of WT and Pld3 KO brain lysates did not 
reveal alterations on APP protein levels, APP cleavage products or the levels of proteases 
involved in APP amyloidogenic pathway (Bace1 and presenilin). It can be assumed that a 
possible effect of PLD3 on APP processing is only revealed under conditions of high 
expression of human APP. However, analysis of 5xFAD and 5xFAD Pld3-/- brain lysates 
showed comparable protein levels of APP and its cleavage products. In agreement with 
these findings, Fazzari et al., using an APP knock-in mice (Appki)	also reported that Pld3 
deficiency did not directly affect APP metabolism.  
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 PLD3	and	spinocerebellar	ataxia		
Based on a combination of exome sequencing, PLD3 was identified as a novel causative 
gene of autosomal dominant spinocerebellar ataxia (SCA) (Nibbeling et al., 2017). The 
described PLD3 variant (L308P) associated to the disease, was localized to the 
endoplasmic reticulum and exhibited a reduced phospholipase D activity. As described 
along this thesis, no canonical phospholipase D activity was conferred to PLD3. Instead, 
the PLD3 L308P mutant revealed impaired exonuclease activity and abrogated PLD3 
proteolytic processing. This hereditary neurodegenerative disorder is characterized by 
loss of coordination and balance, gait abnormalities and slurred speech (Durr, 2010; 
Klockgether, 2011). However, behavioral studies and calbindin labeling of Pld3 KO brain 
sections did not reveal any signs of impaired motor coordination or loss of Purkinje cells 
in the cerebellum, respectively. These data support the finding by Nibbeling et al. that the 
PLD3 L308P variant leads to a loss of function. However, the Pld3 KO analysis as 
performed here, suggests that PLD3	is not a causative gene of spinocerebellar ataxia.  
 
4.4 Concluding	remarks	
The detailed biochemical characterization of PLD3 performed here revealed a new 
biosynthetic intracellular pathway, where the ESCRT machinery is essential for the 
transport and delivery of PLD3 to lysosomes. In late endosomes/lysosomes PLD3 
undergoes proteolytic cleavage releasing the mature soluble form. PLD3 shows highest 
expression in the brain and localizes to distinct neuronal cell populations. PLD3 acts as a 
5’ exonuclease specifically cleaving single-stranded DNA. Elucidating PLD3´s natural 
substrate will further clarify the role of PLD3 as an exonuclease in the brain and in the 
regulation of neuronal function. It remains to be investigated how genetic 
polymorphisms within the PLD3 gene affect and modulate the development of 
neurodegenerative disorders. 
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